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Abstract 
 
AZEZA S. S. GUMA 
 
Genotoxic effects of nano and bulk forms of aspirin and ibuprofen on 
blood samples from prostate cancer patients compared to those from 
healthy individuals 
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Inhibiting inflammatory processes or eliminating inflammation represents a 
logical role in the suppression and treatment strategy of cancer. Several 
studies have shown that anti-inflammatory drugs (NSAIDs) have promise as 
anticancer agents while reducing metastases and mortality. NSAIDs are 
seriously limited by side effects and their toxicity, which can become 
cumulative with their long-term administration for chemoprevention. The huge 
development in nanotechnology allows the drugs to exhibit novel and 
significantly improved properties compared to the large particles of the 
respective bulk compound, leading to more targeted therapy and reduced 
dosage. The overall aim of this thesis is to add to our understanding of cancer 
prevention and treatment through studying the genotoxicity mechanisms of 
NSAIDs agents in lymphocytes. In this study, the genotoxicity mechanisms of 
NSAID in bulk and nanoparticles forms a strategy to prevent and minimise the 
damage in human lymphocytes. Aspirin nano (ASP N) caused a significant 
decrease in deoxyribonucleic acid (DNA) damage compared to aspirin bulk 
(ASP B). Also, ibuprofen nano (IBU N) showed a significant reduction in DNA 
damage compared to ibuprofen bulk (IBU B). Micronuclei (MNi) decreased 
after ASP N, ASP B and IBU N in prostate cancer patients and healthy 
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individuals, and the ibuprofen bulk showed a significant increase of MNi 
formation in lymphocytes from healthy and prostate cancer patients when 
compared to untreated lymphocytes from prostate cancer patients. In order to 
study the geno-protective properties of these drugs, the protective effect of 
NSAIDs and the quantification of the DNA repair capacity in lymphocytes was 
studied. ASP N was found to increase the DNA repair capacity and reduced 
the reactive oxygen species (ROS) formation significantly more than ASP B. 
Finally, the role of NSAIDs on some key regulatory signal transduction 
pathways in isolated lymphocyte cells was investigated by studying their effect 
on ataxia-telangiectasia-mutated kinase (ATM) and ataxia-telangiectasia and 
Rad3-related kinase (ATR) mRNA. ATM mRNA significantly increased after 
treatment with ASP B, ASP N and IBU N. ATR expression also increased after 
treatment with IBU B and IBU N, but was only significant with IBU N. These 
findings indicate that a reduction in particle size had an impact on the reactivity 
of the drug, further emphasising the potential of nanoparticles as improvement 
to current treatment options.  
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1 Introduction 
Prostate cancer (PCa) is the most frequent malignancy among men in 
economically developed countries. The development of prostate cancer involves 
a set of cellular pathways in its initiation and progression, which can be used as 
a target for chemoprevention and the treatment of cancer. For instance, using 
androgens as chemo-preventive agents has been confirmed to decrease the risk 
of prostate cancer (Jafari et al., 2009; Wang et al., 2013). There is growing 
evidence that an inflammatory pathway is involved in the regulation of cellular 
events in prostate cancer (Thapa and Ghosh, 2015). This has led to the 
hypothesis that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) 
may be associated with a reduced risk of cancer. 
1.1 Prostate Anatomy 
 
The prostate is a walnut-shaped exocrine gland. It is located just under the 
bladder and surrounds the urethra. Just behind the prostate are the seminal 
vesicles, which make the fluid for semen. The vas deferens carries sperm from 
the testes to the seminal vesicles. The urethra runs through the middle of the 
prostate, from the bladder to the tip of the penis, and has two functions: urination 
and ejaculation. The portion of the urethra that runs through the prostate is called 
the prostatic urethra. During ejaculation, the muscular component of the prostate 
squeezes the fluid into the urethra, and it is expelled with sperm as semen 
(Figure 1) (Marieb and Koehn, 2015; Scott and Fong, 2013).  
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                              Figure 1. Prostate anatomy (Marieb and Koehn, 2015). 
 
 Prostate Structure 
 
The human prostate can be classified in two different ways: zones or lobes. First, 
the zone classification is usually used in pathology. In this classification system, 
the human prostate gland is divided into several morphological zones: the 
peripheral zone, the central zone and the transition zone. Each zone can harbour 
different prostatic diseases. For instance, most prostate carcinomas develop in 
the peripheral zone (Bhavsar and Verma, 2014; Cunha et al., 1987). In contrast, 
benign prostatic hyperplasia (BPH), which is common in older men, arises from 
the transition zone.  
Second, another way to classify the prostate is by lobes; this classification system 
also divides the prostate into four distinct regions: the anterior lobe, the posterior 
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lobe, the lateral lobes and the median or middle lobe. This classification is usually 
common in the anatomy of the prostate (Aaron et al., 2016).  
 Prostate Function 
 
The main purpose of the prostate gland is to produce an alkaline secretion that 
forms an important component of semen. The alkaline nature of semen can 
extend the lifespan of spermatozoa. The major components of prostatic secretion 
are prostate-specific antigen (PSA), citrate (18.7 mg/ml), zinc (488 μg/ml), 
spermine (243 mg/ml) and cholesterol (78 mg/ml) (Franz et al., 2013).  
1.2 Histology of Prostate Cancer  
 
A normal prostate is composed of two types of cells known as epithelial and 
stromal cells (Krušlin et al., 2015). The epithelial cell layer consists of four main 
cell types: basal cells, transient amplifying (TA) cells, luminal epithelial cells and 
neuroendocrine (NE) cells, which have been identified through their location and 
morphology and by using different marker expressions (Prajapati et al., 2013). 
The basal cell layer is in close contact with the basement membrane containing 
the stem cells that are responsible for the proliferative compartment of the 
prostate epithelium. The basal cells express p63 (a homolog of the tumour 
suppressor gene p53), cytokeratin (CK) 5 and 14, cluster differentiation (CD) 44, 
Bcl-2 (an anti-apoptotic factor), a hepatocyte growth factor (HGF) and have 
reduced or absent expression of androgen receptor (AR). The lack of AR 
indicates that the basal cells are not dependent on androgens for survival (Heer, 
2011) 
The epithelium is divided into two different layers. The basal layer is made up of 
cuboidal epithelial cells, and luminal cells are the prostate’s primary cell type, 
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which shapes a layer of columnar secretory cells whose main role is the 
production of prostate-specific antigen (PSA), prostatic acid phosphatase (PAP) 
and kallikrein-2, which are involved in seminal fluid secretion. Also, the luminal 
cells are androgen independent and can express a low molecular weight CK8 
and 18, CD57 and p27Kip1 (a cell cycle inhibitor) (Heer, 2011). Occasionally, NE 
cells can be found spread in the basal and luminal layers of the prostate. NE cells 
are androgen-insensitive cells and can express chromogranin A, synaptophysin 
and neuron-specific enolase (NSF). Also, they can produce and secrete 
neuropeptides, such as bombesin, calcitonin, and neurotensin, which are 
believed to support epithelial cell growth and differentiation (Prajapati et al., 2013)  
Furthermore, the TA cells differentiate into terminal end-stage secretory luminal 
cells. These cells then give rise to heterogeneous subpopulations of cells through 
cell migration from the basal layer into the luminal layer and have a central role 
in the development of all epithelial cell forms in the prostate. TA cells can express 
both basal as well as luminal cell markers (CK5, CK8, CK14, CK18, AR and PSA) 
(Karthaus et al., 2014).  
1.3 Prostate Carcinogenesis 
 
Cancer can be defined as abnormal growth of cells (Gabriel, 2007; Hanahan and 
Weinberg, 2011). Despite all cell types having the potential to develop malignant 
alterations leading to cancer, only the epithelial cells can become carcinomas. 
The cell cycle is interrupted, and the new tumour cells hyperproliferate in a local 
area before being able to spread and invade surrounding tissue regions and 
eventually all parts of the body through both the lymphatic and vascular system 
(Lowengrub et al., 2010).  
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In carcinogenesis, healthy cells are converted into cancer cells as a result of 
unlimited cell division. The central role of normal cells is to form an epithelium 
and to maintain a balance between proliferation and cell death with tightly 
regulated processes. Deoxyribonucleic acid (DNA) mutations can cause 
disturbances to these processes, leading to much more rapid cell division than 
normal cells, and therefore, can have much higher rates of proliferation (Ayala 
and Ro, 2007). Prostate cancer is believed to develop from early proliferative 
inflammatory atrophy (PIA) a predicted risk factor lesion to prostate cancer and 
prostate intraepithelial neoplasia (PIN) via the accumulation of genetic 
aberrations in epithelial cells (Shen and Abate-Shen, 2010). A basal cell origin 
for PCa has been suggested as human prostate basal cells expressing marker 
proteins, including AR and PSA (Rybak et al., 2015). 
  Prostatic Intraepithelial Neoplasia (PIN) 
 
PIN is a primary precursor of human prostate cancer. PIN is generally 
characterised by the appearance of luminal epithelial hyperplasia, reduction in 
basal cells, enlargement of nuclei and nucleoli, cytoplasmic hyperchromasia and 
nuclear atypia (Shah and Zhou, 2012). PIN can be classified into low grades 
(grade 1) and high grades (grades 2 and 3). Low-grade PIN is characterised by 
crowded and irregularly spaced epithelium cells with elongated hyperchromatic 
and variably sized nuclei (Ayala and Ro, 2007).  
It is difficult to differentiate low-grade PIN from the normal and hyperplastic 
epithelium. High-grade PIN (HGPIN) is widely considered to be the precursor of 
prostate cancer. HGPIN is characterised histologically by an overgrowth of 
epithelial cells with cytological alterations representing carcinomas, such as 
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enlarged nuclei with prominent nucleoli, more noticeable epithelial cell crowding 
and stratification (Jung et al., 2016).  
 Benign Prostatic Hyperplasia 
 
Benign prostatic hyperplasia (BPH) is referred to as benign prostatic hypertrophy. 
The word hyperplasia is derived from the ancient Greek word hyper and plasia, 
meaning excess growth in the amount of organic tissue. BPH is a condition 
characterised by slow progressive enlargement of the prostate gland and 
histologically associated with the deregulated proliferation of both epithelial and 
stromal cells. This noncancerous overgrowth of the prostate cells can exert 
pressure on the urethra and cause an obstacle to urine flow and lower urinary 
tract symptoms (LUTS) (Izumi et al., 2013). 
 Moreover, BPH is considered the main cause of LUTS in elderly males. Despite 
its obvious impact on health, very little is known about the biological processes 
and causes of the development of BPH. A number of theories have been 
suggested to explain the aetiology of the pathogenesis of BPH, including 
abnormal proliferation and apoptosis of stem cells, hormonal imbalance, 
apoptosis, epithelial mesenchymal transition, embryonic awakening and 
inflammation (Notara and Ahmed, 2012) 
1.4 Molecular Changes of Prostate Cancers 
 
Since most human genomes have large quantities of DNA sequences that do not 
code for proteins, protein-coding DNA sequences make up approximately 1.5% 
of the genome, and most mammalian genes are divided into introns (noncoding) 
and exons (coding) (Alberts et al., 2017; Kellis et al., 2014). Only mutations in the 
exon region will have an effect on the amino acid sequences that compose 
8 
 
proteins. Although the genetic causes of prostate cancer remain poorly 
understood, we know that cancers are derived from single somatic cells 
(Stergachis et al., 2013). The cells in the emerging neoplasm undergo a series of 
genetic changes that lead to alterations in gene activity and phenotype and, 
therefore, lead to cancer development (Chatterjee et al., 2017; Ponder, 2001). 
Cancer results from mutations that affect genes involved in the regulation of 
cellular growth or death (Hanahan and Weinberg, 2011). 
There are many different types (and subtypes) of cancer, and their complexity 
makes it difficult to trace a particular tumour’s origin. The past three decades 
have seen a significant rise in biochemistry and cellular and molecular biology 
that aid the understanding of cell cycle processes that involve the transformation 
of a normal cell to a cancerous cell. 
Most of the cancer cell genotypes arise from a manifestation of six essential 
alterations in the cell physiology that collectively dictate tumour development: 
self-sufficiency in growth signals, insensitivity to anti-growth signals, evasion of 
apoptosis, infinite replication and the ability to invade tissue and metastasise 
(Hanahan and Weinberg, 2011). 
Normal cells need external growth signals (growth factors) to stimulate cell 
growth and division. These signals are received by a receptor molecule on the 
cell surface. Cancer cells, however, can divide without external stimuli by 
generating their own growth signals. The second feature is the sensitivity of 
antigrowth signals; the growth of normal cells is controlled by growth inhibitors on 
the surfaces of neighbouring cells. These inhibitors interrupt cell division in the 
interphase; in contrast, cancer cells do not receive signals to inhibit their growth. 
The third capability is the acquired capability of sustained growth.  
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Normally, cells divide on average about 50 to 70 times, which is influenced by the 
length of telomeres. Telomeres are repetitive regions at the end of chromosomes 
that act as buffers to prevent the loss of DNA as a result of incomplete semi-
conservative replication. Each time a cell divides, part of the telomere is lost 
during DNA replication. If the telomeres get too short, the cell will either enter 
cellular senescence or undergo apoptosis. Cancer cells can replicate without 
control and are able to lengthen their telomeres constantly.  
The next capability is evasion of apoptosis. Apoptosis is a major mechanism of 
cancer control, and it is exerted by the p53 tumour suppressor protein in response 
to DNA damage. In order for cancer to progress, the p53 gene is mutated, and 
consequently, apoptosis does not proceed normally. Angiogenesis is the creation 
of new blood vessels that are formed in response to growth factors secreted by 
stromal cells and cancer cells. These processes are required to supply oxygen 
and nutrients to the proliferating tumour cells. Angiogenesis plays a vital role in 
the growth and spread of cancer (Ziyad and Iruela-Arispe, 2011).  
Morever, the next feature is tissue invasion and metastasis, where cancer cells 
spread to the surrounding tissue and distant organs. Cancer metastasis is the 
spread of cancer cells to tissues and organs beyond where the tumour originated 
and the formation of a new tumour (Valastyan and Weinberg, 2011). 
1.5 Tumour Suppressor Genes and Oncogenes 
 
Cancer genes are grouped into three main classes: oncogenes, tumour 
suppressor genes and DNA repair genes. Oncogenes are considered to be 
cancer causing genes, as they activate cellular proliferation and can lead to 
differentiation and unregulated cell growth (Agarwal et al., 2013; Ponder, 2001).  
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Most oncogenes arise from altered versions of the genes known as a proto-
oncogene responsible for normal cell growth and division. Most oncogenes are 
usually dominant mutations that involve a rise in protein activity, an increase in 
protein concentration or chromosomal translocation, causing expression of a 
different cell type (Gabriel, 2007; Lee and Muller, 2010).  
Tumour suppressor genes are also known as anti-oncogenes. Their function in 
normal cells is to regulate cellular proliferation. Mutation in these genes results in 
a loss of gene function, which promotes carcinogenesis. They are generally 
dominant, and common mutations include an increase in protein activity or loss 
of regulation, increase in protein concentration or chromosomal translocation, 
causing gene expression of a different cell type (Leemans et al., 2011).  
1.6 DNA and Chromatin 
 
A replica of our genetic information is kept well-preserved in the nuclei of the cell 
and is organised into chromosomes, which carry heritable material in the long 
molecules of DNA. DNA is made of repeated units called nucleotides consisting 
of three functional groups: a sugar group (2-deoxyribose), a phosphate group and 
a nitrogen base attached to each sugar. The nucleotides are linked together in a 
chain through a sugar group and a phosphate group, creating long DNA strands 
with bases. Two DNA chains are held together by hydrogen bonds between 
bases, and portions of the nucleotides hold the two strands together, creating a 
double helix.  
Each DNA strand serves as a pattern or template to specify the sequence of 
nucleotides in which a new complementary strand passes on the hereditary  
material to the next generation (Alberts, 2017).  
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Our cellular DNA is subjected to constant assaults from both externally and 
internally generated damaging agents. It is estimated that each of the ~1013 cells 
in the human body is assaulted by tens of thousands of DNA lesions per day 
(Cohen et al., 2015). Most of these occasional lesions are raised via physiological 
processes, such as reactive oxygen species compounds generated during a 
normal aerobic metabolism process or through redox-cycling actions involving 
environmental toxins and Fenton reactions mediated by heavy metals (Ienco et 
al., 2011).  
DNA damage can also generated by errors in DNA replication during DNA 
synthesis, and also by exogenous factors, such as genotoxic chemicals and 
ionising radiation (Ciccia and Elledge, 2010). Unrepaired DNA damage can 
cause rearrangements and translocation of the chromosome, which can lead to 
cell death and cancer. For Survival, mammalian cells are equipped with 
sophisticated DNA repair mechanisms to detect and repair different forms of DNA  
damage (Broustas and Lieberman, 2014). 
  DNA Damage 
 
Based on the type of damage sources, a variety of DNA damage is generated. 
The simple form of endogenous DNA damage is a result of the aqueous 
environment around the DNA, by the hydrolysis of the N-glycosidic bond between 
the DNA bases and, therefore, isolating the nucleobase from the deoxyribose, 
thus leaving an apurinic/apyrimidinic (AP) site. Another common reaction 
involving hydrolysis is the deamination of DNA bases carrying exocyclic amino 
groups. The most frequent of these lesions is the conversion cytosine to uracil, 
which will finally lead to mutations (Alberts, 2017).  
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DNA is also subject to chemical alterations by molecular oxygen that is produced 
during normal cellular metabolism. Among the most vital of these molecules are 
reactive oxygen species (ROS), such as superoxide, hydrogen peroxide and 
hydroxyl radicals. ROS are produced endogenously from leaking electrons from 
the respiratory chain in the mitochondria; therefore, during the transition, a metal-
mediated decrease of oxygen or hydrogen peroxide, and during synthesis of 
prostaglandin and leukotrienes, ROS can be highly oxidative to the guanine 
resulting in the generation of 8-oxo-guanine (Birben et al., 2012).  
ROS can cause > 100 types of oxidative DNA adducts, such as single-strand 
breaks (SSBs), double-strand breaks (DSBs), chemical modifications of the 
bases and sugar, and DNA protein cross-linking. Exogenous agents, such as 
ultraviolet radiation (UV) and ionising radiation, can penetrate and damage the 
human genome by inducing different DNA lesions, including the production of 
cyclobutane pyrimidine dimers that, if not repaired or are misrepaired during the 
replication, can also lead to mutations. Adenine and guanine can be 
spontaneously deaminated to produce hypoxanthine and xanthine, respectively 
(Broustas and Lieberman, 2014). 
  DNA Double-Strand Breaks (DSBs) 
 
A DNA double-strand (DSB) results from the breaking of the phosphodiester 
bonds between the sugar backbones on both DNA strands, which occurs with a 
region of 10–20 base pairs (bp) in the same or opposite DNA strands (Sutherland 
et al., 2002). Only 1–10 DSBs is sufficient to induce p53-dependent arrest and 
cell death (Nowsheen and Yang, 2012). A DSB is considered to be the most 
cytotoxic form of DNA lesion and is used in cancer therapy to kill cancer cells 
(Jekimovs et al., 2014). SSBs, in contrast, result from the break of the 
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phosphodiester bond between two neighbouring deoxyribose residues in the 
backbone of DNA. SSBs are eliminated with a half-life of minutes; using a copy 
of the genome as a template to reconstruct the damaged copy, intact DNA being 
utilised to guide the repair. Single-strand DNA damage is consequently not very 
toxic, and in some cases, more than 100,000 SSBs are required to promote cell 
cycle arrest (Polo and Jackson, 2011). 
 DSBs cannot be repaired through the template-directed repair system pathway. 
Therefore, the DSBs can be repaired by two major mechanisms: the DSB ends 
can be directly ligated together with little or no sequence homology between both 
broken ends, known as nonhomologous end joining (NHEJ), or repaired by 
homologous recombination (HR) using an undamaged DNA template on the 
sister chromatid to repair the break (Ciccia and Elledge, 2010).  
DSBs can be generated exogenously by ionising radiation or many 
chemotherapeutic drugs, such as bleomycin and etoposide, and endogenously 
as physiological processes like oxidative respiration that generate ROS, Variable 
Diverse-Joining (V(D)J) recombination, class switch recombination (CSR), 
replication across a nick, meiotic recombination and at eroded telomeres 
(Hoeijmakers, 2009; Koster et al., 2007).  
  Endogenous DSBs 
 
1.6.3.1  V (D) J Recombination 
 
V (D) J recombination is a site-specific recombination event that occurs 
specifically in the development of the lymphocytes and is initiated via induction of 
DNA double strands that are repaired by NHEJ. V (D) J is important for the 
diversity of the B- and T-cells and developing the immune system. Our immune 
response is helped enormously by two major cell types: B and T lymphocytes. B 
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lymphocytes secrete soluble antibodies each with specific antigen-binding site, 
to fight against foreign substances, while T lymphocytes express surface 
receptors—T cell receptors (TCR)—that recognise and react with antigens on the 
surfaces of the other cells. Antibodies are composed of two different kinds of 
polypeptide chains: two identical heavy chains and two identical light chains. 
Each polypeptide chain consists of a C terminal constant region end and an N 
terminal variable region end (Khan and Ali, 2017).  
The range of the variable regions is created by V(D)J recombination that 
recombines numerous other altered gene segments into one continuous exon 
that encodes the variable N-terminal region of both the light and heavy chain. The 
T-cell receptor also has two designed alpha (α) and beta (β) chains, each 
containing variable (V) amino-terminal regions and a constant (C) region that 
similarly are assembled by the V(D)J recombination. 
The variable region’s diversity is generated at several different levels. First, each 
heavy chain has multiple copies of the gene regions V (variable), D (diverse) and 
J (joining) gene segments and can be recombined in multiple ways. Similarly, in 
the light chain, the variable regions have two recombination segments: V and J. 
Second, as the V(D)J recombination individually produces variable regions in 
both heavy and light chains in each B-cell, the arrangement of diverse heavy and 
light chains into one antibody leads to high diversity. Furthermore, NHEJ, a major 
repair pathway in mammalian cells that joins together cleaved coding regions 
during repair of V(D)J breaks, is error-prone and can lead to deletions and 
insertions of nucleotides, thus extra amplifying the diversity of the antibodies’ 
antigen binding region (Roth, 2014). 
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There are two recombination-activating genes (RAG) products called RAG 1 and 
RAG 2 that initiate V(D)J recombination and work as a multi-subunit complex to 
induce a DSB between an antigen receptor coding segment and recombination 
signal sequence (RSS). Broken coding ends are covalently sealed in a hairpin 
structure, while single ends are blunt 5-phosphorylated molecules. Next, the 
broken molecules are ligated to shape single and coding joints. Single coding 
joints are joined precisely in a head-to-head fashion. Coding ends are ligated to 
form imprecise coding joints, thereby, introducing junctional diversity. The first 
phase of recombination is mediated by lymphoid-specific genes RAG 1 and RAG 
2. The later phase of the reaction needs some factors, including many involved 
in DSB repair (Helmink and Sleckman, 2012). 
 
1.6.3.2 Class-Switch Recombination (CSR)  
 
Upon exposure to the antigen, B cells immunoglobulin (Ig) genes undergo some 
DNA alteration events known as classic-switch recombination (CSR) and somatic 
hypermutation (SHM) to enhance antibody diversity. CSR rearranges the 
constant region by transferring the variable region to a constant region and can 
occur anywhere within the switch regions.  Activation-induced deaminase (AID) 
is a key player in both processes by converting cytosine to uracil in single-strand 
DNA in a co-transcriptional manner. These mutations are removed by base 
excision and a mismatch repair pathway that leads to the formation of DSBs that 
enable class-switch recombination. In variable regions, the hypermutation occurs 
from a high frequency of errors during the repair of C–U deamination 
(Wiedemann et al., 2016). 
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1.6.3.3  Meiotic Recombination 
During meiosis, the recombination of the homologous chromosomes is carried 
out through a special pathway for the generation and repair of DNA DSBs induced 
by the endonuclease spo11 (Lu and Yu, 2015). Spo11 appears to act via a type 
II topoisomerase-like reaction to generate protein-linked DSBs (Khan and Ali, 
2017). Spo11 dimers insert in a coordinated manner break both DNA strands, 
producing a DSB in which spo11 covalently binds to the newly created 5-DNA 
ends and the catalytic tyrosine residue in spo11. The spo11 protein must be 
removed by endonucleolytic cleavage, uncovering DSBs and a resection of 
3’-ssDNA for the DSB to be repaired. Meiosis-specific recombinase Dmc1 binds 
with Rad51 and forms the nucleoprotein filaments that are needed for the 
homology search in the homologous chromosome (Lu and Yu, 2015).  
1.7  DNA Damage Repair 
 
Many defence mechanisms defend against spontaneous DNA damage. For 
example, the fitting of the DNA into the cell nucleus isolates it from mitochondrial 
oxygen consumption, and peroxisomes minimise contact with oxygen. 
Furthermore, packaging the DNA into chromatin protects against ROS contact. 
Ferritin and transferrin that are known as iron-containing substances that  
decrease ROS production (Pino et al., 2017). Also, several specialised enzymes, 
such as superoxide dismutase (SOD), peroxidases and peroxiredoxin proteins, 
work by limiting the exposure of DNA to ROS (Bhattacharyya et al., 2014). Cells 
also have an additional DNA repair mechanism that helps protect against DNA 
on a daily basis (Hurov et al., 2010). 
Most of the DNA damaged agents, such as alkylating and ROS drugs, generate 
single-stranded DNA damage that leaves the opposite strand intact. This kind of 
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DNA damage is rapidly repaired by template-directed DNA repair systems, such 
as base excision repair (BER) and nucleotide excision repair (NER). In base 
excision repair, the single damaged bases are recognised and removed from the 
DNA molecules. The resulting short gap is then filled with the right base by newly 
synthesised DNA. NER, in particular, repairs bulky adducts, such as pyrimidine 
dimers and alkyl groups that severely distort the DNA helix.  
The general process begins with excision of a short region of DNA lesions, and 
next, the remaining undamaged complementary strand acts as a template for 
synthesising the removed strand (Whitaker et al., 2017).  
 DNA Repair Mechanisms 
 
To recover from the several types of DNA damage that occur, the cells have 
developed many mechanisms for repairing a different subgroup of lesions. At a 
minimum, most would agree that eukaryotic cells apply five major DNA repair 
mechanisms: BER, NER, mismatch repair (MMR) and DSB repair, which is 
repaired by both HR and NHEJ (Dexheimer, 2013). 
 Double-Strand Break Repair 
 
The repair of the DSB is critical for maintenance of genome integrity and cell 
survival DNA (Khanna and Jackson, 2001; Srivastava and Raghavan, 2015; van 
Gent et al., 2001). In mammalian cells, the DSBs are repaired by two primary 
mechanisms: HR and NHEJ. These two repair pathways differ in their fidelity and 
the homologous template of DNA requirements of DSB repair. HR is considered 
to be the error-free repair mechanism because it employs the genetic information 
that is included in the identical sister chromatid that is available as a template for 
the recombination process. Contrary to NHEJ, HR is highly error-prone and 
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typically involves elimination of DSBs by direct ligation of DNA broken ends 
(Heyer et al., 2010; Lieber, 2010; San Filippo et al., 2008). NHEJ is predominant 
as a DSB repair pathway in mammalian cells that operate in all phases of the cell 
cycle. However, HR is restricted to the late mitosis S and G2 phases (Kass and 
Jasin, 2010). The basic mechanisms and the factors involved in these pathways 
are briefly outlined below. 
  Homologous Recombination (HR) 
 
HR can be conceptually revealed in three separate phases: presynapsis, 
synapsis and postsynapsis. In the presynapsis phase, the DNA ends surrounding 
the DSB are initiated by a 5' to 3' end resection to produce molecules with 3'  
single-stranded tails (Zhang et al., 2013). The heterotrimeric MRN complex 
(Mre11–Rad50–Nbs1), together with CtIP (RBBP8), controls the initiation of 
resectioning in which the 5` ends on either side of the DSB are trimmed back to 
create 3` short overhangs of single-strand DNA (Liu and Huang, 2016). 
The next step in the 5' to 3' resection is most likely continued by a joint action of 
the Bloom syndrome helicase (BLM, RecQ helicase-like) and Exol exonuclease 
(Nimonkar et al., 2008). Then, single-strand DNA is restricted by Replication 
protein-A (RPA) to eliminate the disruptive secondary structure, which is then the 
block binding of the RAD51 recombinase. RPA can be replaced later by RAD51 
in combination with numerous recombination mediator proteins, for instance 
RAD52, BRCA2 and the RAD51 paralogues, including RAD51B, RAD51C, 
RAD51D, XRCC2 and XRCC3 (Forget and Kowalczykowski, 2010). The resulting 
RAD51–ssDNA filament then performs the DNA sequence homology search, 
which is considered the central reaction of HR. When the homologous DNA has 
been recognised, RAD51 catalyses the DNA strand invasion reaction, followed 
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by invading the damaged DNA strand to the template DNA duplex (i.e., sister 
chromatid).  
Next, DNA synthesis of the invading strand is then completed by DNA 
polymerase, which successively ligates them via DNA ligase I, yielding a four-
way junction intermediate structure called a Holiday junction (Rastogi et al., 
2010). The junction is a resolvase (MUS81-EME1/SLX1-SLX4/GEN1) into which 
both noncrossover or crossover yields by dissolving through a mechanism 
involving BLM-mediated branch migration and TOPOIIIα and RMI1-RMI2 (RecQ-
mediated genome instability 1/2) by symmetrical cleavage of GEN1/Yen1 or 
Slx1/Slx4 or by asymmetric cleavage of the structure-specific endonuclease 
Mus81/Eme1, resulting in the error-free correction of the DSB (Croteau et al., 
2014).  
 Non-Homologous End Joining (NHEJ) 
 
NHEJ is a major DNA DSB repair pathway in a human cell system. All proteins 
that participate in NHEJ have a remarkable level of mechanistic flexibility 
compared with their counterparts in other repair processes, which allows NHEJ 
to produce different junction outcomes, although initiating from the same ends 
(Srivastava and Raghavan, 2015). 
The initial stage in the NHEJ process requires recognition and binding of the 
heterodimer (Ku) that consist of Ku 70/ Ku 80 at both ends of the broken DNA 
molecules. Ku70/ku80 heterodimer adopts the shape of the ring that completely 
encircles duplex DNA (Davis and Chen, 2013). After binding Ku to DNA, the Ku-
DNA complex attracts the DNA-dependent protein kinase catalytic subunit (DNA-
PKcs) to produce the DNA-PK holoenzyme, which shows the protein kinase 
activity. Once bound to DNA, Ku can recruit DNA-PKcs and then move inward on 
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the DNA of Ku along the DNA, allowing DNA-PKcs to contact DNA termini 
(Bennett et al., 2012; Yoo and Dynan, 1999). Essentially, when the DNA-PKcs 
molecules bind with high affinity to opposing DSB ends, they form synapsis or 
tethering of the two DNA molecules. The DNA termini become available after 
autophosphorylation of DNA-PK (CS), which results from synapsis of DNA-PKcs 
(Thompson, 2012). Similar to most DNA repair processes, based on the 
complexity and type of the DSBs, DNA ends may need some alteration in 
advance of ligation. For instance, nonligatable DNA termini containing single-
stranded overhang must be processed to become ligatable through DNA 
polymerase-mediated fill-in or nucleolytic reaction. During the NHEJ, the 
resynthesis of the missing nucleotides has been linked to the two members of the 
X family DNA polymerases: Pol μ and Pol λ (Ramsden, 2011). Instead, the effect 
of NHEJ-specific nuclease Artemis activities that include a DNA-PK independent 
5-to-3 exonuclease activity, along with a DNA-PK-dependent endonuclease 
activity, which is obtained through phosphorylation by DNA-PK, can eliminate 
single-strand overhangs (Jeggo and O'Neill, 2002). Other enzymatic components 
that may be involved in the DNA end cleaning process include a number of the 
lesion-specific BER enzymes, such as Tdp1, APE1 and PNKP (Hegde et al., 
2012), in addition to the two functional exonucleases Exo1 and WRN, which are 
altered in Werner syndrome patients (Bahmed et al., 2011; Perry et al., 2006). 
Therefore, the identical enzymes that play a part in the end-processing step of 
the NHEJ pathway are counted as being in control for overhang mispairing and 
involve either removal or addition of nucleotides that are associated with NHEJ-
mediated repair. Next, either appropriately or sometimes inappropriately, DNA 
ligase IV achieves processing of ligation of the DNA end DNA termini in 
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conjunction with its binding partner XRCC4. Another factor, XRCC4-like factor 
(XLF), acts together with XRCC4-DNA ligase IV complex to promote DNA ligation 
(Gerodimos et al., 2017).  
1.8 Non-Steroidal Anti-Inflammatory Drugs   
 
NSAIDs are among the most commonly used over-the-counter medications 
worldwide with analgesic, antipyretic and anti-inflammatory effects. The use of 
NSAIDs have side effects, such as gastrointestinal (GI) complications, 
cardiovascular events and renal toxicity, which severely hinder their potential.  
 Aspirin 
 
Aspirin, also known as acetylsalicylic acid, is one of the most widely used anti-
inflammatory drugs. The active ingredient of aspirin, salicylic acid, was first 
recognised by the ancient Greek physician Hippocrates and came from the bark 
of certain willow trees (Salix spp.). However, aspirin was first chemically isolated 
and synthesised in its stable form by German chemist Felix Hoffmann in 1897 at 
the Bayer Pharmaceutical Company (Gensini and Conti, 2009). Aspirin 
possesses analgesic, anti-inflammatory, antiplatelet and antipyretic properties 
with an elimination half-life of about 15–20 minutes in plasma (Bruno et al., 2012). 
Besides the anti-inflammatory properties, aspirin can also prevent stroke and 
other cardiovascular diseases (Sutcliffe et al., 2013).  
 Ibuprofen  
 
Ibuprofen was introduced in 1969 and its chemical name is 2-(4-isobutylphenyl)-
propionic acid (Halford et al., 2012). It is another well-known NSAID. Similarly to 
aspirin, ibuprofen is a pain reliever that is used for the management of all types 
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of pain, inflammation and fever by suppressing the activity of the enzyme 
cyclooxygenase. Evidence has suggested other anti-inflammatory properties of 
ibuprofen, which include reduced cytokine production, inhibition of free radicals 
and signalling transduction, and modulation of leukocyte activity (Mazaleuskaya 
et al., 2015). Ibuprofen has also been found to help in treating Alzheimer’s 
disease (Imbimbo et al., 2010; Matsuura et al., 2015). It has the least side effects, 
including GI complications, stomach ulcers and myocardial infarction, compared 
to the other NSAIDs (Harirforoosh et al., 2013). 
 Role of NSAIDs in Prostaglandin Synthesis    
 
There is great evidence that indicates that NSAIDs exert their effect by inhibiting 
the activities of the cyclooxygenase enzymes, which is considered the key 
mechanism of NSAIDs’ analgesic, antipyretic and anti-inflammatory properties 
(Meek et al., 2010; Vane, 1971). Inhibition of cyclooxygenase (COX) resulting in 
inhibition of prostaglandin and other eicosanoid synthesis mitigates pain, fever 
and inflammation. 
COX is a key enzyme in the biosynthesis of prostaglandins that are derived from 
arachidonic acid (Day and Graham, 2013). The COX enzyme, also named 
prostaglandin endoperoxide H synthase (PGHS), is found in two isoforms of 
PGHS—PGHS-1 or COX-1 and PGHS-2 or COX-2—which are produced by 
different genes and both convert arachidonic acid to prostaglandin (see Figure 2) 
(Liu, 2011). 
The COX-1 enzyme is constitutively expressed at high levels in particular cells 
and tissues, including platelets, monocytes, the endothelium, renal collecting 
tubules and seminal vesicles (Roth, 2011). In contrast, the COX-2 enzyme is 
produced at the site of inflammation and is known to be the predominant form in 
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the inflamed tissue, where it is induced by some cytokines., including interleukin-
1 (IL-1) and tumour necrosis factor alpha (TNF-α). There are a limited number of 
cells that can express COX-2 in response to mitogens, including endothelial cells, 
smooth cells, fibroblasts, monocytes, macrophages and synovial cells (Sokolove 
and Lepus, 2013).  
NSAIDs can be classified into two categories, nonselective NSAIDs, which block 
both isoforms of COX enzymes, and selective NSAIDs (also called COX-2 
inhibitors), which act by blocking the COX-2 enzymes rather than COX-1 and are 
less likely to cause an unfavourable gastrointestinal effect (Petersen and Nelson, 
2010). Inhibition of COX-2 initiates the control of pain and inflammation (Ricciotti 
and FitzGerald, 2011). NSAID drugs have a variable ability to inhibit both forms 
of the cyclooxygenase enzyme, COX-1 and COX-2. NSAIDs, such as aspirin, 
indomethacin and ibuprofen, act by inhibiting both COX-1 and COX-2 
nonselectivity, while currently a new drug called celecoxib acts as a selective 
inhibitor of  COX-2 (Petersen and Nelson, 2010).  
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Figure 2. The mechanism of action of NSAIDs 
NSAID inhibition of cyclooxygenase-1 and/or cyclooxygenase-2 suppresses prostaglandin G2 
production, promoting apoptosis and blocking angiogenesis, inflammation, and tumour 
progression. Figure adapted from (Ishiguro and Kawahara, 2014). 
 NSAIDs and Cancer 
 
The relationship between aspirin and antimetastatic effects was first determined 
when the link between platelet levels and metastasis was studied. It was 
observed that reduction of the platelet count inhibited the spread of malignant 
tumours, and consequently, a strong relation between the capacity of tumours to 
induce platelet aggregation and its capacity correlated with the metastasis was 
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discovered (Yan and Jurasz, 2016). Also, it has been observed that, in the 
circulation system, platelets were able to protect the tumour cells from the 
immune cells’ system and promote their arrest on the endothelium, assisting the 
establishment of secondary lesions (Gay and Felding-Habermann, 2011). As a 
result of the relation between the thrombocytopenia with the decreased rate of 
metastasis, administration of the anti-platelet agent that inhibits platelet 
aggregation, NSAIDs, such as aspirin, were observed to significantly decrease 
the risk of distant metastasis (Karpatkin and Pearlstein, 1981; Rothwell et al., 
2012), showing the ability of NSAIDs to control the development of cancer.  
Prostaglandin (PG) can promote tumour growth, and therefore, abnormal PG 
synthesis is a characteristic of malignant cells. Thus, the advantage noticed with 
aspirin use was mediated through the inhibition of the COX enzymes that are in 
control of prostaglandin synthesis. Randomised trials for the prevention and 
reduction of colon adenomas demonstrated that aspirin can reduce the colon 
adenomas in patients with a prior history of adenoma, showing that using aspirin 
(600mg/day for ≥ 3 years) reduced the risk of colon adenomas after a 5-year 
latency period (Burn et al., 2012).  
Further studies indicated that use of aspirin can reduce the rate of other cancers, 
including breast (Retsky et al., 2012), lung (Muscat et al., 2003), prostate 
(Kawahara et al., 2010), ovarian (Baandrup et al., 2015; Cramer et al., 1998), 
oesophagus, stomach, colon and rectum (Rose et al., 2011; Thun et al., 2002).   
The expression of COX-2 has been found to be overexpressed in cancer tissue 
and associated with enhanced invasive, raised mutagenesis and proliferation 
mediated by Prostaglandin E2 (PGE2) and the production of reactive oxygen 
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species, and all these lead to an increased interest in NSAIDs for preventing and 
treating different kinds of cancers (Sobolewski et al., 2010).  
In recent years, much attention has been paid to the consumption of selective 
COX-2 inhibitors; however, the relationship between the antitumour effects of 
platelet inactivation through COX-1 inhibition additionally added to the efficiency 
of NASIDs as tumour protective agents (Menter et al., 2014). Other anticancer 
effects include independent COX production by regulating the activation of the 
nuclear factor Kappa B (Stolfi et al., 2013).  
1.9 Nanoparticles 
 
The past decade has shown a huge development in nano biotechnology. Interest 
in nanoparticles (NPs) has increased in the past few decades, as they are 
effectively a bridge between the atomic or molecular structure and bulk material 
(Balavigneswaran et al., 2014). Nanoparticles are particles that vary in size from 
10 nm to 1000 nm, and they can be presented in several forms, such as tubes, 
rods, wires or spheres, with more particular structures prepared, such as nano 
and nano peapods (Imasaka et al., 2006; Warner et al., 2008).   
Nanoparticles have different physio-chemical properties from the bulk compound 
due to the small size of the particles. NPs have a great surface-area-to-volume 
ratio, which leads to an increased reactivity through higher contact between 
nanoparticles and the target tissue (Mu et al., 2014). Nanoscale offers the chance 
to make medicine with huge dissolution with other routes of administration and a 
more targeted delivery system, which can reduce therapeutic toxicity and extend 
the drugs circulating half-life, leading to reduced health care costs (Onoue et al., 
2014). 
27 
 
However, this property is also believed to be responsible for negative biological 
effects. Therefore, in recent years, attention has increased regarding 
nanoparticles from a health and environmental safety point of view. The Royal 
Society and Royal Academy of Engineering (2004) produced the first report in 
this regard, focusing on the obvious shortage of information on how these 
engineered nanomaterials could affect human health and the environment. 
However, nowadays, there is no enough balance between the safety 
considerations and the growth of the material development of the nanotechnology 
industry. Moreover, the reason for the growing concern for nanoparticle toxicity 
is the increase in both the number and types of nanoparticles being encountered 
today (Kong et al., 2011). 
  Nanoparticles and cell interactions 
 
NPs are capable of easily passing through cell membranes. Very small NPs 
(diameter < 4.5nm) can penetrate cell membranes by spontaneous penetration, 
while larger NPs (diameter > 4.5nm) can enter the cells via endocytosis and semi-
endocytosis (Chen et al., 2013). These NPs may then be able to reach the 
nucleus through diffusion across the nuclear membrane or transportation through 
the nuclear pore and, therefore, allow direct activity on the nuclear DNA 
(Magdolenova et al., 2014). NPs can also functionalized with different molecules, 
such as antibodies, peptides and DNA/RNA to particularly target several cells 
(Sperling and Parak, 2010) and with biocompatible polymers (e.g., polyethylene 
glycol) to increase their in vivo circulation for drug and gene delivery applications 
(Ghosh et al., 2008; Nishiyama, 2007).  
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1.10  Methodology to Detect DNA Damage 
 
 Comet Assay 
 
1.10.1.1 Development of Comet assay 
 
The Comet assay, also known as single cell gel electrophoresis (SCGE), is a 
sensitive technique for detecting DNA damage in cells (eukaryotic cells) induced 
by various types of genotoxicants in situ (Olive and Banath, 2006). This technique 
was first introduced by Ostling and Johanson in 1984 and, later in 1998, was 
modified by Singh and co-workers for use under alkaline conditions, which 
increased its reproducibility. The Comet assay has been known for its simplicity, 
sensitivity, time efficiency and cost effectiveness for assessing DNA integrity in 
the cells. It is considered to be a good indicator for measuring and detecting 
genotoxic damage (Gopalan et al., 2011). 
1.10.1.2  Principle of the Comet assay 
 
The principle of this technique is simple; the procedure includes numerous steps. 
Firstly, nucleated cells are suspended in low melting point agarose and placed 
on Superfrost slides pre-coated with 1.0 % normal melting point agarose, the cells 
are then lysed with detergent and high salt concentration (Sodium chloride), to 
remove the cell membrane and proteins. DNA is allowed to unwind in alkaline 
buffer before being electrophoresed. The electrophoresis generates an electric 
field that forces the DNA fragments and single strands to migrate away from the 
nucleus toward the anode (Liao et al., 2009). Under alkaline conditions (pH>13), 
the double-stranded DNA is denatured and becomes single-stranded. 
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The slides are then neutralised with Tris buffer, pH 7.5. DNA is visualised with 
specific DNA binding dye, such as ethidium bromide (EtBr) or Sybr green in the 
dark and Comets are evaluated using a fluorescence microscope. The amount of 
DNA damage is then quantified within the head and the tail regions and measured 
together with the length of the tail. This allows for the analysis of an image that 
looks like a comet with a distinct head and tail. The head contains damaged DNA, 
while the tail consists of damaged DNA segments (Collins, 2004). Thus, the 
quantity of DNA found in the tail region would indicate the amount of damaged 
DNA in proportion to the undamaged DNA in the head region. The tail moment 
and the percentage of DNA in the tail are used as parameters to describe the 
DNA damage (Olive and Durand, 2005).  
  Comet repair assay 
 
The Comet assay is an easy method for measuring DNA strand breaks in cells. 
The test is suitable for evaluating different chemicals for their genotoxicity, usage 
in human biomonitoring and epidemiology, and importantly, it also allows the 
measurement of DNA damage and repair (Azqueta et al., 2014). Controlling or 
monitoring the DNA repair is one of the crucial factors for monitoring cancer risk 
(Figueroa-González and Pérez-Plasencia, 2017). All cells have their own 
machinery for improving or repairing DNA damage before it becomes a 
permanent change in the DNA structure and leads to mutations (Torgovnick and 
Schumacher, 2015). The method of DNA repair is also called the challenge assay 
(Au et al., 2010).   
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1.10.2.1 Principle of the Comet repair assay 
 
Two main methods are available for assessing the repair of cellular DNA damage. 
The first method determines the repair of DNA damage following exposure of 
cells to a DNA damage inducing agent, and then measuring the damage after a 
short time interval (Azqueta et al., 2014). Generally, cells are exposed to 
chemicals such as hydrogen peroxide, bleomycin (BLM) or ionising radiation, and 
the repair percentage is assessed at chosen time intervals, which are usually 
short periods following exposure to the treatment. This is the commonest way of 
measuring lesions in most cell types. Further DNA damage, like UV-induced 
pyrimidine dimers using nucleotide excision repair and oxidised bases using base 
excision repair, can be checked by applying specific enzymes that can identify 
the lesions and convert these to strand breaks (Nikitaki et al., 2015).  One 
enzyme, formamidopyrimidine DNA glycosylase (FPG), is used to convert 8-
oxoguanine and other oxidised purines into single strand breaks (SSBs), whereas 
Alk A converts alkylated bases and T4 endonuclease V converts cyclobutane 
pyrimidine dimers (induced by UV) (Azqueta et al., 2011). Consequently, this 
assay allows monitoring of SSB–re-joining, BER by (tracking the removal of 
oxidised and alkylated bases) and NER by (monitoring the removal of UV-
induced cyclobutane dimers) (Collins, 2014).  
 The micronucleus (MN) assay 
 
Examination of DNA damage at the chromosome level is an important aspect of 
genetic toxicology. The micronucleus assay is an attractive tool for assessing 
chromosome damage as it allows missegregation of chromosomes and 
fragmented chromosomes to be measured reliably and there are OECD test 
guidelines (474, 487). 
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This type of damage can be observed as a micronucleus (MN) in cells during 
interphase. MNs are formed from a centric chromosomal fragment or entire 
chromosomes that lag behind at anaphase during nuclear division and are 
therefore rejected from the main nucleus (Fenech, 2007; Kirsch-Volders et al., 
2011). The MN frequency could decline with repeated cell divisions and therefore 
a comparison between MN frequencies and dividing cell populations could not be 
determined (Fenech, 1997). During interphase, cytokinesis is blocked after 
treatment with cytochalasin B which is an inhibitor of the microfilament ring 
assembly, so producing binucleate cells that express MNs in mammalian cell 
cultures (Fenech, 2007). 
1.10.3.1 Advantages of the CBMN assay 
 
The CBMN assay is used on several cell population types, including primary or 
transformed cell lines, such as mouse lymphoma cell lines and primary human 
lymphocytes. The CBMN assay uses general morphological criteria (Figure 3) 
that permit identification of cytotoxicity and genotoxicity by observing the 
following: chromosome breakage, chromosome loss, chromosome 
rearrangement (including nucleoplasmic bridges), cell division inhibition, 
apoptosis and necrosis (Fenech, 2007).  
The assay also offers the alternative opportunity for chromosome aberration 
testing and the data obtained are not confounded by altered cell division kinetics 
caused by suboptimal cell culture conditions or cytotoxicity of the tested agents. 
Interphase cells can be assessed relatively objectively, which means the cells are 
much faster to score, so that scoring hundreds of cells per treatment group is 
possible and the resulting in data have substantial statistical power. Furthermore, 
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automated processes can be used to reduce scoring time even further (Doherty, 
2012). 
1.10.3.2 Principle of the micronucleus assay 
 
Micronuclei have been known for over 100 years in erythrocytes as the Howell-
Jolly bodies seen on the examination of the blood. The first micronuclei were 
initially realised in Vicia faba (broad bean, fava bean) root tips exposed to X-rays 
(Evans et al., 1959), and this assay was used to study immature bone marrow 
erythrocytes in 1975. This test is regarded as sensitive, reliable and 
straightforward (Schmid, 1975). Micronuclei have been detected in erythrocytes 
using an in vivo assay; however, in recent studies, micronucleus detection has 
been achieved using an in vitro/ex vivo approach. 
The micronucleus test is basically a mutagenic test system capable of identifying 
the cytotoxicity of certain chemicals. This cytotoxicity is demonstrated through 
the production of DNA fragments that are detached from the main nucleus and 
observable in the cytoplasm during interphase (Heddle et al., 2011). These 
pieces form from centric and acentric fragments of whole chromosomes that lack 
centromere regions. Accordingly, in anaphase of the cell-division cycle, these 
fragments are incapable of migrating in synchronisation with the other 
chromosomes, so they form micronuclei that are transferred to the daughter cells. 
Therefore, the development of micronuclei is a characteristic of chromosomal 
damage. Chemical exposure to cells that results in micronucleus formation would 
therefore indicate genotoxicity of that chemical and would be expected to affect 
the chromosome structure or modify segregation patterns (Fenech et al., 2011). 
33 
 
The numbers of micronuclei would indicate the genotoxic potential of a chemical 
(Hayashi, 2016).   
1.10.3.3 Cell culture for the micronucleus assay 
 
The general procedure for producing micronuclei includes a 72 hour cell cycle 
that takes into account the cell culture period and the addition of 
phytohaemagglutinin (PHA) at 0 h. The stimulation is carried out by addition of 
the mitogen, cytochalasin B, at 44 h, followed by cell fixation at 72 h. After fixation 
of cells on slides and staining with a dye, the micronuclei are scored under a 
microscope.  
Cell culture is imperative when working with the micronucleus assay, as 
micronuclei can only be obtained at interphase. The cells must undergo a nuclear 
division to show chromosome damage following in vitro exposure to a genotoxic 
agent. Cell cultures are initiated by the addition of lymphocytes (or other cells) to 
flasks of a medium containing PHA. The PHA stimulates cells by selectively 
stimulating T lymphocytes to enter mitotic cell division (Fenech et al., 2011). 
Cytochalasin B, a microfilament-assemble inhibitor is added to cells in vitro at 44 
h to block cytokinesis, thereby causing the formation of bi-nucleated cells. At 72 
h, the cells are subjected to a hypotonic shock and then fixed. to preserve the 
cytoplasm and cytoplasmic boundaries and to minimise clumping of the cells 
(Kirsch-Volders et al., 2011). The cells are dropped onto slides according to 
methods described by (Fenech, 2007) and then stained with Giemsa stain and 
scored under a microscope.  
The addition of cytochalasin B, as described above, is imperative to halt cell 
division in the micronucleus assay. This particular method is known as the 
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cytokinesis block micronucleus (CBMN) assay. The bi-nucleate presence of cells 
confirms that the cells have divided following the presence of a test agent, thereby 
allowing the scoring of the micronuclei in those cells (Doherty, 2012).  
 
 
         
 
 
Figure 3. Potential fates of cells after cell division. The figure shows the different possible 
fates of cultured cytokinesis-blocked cells following exposure to cytotoxic/genotoxic agents. 
(Fenech, 2007). 
 
1.10.3.4  Types of micronuclei detected in the CBMN assay 
 
Different kinds and forms of micronuclei can be produced. Categorisation first 
involves specification of the cells as mononucleated (containing one nucleus), 
binucleated (two nuclei) or multinucleated (more than two nuclei) (See Figure 4). 
These cell types may include one or several micronuclei. In addition, the CBMN 
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assay can measure nuclear buds (NBUDs), nucleoplasmic bridges (NPBs), and 
cell death (necrosis or apoptosis) (See Figure 4) as well as establish the nuclear 
division rate (Fenech et al., 2011). The presence of NBUDs indicates a lack of 
amplified DNA/DNA repair complexes, whereas nucleoplasmic bridges 
demonstrate DNA mis-repair and/or telomere end fusions (Luzhna et al., 2013).               
                              
Figure 4. Types of Micronuclei (MNi) in CBMN assay. The figure shows Photomicrographs 
of several types of cells and biomarkers scored in the CBMN assay. a) Mononucleated cell; 
(b) BN cell; (c) multinucleated cell; (d)  necrotic cell; (e) late apoptotic cell; (f) BN cell 
containing one or more MNi; (g) BN containing an NPB (and a MN); (h) BN cell containing 
NBUDs (Fenech, 2007).  
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1.11 Aims  
 
The studies described in this thesis aim to assess the DNA damage and repair 
mechanisms induced by two well-known NSAIDs aspirin and ibuprofen in bulk 
and nano forms in human peripheral lymphocytes from prostate cancer patients 
versus healthy volunteers. To achieve this, first the genotoxicity of aspirin and 
ibuprofen were measured using the Comet assay. In addition, the effect of the 
drugs aspirin and ibuprofen in both forms on mitotic phases of the cell cycles was 
investigated by the micronucleus assay. Also, the protective effects of aspirin and 
ibuprofen in both forms were studied using the Comet challenge assay and ROS 
measurements. Furthermore, the p53 and XRCC3 protein expressions were 
investigated using Western blotting. Finally, the effects of anti-inflammatory drugs 
on major signal transduction pathways in isolated lymphocyte cells were studied 
by investigating the gene expression of ataxia-telangiectasia-mutated (ATM) 
kinase and ataxia-telangiectasia and Rad3-related (ATR) kinase in lymphocytes 
treated with aspirin and ibuprofen in bulk or nano forms were studied. 
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2 Material and Methods 
2.1 Materials 
 
The chemicals that were used in this work, as well as their sources and CAS 
numbers, are summarised in the following Table 1.2. 
 
 
Table 1.2 Chemicals with their corresponding sources and CAS numbers.  
 
Chemicals Supplier CAS number 
Aspirin  Sigma-Aldrich, UK 50-78-2 
Acrylamide 30% Sigma-Aldrich, UK 79-06-1 
Anti-XRCC3 antibody Abcam, UK - 
Ammonium persulphate APS Sigma-Aldrich, UK 7727-54-0 
Anti-Mutant p53 antibody  Abcam, UK - 
Anti-beta Actin antibody  Abcam, UK - 
Bovine serum albumin Sigma-Aldrich, UK 9048-46-8 
Bromophenol blue Sigma-Aldrich, UK 115-39-9 
Cytochalasin-B Sigma-Aldrich, UK 14930-96-2 
Disodium hydrogen phosphate 
(Na2HPO4) 
VWR 7558-79-4 
Dimethyl sulfoxide (DMSO) BDH, UK 67-68-5 
Donkey Anti-Rabbit IgG H&L 
(HRP)  
Abcam,UK - 
Dithiothreitol (DTT) Sigma-Aldrich, UK 3483-12-3 
DPX Mountant  Sigma-Aldrich,UK - 
Ethanol Sigma-Aldrich, UK 64-17-5 
Ethidium bromide Sigma-Aldrich, UK 1239-45-8 
FAST SYBR, GREEN  Fisher Scientific, UK 163795-75-3 
Formaldehyde Sigma- Aldrich,UK 50-00-0 
Foetal Bovine serum Sigma-Aldrich, UK N/A 
Giemsa stain  VWR 51811-82-6 
Glacial Acetic Acid Fisher Scientific, UK 64-19-7 
Glycerol  Sigma-Aldrich, UK 56-81-5 
Hydrogen peroxide Sigma-Aldrich, UK 7722-84-1 
Ibuprofen  Albemarle sprt 15687-27-1 
iScript™ cDNA Synthesis Kit Bio-Rad,UK - 
Low melting point (LMP) 
agarose 
Invitrogen, UK 39346-81-1 
Methanol Fisher Scientific, UK 67-56-1 
Mitomycin C Sigma-Aldrich, UK 50-07-7 
Na2EDTA·2H2O Sigma-Aldrich, UK 6381-92-6 
NaCl Sigma-Aldrich, UK 7647-14-5 
NaOH Fisher Scientific, UK 1310-73-2 
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Normal melting point (NMP) 
agarose 
Invitrogen, UK 9012-36-6 
Penicillin-Streptomycin Invitrogen, Ltd - 
phosphate buffered saline Sigma, UK N/A 
Phytohemagglutinin Invitrogen UK 9008-97-3 
RPMI-1640 Medium Sigma-Aldrich UK N/A 
Trizma Base Sigma, UK 77-86-1 
Trition X-100 Sigma, UK 9002-93-1 
Trypan blue Sigma, UK 72-57-1 
Potassium chloride Sigma-Aldrich, UK 7447-40-7 
Sodium phosphate diabasic Sigma-Aldrich, UK 7558-80-7 
Sodium phosphate monobasic  7558-80-7 
Western ECL Substrate Bio-Rad,UK - 
Precision Plus Protein™ Dual  Bio-Rad,UK - 
Quick Start™ Bradford 1x Dye 
Reagent  
Bio-Rad,UK - 
QIAamp RNA Blood Mini Kit  Qiagen, Germany - 
RNase Sigma - 
2-Mercaptoethanol Sigma-Aldrich, UK 60-24-2 
Protease inhibitor cocktail Sigma-Aldrich, UK 66701-25-5 
Supported nitrocellulose 
membrane 0.45µM 
Bio-Rad,UK 9004-70-0 
Trypan blue  Sigma-Aldrich, UK  72-57-1 
Tween 20 Sigma-Aldrich, UK 9005-64-5 
Laemli sample buffer 2x Sigma-Aldrich, UK - 
Quick Start Bovine Serum 
Albumin Standard 
Bio-Rad, UK 9048-46-8 
Hs_ACTB_1_SG QuantiTect 
Primer 
Qiagen, Germany - 
Hs_ATM_1_SG QuantiTect 
Primer 
Qiagen, Germany - 
Hs_ATR_1_SG QuantiTect 
Primer  
Qiagen, Germany - 
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Table 2.2 Equipment and other materials. 
 
Equipments and other Services Company / Distributor 
Centrifuge Mistral 3000 MSE, Albertville, USA 
Centrifuge (biofuge 28 RS) Heraeus, Sepatech, Germany 
CCD camera Hitachi KPMI/EK Monochrome, 
Japan Coplin jar VWR, Lutterworth, UK 
Cover slip VWR, Lutterworth, UK 
Culture flasks (25&75 Cm3) Corning Incorporated Costar®, 
NY, USA Dry incubator (37º C) LKB BIOCHROM Leec LTD, Nottingham, UK 
Electrophoresis power supply Consort (E861), Belgium 
Electrophoresis tank (HU20) Scie-Plas, Renfrewshire, UK 
Falcon tubes BD, Swindon, UK 
Freezer -20º C Sanyo, Ultra low, Japan 
Freezer -80º C Sanyo, Ultra low, Japan 
Fluorescent microscope Leica, Weztler, Germany 
Fume cupboard Milton, UK 
Fume hood ray air Maiche Aire, Bolton, UK 
Ice maker (Scotsman AF 100) Namur, Belgium 
Incubator 37º C with 5% CO2 Andor Technology Ltd, Belfast 
Heraeus, Germany Light microscope Nikon, Japan 
Komet 6 software Kinetic Imaging, Nottingham, UK 
Microcentrifuge MSE GMI, Alberville, USA 
Microplate reader Dynex technology, Sussex, UK 
Microscope (ortholux) Leitz, Sturttgart, Germany 
Mini protein 11 gel electrophoresis Bio- Rad, Hertfordshire, UK 
Pipettes Gilson, Middleton, WI, USA 
pH meter Dunmow, UK 
Power pack supply Pharmacia LKB, Uppsala, Sweden 
Super frost slides VWR, Lutterworth, UK 
Water bath Grant instruments, Cambridge, UK 
Zeta sizer-nano Malvern instruments, UK 
microplate reader  (Tecan, Switzerland). 
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2.2 Methods 
 
2.2.1 Ethical approval 
 
The study was approved by the Ethics Committee of the University of Bradford, 
UK (reference number (0405/8), by Research Support & Governance Office, 
Bradford Teaching Hospitals reference number (Ref: RE DA 1202) and IRAS 
approval was obtained from Leeds East Research Ethics Committee Reference 
No, 12/YH/0464. All peripheral blood samples were collected after the patients 
signed informed consent 
 
2.2.1.1  Blood collections  
 
Whole blood samples were collected by venipuncture from 20 healthy male 
volunteers and 20 prostate cancer patients (see tables 2 and 3) after signing a 
consent form (Appendix I); a questionnaire (Appendix II) was completed prior to 
sample collection and information sheet provided (Appendix III). Samples were 
diluted at the rate of 1:1 with RPMI-1640 medium (Sigma Aldrich) supplemented 
with 10% dimethyl sulfoxide (DMSO). The mixture was transferred into labelled 
Eppendorf® tubes and was immediately frozen in the -80°C freezer. 
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Table 2.3 Brief information about the samples used from healthy donors.  
 
No Sample code Age Ethnicity Gender Smoking 
history 
Family 
history 
1  NG 47 Asian Male Smoker - 
2 M.26-9.14 42 Arab Male Smoker - 
3 Y.23.10.14 55 Arab Male Non-
smoker 
- 
4 A6.10-24 45 Arab Male Smoker - 
5 W23-09-14 47 Arab Male Non-
smoker 
- 
6 J12-6-13 35 Asian Male Non-
smoker 
- 
7 F26-9-14 56 Arab Male Non-
smoker 
- 
8 P.18-6-13 37 Asian Male Non-
smoker 
- 
9  AA 26 Asian Male Non-
smoker 
- 
10 O-12-6-13 40 Asian Male Non-
smoker 
- 
11 M5-12 50 Caucasian Male Smoker - 
12  NA 34 Asian Male Smoker - 
13 M5.12.14 42 Asian Male Smoker - 
14 J15-1.15 34 Arab Male Non-
smoker 
- 
15 001PAG 
06.09.17 
40 Asian Male Non-
smoker 
- 
16 S16.12.14 38 Asian Male Smoker - 
17 SH17.01.17 56 Asian Male Smoker - 
18 K12-05-15 66 Caucasian Male Smoker - 
19 M23-01-15 
 
63 Caucasian Male Non-
smoker 
- 
20 A12-06-15 48 Caucasian Male Non-
smoker 
- 
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Table 2.4.  Brief information about the prostate cancer patients. 
 
 
N0 Sample code Age Ethnicity Gender Smoking 
history 
Family 
history 
1 4239 PSC 61 Caucasian M Smoker - 
2 3497 PSC 80 Asian M Past smoker - 
3 3498 PSC 64 Caucasian M Past smoker - 
4 3511PSC 82 Caucasian M Past smoker - 
5 3514 PSC 65 Caucasian M  Smoker - 
6 3515 PSC 73 Caucasian M Past smoker - 
7 4232 PSC 
 
63 Asian M Non-smoker - 
8 4233 PSC 67 Caucasian M Non-smoker - 
9 4234 PSC 55 Caucasian M Smoker - 
10 4240 PSC 67 Caucasian M Past 
Smoker 
- 
11  4244 PSC 
   
66 Asian M Past smoker - 
12 4245 PSC 79 Caucasian M Past smoker - 
13 4249 PSC 76 Caucasian M Past smoker - 
14 5333 PSC 60 Caucasian M Non-smoker - 
15 5376 PSC 
 
68 Caucasian M - - 
16 3499 PSC 72 Caucasian M Smoker - 
17 5178 PSC 
 
72 Caucasian M Past smoker - 
18  4231 PSC 83 Caucasian M Past smoker - 
19 5371 PSC 
 
77 Caucasian M Past smoker - 
20 5374PSC 60 Asian M Smoker - 
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 Preparation of milled nano-suspensions and quality control   
 
Suspensions of both aspirin and ibuprofen were made at solids loads of 5% (w/w) 
and 4% (w/w) respectively in a medium consisting of hydroxypropyl 
methylcellulose (HPMC) (0.5%, w/w), polyvinylpyrrolidone K-30 (0.5%, w/w) and 
sodium lauryl sulphate (0.1%, w/w). The 5% (w/w) aspirin and 4% (w/w) ibuprofen 
solutions were processed in deionised water at neutral pH. A Lena Nanoceutics 
Technology DM-100 machine was used for the milling process. The milling of 
250ml of each suspension was performed for 60mins with 150ml of 0.2mm yttrium 
stabilised zirconium beads (Glen Mills, USA). The suspensions were transferred 
to an impervious glass bottle and stored in the refrigerator at 4°C for the duration 
of the experiments. 
 
 Zeta potential 
 
The mean particle sizes in the stock solutions of both aspirin and ibuprofen were 
measured by Photon Correlation Spectroscopy using a Zetasizer Nano ZS-90 
Model ZEN3600 (Malvern Instruments Ltd, UK). All measurements were carried 
out at room temperature (RT) using disposable sizing cuvettes.   
 
 Particle morphology and visualisation  
 
To examine the particle surface morphology of the aspirin and ibuprofen nano-
particles, a scanning electron microscope was used (FEI Quanta 400, Cambridge, 
UK). Both samples were placed on a graphics layer on an aluminium stub with a 
conductive double-sided carbon tape. The photographs were taken at a variety 
of magnifications operated at 10kV. To visualise the inherent matrix of individual 
particles and their shape, transmission electron microscopy TEM Tecnai 12 (FEI 
45 
 
Company, Netherlands) was used. Aspirin and ibuprofen suspensions were 
diluted to 1ml with purified water, and then 7μl of diluted samples were mounted 
on carbon-coated copper TEM grids allowing thorough air-drying before viewing.  
 Stability of the aspirin and ibuprofen nano-suspensions 
 
Aspirin and ibuprofen nano-suspensions were checked each month for any 
sedimentation and changes in particle size to determine any agglomeration or 
aggregation. The particle size was measured using the Zetasizer Nano. 
  Aspirin and ibuprofen doses 
 
In this study, two different forms of aspirin and ibuprofen were used (NPs and 
bulk). In both forms, the same concentration 500µg/ml was used for the Comet 
assay, while 200µg/ml were used for ibuprofen nano and bulk, and 500µg/ml of 
aspirin nano and bulk were used for the micronucleus assay.  
 Comet assay 
 
2.2.7.1 Cell treatment 
 
A volume of 890μl of RPMI medium was used as a suspension and 10μl of 
treatment solutions (aspirin, ibuprofen at 500 µg/ml and Hydrogen peroxide (H2O2) 
at 50 µM) , and 100μl of whole blood was added in Eppendorf® tubes with a final 
volume of 1,000μl and then incubated for 30mins at 37°C. The tubes were 
centrifuged at 3000 rpm for 5mins, and then 900μl of the supernatant was 
discarded. The cell pellet was re-suspended and mixed in 100μl of 0.5% low 
melting point (LMP) agarose prepared with PBS; then 100μl of cell suspensions 
were placed on a dry slide pre-coated with 1% of normal melting point agarose 
(NMP). An appropriately sized coverslip was employed quickly to spread out each 
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agarose layer; the agarose was allowed to set on ice for 5mins. 
2.2.7.2 Cell lysis 
 
Once the slide held two agarose layers, the coverslip was then removed, and the 
slide was immersed in freshly prepared cold lysis solution, a high salt solution 
containing a detergent (100mM EDTA, 2.5M NaCl, 10mM Trizma base, 10% 
DMSO and 1% Triton X-100, at pH 10) for at least one hour or overnight. 
2.2.7.3  Electrophoresis 
 
Before electrophoresis, the slides were placed in a horizontal gel electrophoresis 
tank and equilibrated in fresh cold alkaline electrophoresis solution (10M NaOH 
and 200mM EDTA, pH >13). The slides were kept in an electrophoresis tank for 
30mins at 4°C. Electrophoresis was conducted at 4°C for 30mins using constant 
voltage at about 25 volts and 300mA current.  
2.2.7.4 Neutralisation 
 
After electrophoresis, the slides were removed from the electrophoresis solution 
and a neutralising buffer (0.4M Trizma base, pH 7.5) was applied three times for 
5mins. The DNA was visualised by staining the slides with 60μl of (20µg/ml) 
ethidium bromide and the slides were covered with a coverslip.  
2.2.7.5 Scoring of slides  
 
All slides were coded before scoring, and 100 cells were scored double blind per 
observation using a fluorescence microscope equipped with a CCD camera and 
computer system. Data were generated measuring the Olive tail moment and % 
Tail DNA using Komet 6 software, Kinetic imaging (Andor Technology Ltd, 
Belfast, UK).  
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2.2.7.6 Statistical analysis 
 
Mean data were generated with standard errors. The data obtained were tested 
for normality of distribution using the Kolmogorov-Smirnov test. Data were 
analysed using one-way analysis with post hoc test to determine significance 
relative to control. In all cases, P was considered significant at P <0.05. All 
analyses were performed using SPSS for Windows statistical package (version 
22).  
 Micronucleus assay 
 
Fresh blood samples were obtained from five healthy men and five prostate 
cancer patients. Samples were used for cell culture after collection in heparinised 
tubes.  
2.2.8.1 Cell culture and treatment 
 
All culture steps were carried out under sterile conditions and any chemicals were 
added to the culture flasks using a fume hood. 4.5ml of the basic culture medium 
(RPMI-1640 containing 25mM HEPES and L-Glutamine, 15% foetal bovine 
serum, 1% penicillin-streptomycin solution) was transferred into each 25cm3 
Corning® vented cap culture flasks and stored at -20ºC until ready for use. The 
flasks were equilibrated in a 37°C incubator (5% CO2) at least 30mins before use. 
2.2.8.2  Culture started 
 
At 0hrs, 130μl of phytohaemagglutinin (PHA) and 300μl of fresh blood were 
added to each flask. The culture flasks were mixed gently and then incubated at 
37°C for 24hrs in the presence of 5% CO2.  
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At 24hrs, 50µl of each chemical was added, 50µl of RPMI-1640 was added to the 
negative control (NC) cultures. 0.4 µM of mitomycin C was used as a positive 
control (PC) and ASP B, ASP N were added at 500 μg/ml, IBU B and IB N at 200 
μg/ml. The culture flasks were then incubated for an additional 20hrs.  
 
At 44 h, 30µl of 1mg/ml of cytochalasin-B (cyto-B) was added to each culture to 
halt cytokinesis. The flasks were then incubated for an additional 28hrs.  
 
At 72hrs, flasks were removed from incubation and then the contents transferred 
into 15ml Falcon® tubes. At this time sterile conditions were no longer required. 
The 15ml Falcon® tubes were centrifuged for 8 min and elsewhere at 800 rpm. 
Then, for each culture, the supernatant was removed using a vacuum pump until 
500µl remained. To allow the hypotonic shock to take effect on the cells, 5ml of 
cold (4°C) 90mM KCl was added to each tube while being gently mixed on a 
vortex followed by a 15mins incubation at 4°C. Tubes were centrifuged, and a 
vacuum pump was used to discard the supernatant with retention of 500µl each. 
2.2.8.3 Fixation of cells 
 
Five ml of freshly prepared Carnoy’s solution (one part glacial acetic acid and 
three parts methanol; the solution was always freshly prepared) was added drop 
by drop while being gently mixed on a vortex followed by three drops of 38% 
formaldehyde to each tube mixed with a Pasteur pipette (Fisher Scientific). The 
cell suspensions were centrifuged at 800 rpm for 8mins, and the supernatants 
were discarded using a vacuum pump, retaining approximately 500µl each. The 
fixation process was repeated twice without the addition of formaldehyde. The 
tubes were left overnight at 4°C. 
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2.2.8.4 Slide preparation, staining and mounting slides 
 
The following day, the cell solutions were centrifuged for eight minutes and the 
supernatant discarded until approximately 100µl remained. Then, depending on 
cell density and pellet size, between 200-600µl of fresh Carnoy’s solution was 
added. A volume of 20µl of cell suspensions was dropped twice onto a labelled 
frosted glass slide (centre left and centre right) and left to air-dry. Four slides were 
used for each treatment group, and the cell density was checked using a phase-
contrast microscope (Nikon Eclipse Ti-S) before being left to dry at room 
temperature overnight. The slides were stained for 20mins in a Giemsa in 
Sorenson buffer (5% Giemsa solution in phosphate buffer at pH 6.8). Slides were 
gently washed for approximately 2mins and left to air-dry.  Coverslips 24 × 50mm2 
(VWR) were mounted onto the prepared slides using three drops of DPX 
Mountant on heating block at 40°C and left to set overnight. The slides were 
viewed under a light microscope (Nikon Eclipse E-200). 
 
2.2.8.5 Micronuclei (MN) scoring 
 
For determining the MN frequency detected with the assay, 1,000 cells for each 
dose point were scored under 40x magnification using a light microscope. Scoring 
was done according to the criteria described by Fenech (2007) (Figure 1.2). The 
frequency of MN in 1,000 binucleated (BiNC) lymphocytes was used to calculate 
the nuclear division index (NDI); M1-M3 representing the number of cells 
containing 1-3 nuclei and N is the total number of viable cells scored. 
NDI = (M1 + 2(M2) + 3(M3)) /N  
M1 = mononucleated cells, M2 = binucleated cells, M3 = multinucleated cells, N 
= the total number of viable cells scored.  
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The number of cells scored for the investigation was 1,000 cells/person/treatment 
group. The NDI provides a measure of the mitogen-induced cell cycle of viable 
cells and the effect of the compound on the cell cycle. The NDI values frequently 
range from 1.0 to 2.0. However, if all the viable cells have been able to complete 
more than one nuclear division during the cytokinesis-block phase with the 
number of mononucleated cells (MoNC) having decreased and the number of 
multinucleated cells (MultiNC) greatly increased, the NDI value may even be 
greater than 2.0.  
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Figure 2.1 MN scoring criteria adapted from Fenech (2007) and Eastmond and 
Tucker(1989). 
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2.2.8.6 Statistical analysis 
 
 
Each experiment was done five times independently. All values presented are 
represented as mean values ± standard deviations (SD). To determine the 
difference between the different treatment groups, a normality test was 
performed. One-way ANOVA and an independent t-test were used to determine 
association and comparisons between independent groups using SPSS 22.0 for 
Windows (SPSS Inc.). 
 Methods for Western blot 
 
2.2.9.1 Human lymphocyte isolation 
 
Fresh peripheral blood from prostate cancer patients and healthy individuals were 
used for isolating the lymphocytes. The whole blood was transferred to a 
Falcon™ tube and diluted in 1:1 with 0.9% saline. Six ml of this dilution was 
carefully loaded on the 3ml lymphoprep layer, followed by centrifugation for 
20mins at 1,900rpm without disturbing the lymphoprep layer. The middle white 
buffy coat layer, containing the lymphocytes, was transferred to tubes prefilled 
with 10ml of normal saline for another washing and centrifuged at 1,500rpm for 
15mins at RT. The supernatant was carefully discarded, and the pellet was re-
suspended in 900µl of RPMI-1640 medium. 
2.2.9.2 Determination of the cell concentration and density  
 
After the isolation, the concentration of the lymphocytes was determined by 
counting the cells using a haemocytometer. Fifty µl of 0.4 trypan blue solution 
(Sigma, UK) was added to 350µl of RPMI medium, and 100µl of cell stock 
suspension was added to a 1.5ml Eppendorf® tube and mixed vigorously by 
vortexing. Ten µl of cells/trypan mixture was transferred to each chamber of the 
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haemocytometer by pipetting very gently both chambers underneath the 
coverslip and cells were allowed to settle over the grid. The total number of the 
lymphocyte cells was counted in the four squares of the corner of each chamber 
under the light microscope using the 10x objective lens and focusing on the grid 
lines of the chamber.  
The lymphocyte cells concentration was calculated from the following formula: 
Cells/ml = Average number of cells in one large square × dilution factor* × 
10
4
** 
Dilution factor was 5 (1 volume cell suspension: 4 volume of diluted trypan blue) 
**10
4 is the conversion factor to convert 10-
4
ml (volume of one large square) to 
1ml. 
 
 
2.2.9.3 Exposure of lymphocyte cells to the chemicals 
 
The lymphocyte cells were seeded at a concentration of 1 x 106 cells in six well 
plates and cultured for 24hrs in complete RPMI-1640 medium containing 15% 
fetal bovine serum (FBS) (Invitrogen Ltd, Paisley, UK) and 1% penicillin-
streptomycin from Gibco, Paisley, UK at normoxic condition (37ºC, 5% CO2 and 
100% humidity). After 24hrs’ incubation, RPMI media was replaced with fresh 
basic RPMI medium and cells were treated with 500µg/ml aspirin bulk, nano-size 
and 200µg/ml both forms of ibuprofen respectively and the negative control was 
cultured without treatment. Cells were incubated for another 24hrs. 
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2.2.9.4 Protein extraction and sample preparation 
 
After 24hrs of treatment, the medium was discarded, and the lymphocytes 
washed twice with 2ml of cold PBS. Then the cultured cells were lysed in 150µl 
of lysis buffer (0.048M Tris-HCl, pH 6.8 containing 0.8mM sodium 
pyrophosphate, 5mM EDTA, 2% w/v sodium dodecyl sulphate (SDS), 10% 
glycerol, 50 mM dithiothreitol (DTT), 0.01% w/v bromophenol blue). A cell 
scraper was used to harvest the cells and homogenised by passing the lysate 
through a 23G gauge needle several times. Next, samples were transferred to 
new labelled microcentrifuge tubes and then stored at -20°C until analysis.  
2.2.9.5 Determination of protein concentration and sample    preparation 
 
The protein concentration was qualified using a Bio-Rad Bradford assay kit 
following the manufacturer’s instructions. This assay is based on colourimetric 
changes caused by an absorbance shifting in the dye coomassie (red colour) 
into coomassie blue by binding to the protein.  Five serial dilutions (0.125mg/ml 
to 2mg/ml) of Bovine Serum Albumin (BSA) were used as standers, and distilled 
water was used as a blank. Five µl of each unknown sample, standard and 
distilled water, were pipetted into separate wells of 96 well plates (Sigma, UK) 
in triplicate, and 250µl of diluted Bio-Rad dye reagent (Bio-Rad, Hertfordshire, 
UK) added to each well. The plate was incubated at room temperature for 5mins 
and absorbance measured at wavelength 595nm on a microplate reader (Tecan, 
Switzerland). The results of the absorbance values for unknown samples were 
used to produce a standard curve, and the protein concentrations of the samples 
were calculated. 
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2.2.9.6 Polyacrylamide gel preparation 
 
The gel loading assembly (Bio-Rad) was assembled following the 
manufacturer’s instructions. Tris buffers at pH 6.8 and pH 8.8 were prepared for 
the resolving (1.5M Tris and 0.4% w/v SDS, pH 8.8) and stacking gels (0.5M 
Tris and 0.4 w/v SDS, pH 6.8), then stored at room temperature. A 12% resolving 
gel was prepared and poured directly into the assembled apparatus (Appendix 
V) and the mixture overlaid with 0.5ml of 0.1% (w/v) SDS. The gel was allowed 
to set at RT for one hour. After pouring the SDS off, a 5% stacking gel was 
prepared with pH 6.8 and then added on the top of the solidified resolving gel 
(Appendix V). A gel comb was inserted, and the gel was allowed to sit at room 
temperature for about 30mins. After that, the comb was then removed, and the 
gel apparatus was transferred to an electrophoresis buffer tank (Bio-Rad) filled 
with 1 x running buffer (25mM Tris base, 192mM glycine and 0.1% w/v SDS, pH 
8.3). While gels were setting, the protein samples were prepared by re-
suspending in 4x laemmlis loading buffer and denaturised at 95ºC for 7mins; the 
samples were left to cool down at RT.  Once the gel set, the gel apparatus was 
placed in an electrophoresis buffer tank (Bio-Rad) containing 1 x running buffer. 
Thirty µg/ml of protein samples were loaded into the separate gel and 9µl pre-
stained protein ladder (Bio-Rad, UK). The polyacrylamide gel was run at 50 volts 
for 30mins, then run at 100 volts for 1hr 30mins.   
2.2.9.7 Protein transfer to membrane 
 
After the electrophoresis, a Bio-Rad mini transfer kit was used for transferring 
the proteins to a nitrocellulose membrane under wet blotting condition. A transfer 
was prepared by placing the gel against a nitrocellulose membrane (Bio-Rad, 
UK) and sandwiched with filter papers and sponges. A transfer tank was filled 
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with blotting buffer (25mM Tris base, 192mM glycine and 20% v/v methanol) and 
run at 100 volts for about 2hrs.  
2.2.9.8    Detection of the protein 
 
Once the transfer was completed, the membrane was immersed in 25ml of 
blocking buffer of 5% w/v Bovine Serum Albumin (BSA) in Tris buffer saline 
containing Tween 20 (TBS-T) (150mM sodium chloride, 20mM Tris base, 0.1% 
(v/v) Tween 20, pH 7.4) on a shaker for one hour at room temperature to block 
nonspecific site binding sites. The blocking solution was poured off, and the 
membrane was then incubated with the p53 mouse (1:2,000) or XRCC3 (1:500) 
or P21 (1:2000) (Table 2.1) at 4ºC on a shaker overnight. The following day, the 
membrane was washed with TBST (3 × 5mins) and afterwards incubated with 
20ml of 5% blocking solution containing either horseradish peroxidase (HRP)-
conjugated sheep anti-mouse IgG (1:10,000) or horseradish peroxidase (HRP)-
conjugated sheep anti-rabbit IgG (1:10,000) for 1hr at room temperature 
depending on which primary Ab was used on shaker at RT. Finally, the 
membrane was washed with TBST (3 × 5mins) and then prepared for the 
detection of the bands. 
2.2.9.9    Enhanced chemiluminescent (ECL) detection 
After the final wash, the membrane was enhanced by incubating the membrane 
with the same amount of ECL solution 1 and 2 for 1min at room temperature. 
Excess of detection reagent was removed, and the membrane was placed on 
GB Box (Gene flow, UK). The same membrane was washed with TBST (3 × 
5mins) and re-blotted with primary and secondary antibodies to detect actin 
protein (Table 2.1). 
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2.2.9.10 Data analysis 
 
All western blotting experiments were carried out with at least three independent 
samples. Image J software was used to analyse the band intensity. The 
expression level of a protein of interest was normalised to housekeeping 
proteins (ß-Actin) of the same sample. The fold change in the expression of the 
target proteins upon treatment was calculated and the expression level in 
treated samples was normalised to untreated controls. 
   Methods for qPCR 
 
2.2.10.1 RNA extraction and quantification 
 
Total RNA was extracted from the whole blood samples obtained from healthy 
individuals and prostate cancer patients exposed to both forms of aspirin and 
ibuprofen using RNeasy Mini Kit (QIAGEN) according to the manufacturer’s 
instructions. Briefly, 2ml of whole human blood was mixed with 10ml of Buffer 
EL in a 15ml Falcon™ tube and then incubated in ice for 15mins with mixing two 
times during the incubation. The mixer was centrifuged at 800rpm for 10mins at 
room temperature and then completely removed and discarded supernatant. 
The pellet cells were suspended in 8ml of EL buffer by vortexing briefly, then the 
cells were pelleted by centrifuging for 10mins at 800rpm. EL buffer was 
discarded and removed. Cells pellets were disrupted in 350µl of the Buffer RLT 
and homogenised by centrifuging for 2mins at maximum speed using a 
QIAshredder spin column in a 2ml collection tube. About 600µl of 70% ethanol 
was added to the homogenised lysate and mixed well by pipetting. Th e  
sample was pipetted, including any precipitate which may have formed, into a 
new QIAamp spin column placed in a 2ml collection tube (QIAGEN) and 
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centrifuged for 15s at 10,000rpm. The Q IAa m p  spin column was washed 
once  with 350μl Buffer RW1 in advance performance on-column DNase 
digestion with the RNase-Free DNase set (QIAGEN). Briefly, DNase I 
incubation mix was prepared from DNase I stock solution according to the 
manufacturer’s instructions. Eighty μl of DNase I incubation mix was added 
directly to QIAamp spin column membrane and placed on the bench for about 
25mins. Following this, the spin column membrane was washed with 350µl of 
W1 Buffer and centrifuged for 15s at 10,000rpm. The spin column was washed 
twice with RPE Buffer then centrifuged at 14,000rpm for 3mins to avoid carrying 
over of ethanol. Finally, the QIAamp spin column was transferred to a new 1.5ml 
microcentrifuge tube, and RNA was eluted by pipetting 50µl of RNase-free water 
directly onto the QIAamp membrane followed by centrifugation for 1min at 
10,000rpm. The purity and quality of RNA were measured using a NanoDropTM 
1000 spectrophotometer that measures the absorbance of UV light and 
calculates the 260/280 ratio (Thermo Scientific). Finally, RNA samples were 
used for cDNA synthesis and stored at -80ºC until being used for qPCR.  
2.2.10.2 Complementary DNA synthesis 
 
To synthesise single-stranded cDNA from total RNA the iScript cDNA Synthesis 
Kit (Bio-Rad) in 20µl reaction volumes was used by mixing the following 
component in order: 4µl of 5x iScript Reaction Kit, RNase-free water, and one µg 
of specimen RNA. PCR reactions were performed in Bio-Rad PTC-200 Peltier 
Thermal Cycler (Bio-Rad Laboratories, Inc. Hercules, CA, USA), using the 
amplification conditions listed in (Table 2.5) below.  
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Step Time Temperature 
Incubation/ primer annealing 5 min 25ºC 
cDNA synthesis 15 min 42ºC 
Enzyme inactivation 5 min 95ºC 
 
Table 2.5 the reaction protocol of cDNA synthesis.  
 
 
2.2.10.3 QRT-PCR method 
 
After synthesising the cDNA, the real-time PCR reaction was set up in 96 well 
plates (MicroAmpTM) for each gene of interest to be quantified in triplicate to 
reduce variation in a UV-irradiated hood on 7500 RT-PCR System (Applied 
Biosystems). 
Real-time PCR reaction was mixed for 20μl volume reactions consisting of 2µl 
of primer for the target gene ATM, ATR and β-Actin (Qiagen, UK), 10µl  of  
SYBR™ Green PCR Master Mix Brands (ThermoFisher Scientific, UK), 4µl of 
RNase/DNase-free water (Qiagen, UK) and 4µl of diluted cDNA. The 
endogenous control (β-Actin) was used as a housekeeping gene for the 
normalisation of the reaction. The qRT-PCR thermal conditions were set up as 
follows. Firstly, denaturation at 95°C for 10mins then 40 cycles of denaturation 
at 95°C for 15s, annealing and extension at 60°C for 1min. Finally, a melting 
curve of 95°C for 15s, 60°C for 15s and 95°C for 15s. 
 
2.2.10.4 Data analysis 
 
Real-time PCR assay selected in this experiment is based on the detection of 
the fluorescence by using fluorescence reporter molecules such as SYBR Green 
that includes dyes that bind to double strand DNA. The increase in the 
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fluorescence intensity is proportional to the accumulation of PCR product with 
each cycle of amplification, with qPCR instrument systems (7500 Applied 
Biosystems) and then collecting the data for each sample during each PCR 
cycle. 
The early cycle at which the amplification formed fluorescence can be detected    
mainly as setting slightly above the ambient background signal is called the 
threshold cycle ‘CT’. The numerical value of the CT is represented as the 
amount of genes of interest in the reaction (i.e. the lower the CT level, the greater 
the amount of target) (Schmittgen and Livak, 2008).    
The quantification analysis was employed to quantify the expression of the 
target gene and then compared with the normalising gene β-Actin. The ∆CT 
method was processed to determine the relative expression of the target gene. 
 This method is a convenient way to calculate CT values and inversely correlated 
gene expression by directly using the threshold cycles (CTs).   
The lowest ∆CT value is the highest expression). The ∆CT values were 
calculated using the following:  
∆CT (sample) = CT gene of interest - CT internal control gene  
The 2-∆∆CT method was used to compare the fold change of gene expression 
between untreated lymphocytes (control cells) from prostate cancer patients and 
healthy individuals, and lymphocytes treated with both forms of aspirin and 
ibuprofen. 
The ∆CT value was firstly calculated for each sample using the following 
equation: 
∆CT (sample) = CT target gene - CT housekeeping gene 
62 
 
∆CT (untreated cells) = CT target gene - CT housekeeping gene. Subsequently, 
the ∆∆CT value for each sample was calculated using the following equation:  
∆∆CT = ∆CT (sample) - ∆CT (control cells).  
Finally, the ∆∆CT formula was used to estimate the fold change values between 
untreated and treated lymphocytes (fold change = 2-∆∆CT). 
2.2.10.5 Statistical analysis 
 
The significance was calculated by using a two-tailed student t-test. The result 
was expressed as the mean ± standard deviation. P value was calculated to 
determine the statistical significance of the results.
 
 Bleomycin Challenge assay 
 
A modification of the basic alkaline comet assay was introduced to measure DNA 
repair capacity in human lymphocytes from healthy individuals and prostate 
cancer patients. Treatment groups for all samples have been described in this 
section. Scoring of cells and statistical analysis has been described in sections 
2.2.7.5, 2.2.7.6. 
2.2.11.1 Experiential design  
 
This experiment was performed to evaluate the baseline and DNA repair capacity 
of lymphocytes, after bleomycin exposure to lymphocytes from healthy control 
individuals and prostate cancer patients. In addition to the baseline Comet assay 
described before in section 2.2.6, lymphocytes were treated with bleomycin at 
concentration; 5µg/ml in RPMI medium for 30mins. After 30mins of incubation,  
all cells were washed twice with PBS to remove the BLM prior to being treated 
with aspirin and ibuprofen, each in nano form and the standard bulk form and 
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incubated for a further 30mins, except one set treated with bleomycin alone which 
processed the normal Comet without repair.  
The purpose was to measure the influence of these compounds on the repair of 
DNA using the alkaline comet assay, and compared with two sets of samples; 
one post-bleomycin treatment and not repaired, and the other sample was 
incubated with complete RPMI-1640 medium and repaired without any NSAIDs 
in a CO2 incubator for 30mins (37°C) to allow cells to repair damage induced by 
bleomycin. Different types of statistical analysis were used (see section 2.2.11.2 
below). 
2.2.11.2 Statistical analysis  
 
 
Two slides were scored from each sample. At least 100 cells were scored 
randomly. The analysis was performed using a microscope equipped with a CCD 
camera and computer system using Comet Kinetic Imaging Software© 6.0 
(Liverpool/Andor Technology, Belfast, UK). Each experiment was repeated 15 
times independently for samples from healthy individuals and prostate cancer 
patients. Mean data and standard errors were generated. 
Data obtained as Olive tail moment and % Tail DNA were tested for normality 
using the Kolmogorov-Smirnov test. The non-parametric Mann-Whitney U test 
was used to compare treated samples with the negative control values to obtain 
the P values. Data from Olive tail moment and % Tail DNA values were used to 
perform SPSS statistics (Version 20). P values of <0.05 were considered 
statistically significant. Significant differences *P<0.05; **p<0.01 ***p< 0.001 
compared to (control) untreated lymphocytes. Significant differences (+++ p = < 
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0.001, ++ p = < 0.01, + p = < 0.05) compared to treated with BLM. Significant 
differences (∆∆∆ p = < 0.001, ∆∆ p = < 0.01, ∆ p = < 0.05) compared to self-repair. 
  Detection of reactive oxygen species (ROS) 
 
1.5 x 105 isolated lymphocytes were seeded in phenol red-free RPMI medium 
into 25cm2 flasks. After 24hrs, cells were re-suspended in complete media 
without phenol red to a concentration of 1 x 106 cells/ml and treated with both 
forms of aspirin. Another set, aspirin and TBHP, were simultaneously added to 
lymphocytes. Lymphocytes not treated with TBHP were considered as normal 
control and the second well was treated with 50µmTBHP and used as a positive 
control. One blank well with no cells, but with the compound, was incubated. 
Next, 1hr prior to completion of the treatment, cells were stained by adding the 
diluted 2ml of phenol red-free RPMI containing 25µM of 2’,7’ –
dichlorofluorescein diacetate (DCFDA) (DCFDA, Abcam) at a concentration of 
1 x 106 cells/ml and incubated for 45mins in the dark at 37ºC. Cells were 
transferred to a dark bottom 96-well microplate with 100,000 stained cells/well 
and were measured on a fluorescence plate reader at Ex/Em=485/535nm. 
Carboxy-H2DCFDA is a chemically reduced, acetylated form of fluorescein 
used as an indicator for ROS in cells. Carboxy-H2DCFDA is readily converted 
to a green-fluorescent form when the acetate and ester groups are removed by 
intracellular oxidation (i.e. by the activity of ROS). The ROS change was 
determined as a percentage of control and treated wells after background 
subtraction.  
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2.2.12.1 Statistical data analysis 
 
The significance of results were assessed through a comparison of means 
using two-tailed student t-test. Results were expressed as the mean ± standard 
deviation. P values were calculated to determine statistical significance of the 
results. 
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3                    Chapter 3 
The genotoxicity of aspirin and 
ibuprofen bulk and nano particles 
on peripheral lymphocyte
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3.1 Introduction 
 
Epidemiological studies support the idea that prolonged inflammation, (chronic 
inflammation), contributes to the pathogenesis of various forms of human cancer 
(Crusz and Balkwill, 2015). Approximately 20% of cancers in adult humans 
reportedly result from chronic inflammatory conditions caused by infectious 
agents, chronic non-infectious inflammatory diseases, and other environmental 
factors. Furthermore, research also suggests that chronic inflammation plays a 
role in the aetiology of prostate cancer. In particular, recent research has focused 
on the following: (i) potential stimuli for prostatic inflammation; (ii) prostate cancer 
immunobiology; (iii) inflammatory pathways and cytokines in prostate cancer risk 
and development; (iv) proliferative inflammatory atrophy (PIA) as a risk factor for 
prostate cancer development; and (v) the role of nutritional or other anti-
inflammatory compounds in reducing prostate cancer risk (Sfanos and De Marzo, 
2012).  
Some studies have linked chronic prostatitis with prostate cancer (Sfanos et al., 
2014). Additional evidence linking inflammation and cancer comes from clinical 
studies of nonsteroidal anti-inflammatory drugs (NSAIDS) that found that long-
term users of NSAIDS, including aspirin, have a reduced risk of developing 
prostate cancer (Jacobs et al., 2007).Furthermore, blocking either inflammatory 
mediators or signalling pathways that regulate inflammation decreases tumour 
frequency and delays tumour growth, while heightened levels of proinflammatory 
mediators or the adoptive transfer of inflammatory cells increases tumour 
development (Mantovani et al., 2008). 
Chronic inflammation is believed to promote onset and progression through both 
immune and nonimmune mechanisms. The immune mechanism involves the 
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perturbation of myelopoiesis and hemopoiesis, which initiates a deficiency in 
antigen presenting (Ag-presenting) dendritic cells (DC) and dysfunctional cell-
mediated antitumour immunity (Gabrilovich, 2004).  
The non-immune mechanisms include the production of reactive oxygen species 
(ROS) which cause DNA damage, an initiating event leading to cancer (Eiró and 
Vizoso, 2012) .the production of pro-angiogenic factors for instance, vascular 
endothelial growth factor (VEGF), which stimulates tumour neovascularisation 
(Ellis and Hicklin, 2008) and the production of matrix metalloproteases, which are 
essential for promoting metastasis and invasion (Yang et al., 2008). DNA damage 
in somatic cells can potentially result in the development of cancer (Gopalan et 
al., 2011). Additionally, several factors can influence susceptibility to cancer, such 
as exposure to genotoxins, genome sensitivity and possibly the functionality of 
DNA repair mechanisms (Collins, 2004).  
In humans, the Comet assay is used to explore genetic damage with the goal of 
assessing exposure to genotoxic agents from occupational hazard, drug 
treatments, and environmental pollution (Faust et al., 2004). It has also been 
used for DNA repair studies in radiation and chemical biology, for environmental 
bio-monitoring, and in genetic toxicology and human epidemiology (Faust et al., 
2004). In the last decade, this assay has been used to examine the genotoxicity 
of nanoparticles (NPs) and has proven suitable for such measurements (Karlsson 
et al., 2015; Magdolenova et al., 2014). 
 In addition, the micronucleus assay (MN) is an essential test in genotoxicity for 
studying DNA damage at the chromosomal level, as chromosomal mutation is a 
crucial event in carcinogenesis (Fenech, 2007).  
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It has been proven that inflammatory processes can influence cancer 
development by inducing mutations, which cause further increases in genomic 
lymphocyte damage (Ben-Baruch, 2006). As all cells share the same DNA, 
lymphocytes were used in previous studies as surrogate cells to examine the 
degree of DNA damage (Anderson et al., 2014).  
Additionally, for the last decade, lymphocytes have been used widely as 
cytogenetic biomarkers to survey genotoxic risks in work environments (Garaj-
Vrhovac and Oreščanin, 2009). 
Nano-medicine can potentially improve drug efficacy. Therefore, this study 
examines the effect of aspirin and ibuprofen in bulk and nanotised states on 
lymphocytes from both healthy volunteers and prostate cancer patients using the 
Comet assay and micronucleus assay to evaluate whether the increase in the 
activity of aspirin and ibuprofen by producing the nano sized of aspirin and 
ibuprofen could lead to an increase genetic damage or could confer a geno-
protective effect.  
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3.2 Materials and methods  
 
All chemicals used in the Comet assay and micronucleus assay are listed in 
Table 2.1. 
The methods for the Comet assay are as described in chapter 2 section 2.2.7 
For the micronucleus assay methods, please refer to chapter 2 section 2.2.8 
3.3  Results 
 Particle size and stability 
 
3.3.1.1 Characterisation of NPs, bulk powder and their stability 
 
Dynamic light scattering (DLS) is a standard technique used to measure the size-
distribution profile of small particles in suspension (Hiroi and Shibayama, 2017). 
Accordingly, the particle sizes of aspirin and ibuprofen were measured using the 
DLS technique of the Zetasizer Nano ZS (Malvern Instruments, UK). After the 
sample was illuminated with a laser, fluctuations of the scattered light were 
analysed and the size of the particles was measured. DLS measurements were 
taken before and after cell treatment and at the monthly intervals for the nanotised 
version in order to avoid particle aggregation for both aspirin and ibuprofen 
nanoforms.  
 
The zeta potential (ZP) was also measured in order to ensure the stability of the 
suspensions. ZP is a measure of the magnitude of the electrostatic potential 
between particles, with a higher ZP indicating a greater stability and greater ability 
to resist aggregation, while a low ZP indicates a tendency to flocculate. The initial 
mean particle size in aspirin nano-suspension (5%) was 289 ± 3nm with a 
polydispersity index of 0.3 ± 0.03 and a zeta potential of -6.1 mV, indicating that 
nanotised aspirin is relatively unstable and could potentially aggregate; therefore, 
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new suspensions were prepared monthly. Moreover, the mean particle size 
distribution (Z-average) in the ibuprofen nano-suspension (4%) was 323 ± 6.4 nm 
with a polydispersity index of 0.2 ± 0.01 and a ZP of -2.1 mV, indicating that the 
ibuprofen was more stable. The particle size distributions of the cells before and 
after treatment with both the aspirin and ibuprofen nano-suspensions were 299 ± 
6.3 nm, and 340 ± 1.2 nm with polydispersity indexes of 0.3 ± 0.05 and 0.3 ± 
0.001, respectively.  
The mean particle sizes of aspirin and ibuprofen bulk powders was determined 
using laser diffraction (Sympatec Helos, UK) (see Table 3.1).  
Suspension name Average particle 
size (µm) 
 Volume Mean 
Diameter(µm) 
Ibuprofen 52.80 ± 4.37 20.50 
Aspirin 78.30 ± 0.23 44.57 
Table 3.1 Average particle size and volume mean diameter of the aspirin and 
ibuprofen bulk powder (n=3). This table was provided by Dr Mohammed Isreb, 
School of Pharmacy, University of Bradford. 
 
3.3.1.2 Transmission electron microscopy  
 
Transmission electron microscopy (TEM) is a microscopy technique that creates 
detailed images of tiny objects by transmitting a beam of electrons through an 
ultra-thin specimen, interacting with the specimen as it passes through. The TEM 
image of aspirin nanoparticles demonstrates their nearly spherical shape and 
their size of 289 ± 3 nm. The images showed that aspirin crystals are larger than 
those of ibuprofen (see Figures 3.1 and 3.2).   
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       Figure 3.1. TEM image of ibuprofen nanoparticles  
 
       
 
     Figure 3.2 TEM image of aspirin nanoparticles, indicating the nearly spherical   
     shape.         
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 The effect of aspirin and ibuprofen, bulk and nano particles on 
lymphocytes DNA from healthy volunteers.   
The Comet assay (Alkaline version) was used to investigate the effect of bulk and 
nanoform aspirin and ibuprofen on lymphocytes from healthy individuals. Bulk 
and nanotised preparations were examined to determine if a decrease in particle 
size induced DNA damage. Results are showed as Olive Tail Moment (OTM) and 
the percentage of DNA in the tail. 
As shown in figures 3.3 and 3.4, our data from the OTM indicate that exposure 
to aspirin bulk (ASP B), aspirin nanosuspension (ASP N), ibuprofen bulk (IBU B), 
and ibuprofen nanosuspension (IBU N) caused a reduction in DNA damage, as 
compared to an untreated control, in lymphocytes from healthy donors, only the 
IBU N, ASP B and ASPN were significant (p< 0.01, 0.01 and 0.001, respectively). 
In both drugs tested, the reduction of the DNA damage of the nanosuspension 
was greater than that of bulk form. The ASP N induced a significant decrease in 
DNA damage compared to ASP B. Also, IBU N showed a significant reduction in 
DNA damage compared to IBU B (Figure 3.3 and 3.4; Table 3.2).  
The maximum reduction in Olive Tail Moment (OTM) and percentage of Tail DNA 
was around 1.3-fold and 6.1-fold respectively in healthy cells treated with ASP N 
compared to untreated control. Indicating that the reduction in the particle size for 
aspirin and ibuprofen had a significant effect. ASP N was the most effective 
compound compared to ASP B form, and both forms of ibuprofen. The reduction 
of the DNA damage seen in aspirin from the bulk to the nano form was less than 
of that of ibuprofen; a similar trend was seen in the percentage of DNA in the tail 
(Figure 3.4 and Table 3.2).  
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Figure 3.3. Effects of bulk and nanotised aspirin and ibuprofen preparations on 
lymphocyte DNA from healthy individuals using OTM. Figure shows mean of Olive Tail 
Moments for the effect of five different groups of treatment, ibuprofen bulk (IBU B), ibuprofen nano 
(IBU N), aspirin bulk (ASP B), aspirin nano (ASP N), the positive control (PC) H2O2 and an 
untreated lymphocyte. The DNA damage was measured immediately after treatment by alkaline 
comet assay in human lymphocyte cells obtained from 20 healthy individuals. Data are expressed 
as mean±SEM. Statistical significance was calculated and illustrated after comparing 1) untreated 
control score values with values obtained with all treatment groups. 2) IBU N suspension was 
compared to bulk suspension. 3) ASP N suspension was compared to bulk suspension. *P< 0.05 
compared with the negative control group. # P< 0.05 compared IBU B with IBU N and ¥P< 
compared ASP N with ASP B. ns, non-significant, *P<0.05; **P<0.01 ***P< 0.001.  
 
 
Figure 3.4. Effects of aspirin and ibuprofen bulk and nanotised preparations on 
lymphocytes DNA from healthy individuals using percentage of Tail DNA. Figure shows 
mean of percentage of Tail DNA for five different groups of treatment ibuprofen bulk (IBU B), 
ibuprofen (IBU N), aspirin bulk (ASP B), aspirin nano (ASP N), the positive control (PC) H2O2, and 
an untreated lymphocyte group in human lymphocyte cells obtained from 20 healthy individuals. 
All treatment groups were compared with the negative control group, ASP N suspension was 
compared to bulk suspension and IBU N suspension was compared to bulk suspension. All data 
have been expressed as means and standard error (SE); asterisks (*) represents significant 
differences between five different groups of treatment *P<0.05; **p<0.01 ***p<0.001. *P < 0.05, 
untreated control versus all the treatment group. # P< 0.05, IBU B versus IBU N. ¥P< 0.05, ASP B 
versus ASP N. 
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Table 3.2 Olive Tail Moment and Percentage of Tail DNA in Healthy Donors. 
 
Treatment  Olive Tail Moment 
Mean ± SEM 
P  value percentage of 
Tail DNA 
Mean ± SEM 
P  value 
Untreated   1.8 ± 0.16 - 9.6 ± 0.4  
H2O2 7.3 ± 0.5 
 
***p<0.001 26.8 ± 0.9 ***p<0.001 
Ibuprofen Bulk (IBU B) 1.6 ± 0.15 
 
   ns 9.0 ± 0.43 ns 
Ibuprofen Nano (IBU N) 0.7 ± 0.09  **p<0.01  
  ##p<0.01 
4.5 ± 0.28 **p<0.01                    
##p<0.01 
Aspirin Bulk (ASP B) 0.8 ± 0.09 **p<0.01 5.0 ± 0.27 
 
**p<0.01 
Aspirin Nano (ASP N) 0.5 ± 0.03 ***p<0.001   
¥p<0.05 
3.5 ± 0.20 ***p<0.001   
¥p<0.05 
            ¥= P < 0.05 ASP N suspension compared to ASP B. 
           ##= P <0.01 IBU N suspension compared to IBU B. 
3.3.3 Treatment of lymphocytes of prostate cancer patients with aspirin 
and ibuprofen bulk and nanoforms 
 
The primary aim of this study was to evaluate the effect of aspirin and ibuprofen 
bulk and nanotised preparations to examine their anti-cancer efficacy further to 
determine their potential mechanisms of action. Results from the OTM from the 
prostate cancer patients (Figure 3.5) show a significant reduction in DNA damage 
with ASP B (p <0.01), ASP N (p<0.001) and IBU N (p<0.01) when compared to 
the untreated controls (table 3.3). In aspirin and ibuprofen, the nanotised version 
exhibited a significant decreased damage to the DNA when compared to bulk 
counterpart 1.3-fold and 2-fold, respectively (Figure 3.5). Also, Aspirin was the 
most effective agent, with both bulk and nano formulation exceeding that of the 
Ibuprofen. A similar trend was seen in the percentage of DNA in the tail 
(Figure3.6) with a significant decrease observed in ASP B (p <0.01), ASP N 
(p<0.001) and IBU N (p<0.01). 
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Figure 3.5. The effect of bulk and nanotised-NSAIDs on lymphocytes DNA from prostate 
cancer patients using OTM. The figure shows five different groups of treatment ibuprofen bulk 
(IBU B), and ibuprofen nanoform (IBU N), aspirin bulk (ASP B), aspirin nanoform (ASP N) and 
the positive control (PC) H2O2, and an untreated lymphocyte group in human lymphocyte cells 
obtained from 20 prostate cancer patients. All treatments were compared with the negative 
control. The mean values for the Olive Tail Moments obtained from twenty experiments involving 
100 cells each. The positive control (50 µM H2O2) had a maximum mean 8.4 value for Olive Tail 
Moments. All data have been expressed as means and standard errors (SEs); asterisks (*) 
represent significant differences between untreated control and the five different groups of 
treatment *p < 0.05; **p < 0.01 ***p < 0.001. # P< 0.05 represent significant between IBU B and IBU 
N and ¥P< represent significant differences between ASP N and ASP B. 
 
 
  
 
Figure 3.6. The effect of bulk and nanotised NSAIDs on lymphocytes DNA from prostate 
cancer patients using the percentage of Tail DNA. The figure shows the mean of percentage 
of Tail DNA for five different groups of treatment ibuprofen bulk (IBU B), and ibuprofen nanoform 
(IBU N), aspirin bulk (ASP B), aspirin nanoform (ASP N) and the positive control (PC) H2O2 and 
an untreated lymphocyte group in human lymphocyte cells obtained from 20 prostate cancer 
patients. All treatments were compared with the negative control group. The positive control (50 
µM H2O2) had a maximum mean value of 28.5 for percentage of Tail DNA. All data are expressed 
as means ± standard error (SE); asterisks (*) represents significant differences between five 
different groups of treatment compared to untreated control *p < 0.05; **p < 0.01 ***p < 0.001. (#) 
represent significant between IBU B and IBU N and (¥) represent significant differences between 
ASP N and ASP B. 
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Table 3.3 OTM and percentage Tail DNA in prostate cancer patients 
 
Treatment  Olive Tail Moment 
Mean ± SEM 
P  value Percentage of 
Tail DNA 
Mean ± SEM 
P  value 
Untreated           3 ± 0.2 
 
- 13.7 ± 0.4 
 
- 
H2O2       8.4 ± 0.36 ***P <0.001 28.5 ± 0.76 
 
***P <0.001 
Ibuprofen Bulk (IBU B)       2.6 ± 0.24 ns 12.47 ± 0.52 
 
 ns 
Ibuprofen Nano (IBU N)       1.2 ± 0.19 **P<0.01 
 ##P <0.01 
6.0 ± 0.66 
 
**P<0.01 
##P <0.01 
Aspirin Bulk (ASP B)      1.4 ± 0.17 **P<0.01 6.5 ± 0.54 
 
**P<0.01 
 Aspirin Nano (ASP N)       1.1 ± 0.14 
 
***P<0.001 
  ¥P <0.05 
5.3 ± 0.45 
 
***P<0.001 
¥P <0.05 
   ¥P <0.05 ASP N suspension compared to bulk suspension 
    ##P <0.01 IBU N suspension compared to bulk suspension 
3.3.4 Comparing the effect of aspirin and ibuprofen (NPs and bulk) on 
lymphocytes DNA from prostate cancer patients and healthy 
individuals. 
A difference between healthy donors and prostate cancer patients was observed 
when the level of DNA damaged was assessed in untreated lymphocytes: the 
cancer patients showed a significantly higher level of DNA damage on 
lymphocytes than healthy donors (***p<0.001). Also, DNA damage decreased in 
lymphocytes from healthy individuals and prostate cancer patients after treatment 
with ASPB, ASPN, IBU B and IBU N. However, this reduction was significant with 
ASPB, ASPN and IBU N. Furthermore, healthy individual saw a significant 
reduction of DNA damage with ASP B (**p < 0.01), ASPN (***p < 0.001), IBU B 
(***p < 0.001), and IBU N (**p < 0.01) when compared to prostate cancer patients 
treated with ASP B,ASP N, IBU B AND IBU N respectively (Figure 3.7). This result 
indicates that lymphocytes from prostate cancer patients exhibited more DNA 
damage than healthy lymphocytes.  
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Figure 3.7. Comparing aspirin and ibuprofen (NPs and bulk) effects on lymphocyte DNA 
from prostate cancer patients and healthy individuals. The effect of both aspirin and 
ibuprofen, bulk and nanotised forms, on DNA in lymphocyte cells obtained from healthy 
individuals compared to prostate cancer patients as measured by the Comet assay parameter 
using OTM. Cells were treated with both aspirin and ibuprofen in both forms at concentrations of 
500 µg/ml, with a negative control of untreated lymphocytes and a positive control of 50 µM of 
H2O2 for 30 minutes. All data is expressed as means ± standard error (SE); asterisks (*) represent 
significant differences between five different groups of treatment *p<0.05; **p<0.01 ***p< 0.001 
compared to untreated control. (♦) represent significant differences between the DNA levels of 
healthy individual compared to prostate cancer patients. 
 
 Analysis of Confounding Factors 
 
The effect of the variables studied (age, ethnicity, drinking habits, smoking habits) 
on comet values were evaluated in both the healthy donor group and prostate 
cancer group. In general, we found no relationship among the confounding 
factors in any of the treatment groups (see Table 3.4). 
   3.3.5.1   Age 
 
Tables 3.5 and 3.6 show that the two oldest patient age groups (65-75 and > 
70) expressed  similar results, exhibiting higher basal DNA damage (♠p < 0.001) 
than patients in the 55-65 age group, who nevertheless featured significant basal 
damage (♦p < 0.05) in comparison to the two untreated age controls.  
ASP N treated lymphocytes showed decreased DNA damage in terms of OTM 
according to patient age: prostate cancer patients between 55-65 expressed 
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a significant (p < 0.001) decrease in DNA damage, followed by patients between 
65-75 (p < 0.05), and patients < 75 (p < 0.05). ASP B treated lymphocytes showed 
a decrease in DNA damage in all age groups. However, this decrease was only 
significant in the 55-65 patient age group, which showed a significant (p < 0.01) 
reduction in DNA damage compared to untreated controls. Treatment with IBU N 
showed a significant reduction in DNA damage (p < 0.05) in patients in the 65-75 
and < 75 age groups. However, treatment with IBU B showed no significant 
differences in all age groups. In addition, there was agreement between OTM 
and % of tail DNA.  
3.3.5.2   Ethnicity 
 
Tables 3.5 and 3.6 demonstrate no statistically significant differences between 
healthy Asian patients after treatment with IBU B and ASP B when compared to 
untreated controls. However, ASP N and IBU N showed a significant reduction 
in DNA damage. There was also a significant reduction in DNA damage in 
Caucasian patients after lymphocyte treatment with IBU B, IBU N, ASP B, and 
ASP N. In addition, there were no statistically significant differences between 
the lymphocytes of Asian and Caucasian cancer patients. Moreover, the 
Caucasian control participants not differed from the Asian control participants 
after treatment with ASP B and ASP N (see Table 3.4). 
3.3.5.3   Drinking Habits 
 
There was a statistically significant reduction of prostate cancer DNA damage in 
lymphocytes treated with IBU N, ASP B, and ASP N compared to untreated 
lymphocytes. We found no relationship between drinking habits and comet 
parameters nor increased or decreased DNA damage in any of the groups (see 
Table 3.4).  
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3.3.5.4   Smoking Habits 
 
Tables 3.5 and 3.6 demonstrate that patients who smoked showed the most 
significant DNA damage for both comet parameters; the non-smoking controls 
had the lowest damage when compared with both smoking and nonsmoking 
patients. Smoking patients had the highest DNA baseline damage (♠p < 0.001), 
followed by nonsmoking patients (♦p < 0.05). Further, ASP N showed a 
significant reduction (***p < 0.001) in DNA damage in lymphocytes in smoking 
patients, followed by ASP B (**p < 0.01) and IBU N (*p < 0.05), when compared 
to untreated lymphocytes in smoking patients. 
 
Table 3.4: Confounding Factors 
Confounding Factors p value 
Age p < 0.85 
Ethnicity p < 0.47 
Drinking habits p < 0.701 
 Smoking habits P < 0.33 
 
Table 3.4. The effect of confounding factors on DNA damage. The table shows the 
relationship between the age, ethnicity, drinking habits, smoking habits on DNA damage 
evaluated in both the healthy donors and prostate cancer patients.  
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Group type and 
confounder 
 
 
NC 
 
PC 
 
 
IBU B 
 
IBU N 
 
ASP B 
 
ASP N 
  
  
  
  
  
  
  
  
  
  
  
  
 A
g
e
 
 
Controls < 50 
 
 
0.75 ± 0.3 
 
6.9 ± 2 *** 
 
1.6 ± 0.5 ns 
 
0.6 ± 0.2 ns  
 
1.4 ± 0.5 ns 
 
0.6± 0.19ns 
 
Controls 55-65 
 
 
1.5 ± 0.5 ns 
 
7.1 ± 2.2*** 
 
1.4 ± 0.8 ns 
 
0.7 ± 0.2  ns 
 
0.89 ± 0.3  
ns  
 
0.50 ± 0.1 
ns 
 
Patients 55-65 
 
 
2.7 ± 0.7 ♦ 
 
8.3 ± 0.9*** 
 
2.1 ± 0.7 ns 
 
0.95 ± 0.5 
** 
 
1.18 ± 0.7 
** 
 
0.8 ± 0.3*** 
 
Patients 65-75 
 
 
3.1 ± 1.3♠ 
 
 
9.0 ± 2.7*** 
 
2.7 ± 1.4 ns 
 
1.1 ± 0.4* 
 
1.2 ± 0.5 ns 
 
0.9 ± 0.2 * 
 
Patients >75  
 
 
3.5 ± 0.8♠ 
 
7.9 ± 1.5 
*** 
 
2.7 ± 1.4 ns 
 
1.3 ± 1.2 * 
 
1.5 ± 0.8 ns  
 
1.1 ± 0.7 * 
  
  
  
  
  
  
S
m
o
k
in
g
  
H
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to
ry
 
 
 
Non-smoking 
Controls 
 
 
1.0 ± 0.6 
 
7.3 ± 3.3 
*** 
 
1.9 ± 1.1 ns 
 
0.8 ± 0.66 
ns 
 
1. 9 ±  0.8 
ns 
 
0.5 ± 0.18 
ns 
 
Smoking Controls 
 
 
1.2 ± 1.4 ns 
 
9.7 ± 5.8 
*** 
 
2.8 ± 3.2 
*** 
 
1.3 ± 2  ns 
 
2.3 ± 2.6 ns 
 
1.2 ± 0.6 ns 
 
Non-smoking  
Patients 
 
 
2.4 ± 0.8 ♦ 
 
8.4 ± 2.2 
***   
 
2.6 ± 0.6 ns  
 
1.0 ± 0.56 
ns  
 
1.8 ± 0.5 ns 
 
1.1 ± 0.2 ns  
 
Smoking patients  
 
 
3.0 ± 1.0 ♠ 
 
8.3 ± 1.7 
***   
 
2.5 ± 1.3  
ns 
 
1.1 ± 0.9 * 
 
1.1 ± 0.5 ** 
 
0.9 ± 0.5 
*** 
  
  
  
  
  
  
  
  
  
 E
th
n
ic
it
y
 
  
 
Caucasian controls 
 
 
1.2 ± 0.1◘  
 
5 ± 1.5 ***  
  
 
1 ± 0.3 ns 
 
0.6 ± 0.07 
ns 
 
0.6 ± 0.08 
ns 
 
0.4 ± 0.05 
ns 
 
Caucasian patients 
 
 
3 ± 0.9◘ 
 
8.5 ± 1.6*** 
 
2.6 ± 1* 
 
1± 0.8 ** 
 
1.5 ± 0.7 ** 
 
1± 0.6*** 
 
Asian controls 
 
 
1.7 ± 0.8 
 
7.5 ± 2.4*** 
 
1.7 ± 0.7 ns 
 
0.7 ± 0.4*  
 
0.9 ±  0.4ns 
 
0.6 ± 0.18 
** 
 
Asian patients 
 
 
3.7 ± 1 
 
7.7 ± 1.4*** 
 
3 ± 1.5 ns 
 
2 ± 1.3 ns 
 
2 ± 0.6 ns 
 
1.9 ± 0.8 ns 
  
  
  
D
ri
n
k
in
g
 h
a
b
it
 
 
Drinking  Controls 
 
Non-drinking  
Controls 
 
1.9 ± 0.88 
 
1.65 ± 0.7 
 
7.6 ± 2.9*** 
 
7 ± 2 *** 
 
1.7 ± 0.8 ns 
◘ 
1.6 ± 0.6 ns 
 
1 ± 0.5 ns  
◘ 
0.6 ± 0.1 * 
 
0.8 ± 0.5 ns 
◘ 
0.87 ± 0.4 
ns 
 
0.6 ± 0.2 ns 
◘ 
0.5 ± 0.1 * 
 
Drinking Patients 
 
Non-drinking 
Patients 
 
3 ± 0.97♦ 
 
3 ± 1♠ 
 
 
8 ± 1.6*** 
 
8.8 ± 1.7*** 
 
2.6 ± 1ns ◘ 
 
2.6 ± 1 ns 
 
 
1.3 ± 0.8 ** 
◘ 
1 ± 0.5** 
 
1.4 ± 0.7 ** 
◘  
1 ± 0.5 ** 
 
 
1 ± 0.6*** 
◘ 
0.8 ± 0.3*** 
3.5 
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Tables 3.5 and 3.6. The effect of the age, ethnicity, drinking habits, smoking habits on 
DNA damage. Both tables show Mean ± SD of Olive tail moment (OTM) and Mean ± SD of 
% o f  tail DNA in the lymphocytes of healthy controls and prostate cancer patients were 
divided by the confounding factors. In each group, the mean OTM of treated lymphocytes was 
compared with the mean OTM of untreated control lymphocytes (Nc); ANOVA (*p < 0.05, **p 
< 0.01, ***p < 001) and ns (not significant) were not found to be significant (◘p < 0.05, ♦p < 0.01, 
♠p < 0.001) when patients and confounding factors were compared with corresponding control 
samples. The positive control (Pc) 50µM H2O2 was included. 
 
Group type and confounder 
 
 
NC 
 
PC 
 
 
IBU B 
 
IBU N 
 
ASP B 
 
ASP N 
  
  
  
  
  
  
  
  
  
  
  
 A
g
e
 
 
Controls < 50 
 
 
8.7 ± 1.9 
 
27 ± 4.6  *** 
 
8.3± 1.6 ns 
 
4.5 ±  1.4ns 
 
5.9 ± 2.2 ns 
 
3.5 ± 1 ns 
 
Controls 55-65 
 
 
10 ± 2.6 
 
28 ± 3.8 *** 
 
8.8 ± 1.5 ns 
 
4.8 ± 1.4 ns 
 
4.7 ± 1.4 ns 
 
3.7 ± 0.6 ns 
 
Patients 55-65 
 
 
13 ±2.6 ♦ 
 
29 ± 3*** 
 
11 ± 2  ns 
 
5.6 ± 3.7 ** 
 
6.9 ± 2.9** 
 
4 ± 1.6***  
 
Patients 65-75 
 
 
13.7 ± 1 ♠ 
 
28 ± 3*** 
 
12.7 ±  2  ns 
 
6 ± 3.5 * 
 
6.5 ± 2.9 ns 
 
5.5 ± 2.5 * 
 
Patients >75  
 
 
13.9 ± 2 ♠ 
 
28 ± 4*** 
 
12.9 ± 2.8 
ns 
 
5.5 ±1.4 * 
 
5 ±1 ns 
 
4.7 ± 1* 
  
  
  
  
  
 S
m
o
k
in
g
  
H
is
to
ry
 
 
 
Non-smoking Controls 
 
              
8.0 ± 1.9 
 
26 ± 5*** 
 
9 ± 1.5 ns 
 
4.7 ± 1.3 ns 
 
5.5 ± 2 ns 
 
3.8 ±1.1 ns 
 
Smoking Controls 
 
 
9.6 ± 2.5♠ 
 
28.8 ± 3.6 
*** 
 
10 ± 1.6  ns 
 
4.5 ± 1.7 ** 
 
6.1 ±  2.3 ** 
 
3.2 ± 0.6 *** 
 
Non-smoking  Patients 
 
 
12 ± 1.1 ♦ 
 
28.7 ± 3.7 
*** 
 
12 ± 1.5 ns 
 
5.3 ± 3 ns 
 
7.8 ± 4 ns 
 
5 ± 1.8 ns 
 
Smoking patients  
 
 
14 ± 2.3 ♠ 
 
29 ± 1.9*** 
 
 
12 ± 2.6 ns    
 
5.5 ± 2.5** 
 
5.6 ± 1.5*** 
 
4.8 ±  1.8 
*** 
  
  
  
  
  
  
 E
th
n
ic
it
y
 
  
 
Caucasian controls 
 
8.6 ± 1.2 
 
23.9 ± 5*** 
 
9 ± 1.3 ns 
 
4 ± 1.7 ns 
 
4.9 ± 1.3ns 
 
3 ± 0.3 ns 
Caucasian patients 
 
  
13.7 ± 2 
 
28.5 ± 3*** 
 
12.5 ± 2* 
 
6 ± 2 ** 
 
6.5 ± 2 ** 
 
5 ± 2*** 
Asian controls 
 
9.7 ± 1.9 26.8 ± 4.5 
*** 
9 ± 2 ns 4.6 ± 1* 5 ± 1.3 ns 3.5 ± 0.9 ** 
 
Asian patients 
 
 
14.6  ± 2 
 
23.5  ± 2 *** 
 
13.6  ± 3  ns 
 
9  ± 3 ns 
 
8.5  ± 1.7 ns 
 
7.6  ± 2 ns 
  
  
 D
ri
n
k
in
g
 h
a
b
it
 
 
Drinking  Controls 
 
Non-drinking  Controls 
 
 
8.9 ± 1.6 
◘ 
10 ± 2 ◘ 
 
 
25 ± 4.7*** 
 
28 ± 3.6*** 
 
7.9 ± 2 ns 
 
9.9 ± 1.4 ns 
 
4.5 ± 1 ns 
 
4.6 ± 1.4 * 
 
4.9 ± 0.8 ns 
 
5  ± 1.5 ns 
 
3.5 ± 1 ns 
 
3.6 ± 0.8* 
 
Drinking Patients 
 
Non-drinking Patients 
 
13.8 ± 2 
♦ 
14 ± 1.6 ♠ 
 
28.5±  3.4 
*** 
29.5 ± 2.7 
*** 
 
12.5 ± 2.4 
ns 
12.5 ± 2 ns 
 
 
6 ± 3 ** 
 
5.3 ± 1.9** 
 
6.5 ± 2.5** 
 
5.7 ± 1** 
 
5± 2 *** 
 
4.6 ± 1*** 
3.6 
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 The effect of human lymphocyte treatment with aspirin and 
ibuprofen bulk and nano formulation in the cytokinesis block 
micronucleus assay (CBMN). 
Lymphocytes from prostate cancer patients and healthy individuals were treated 
with 200µg/ml of IBU B, IBU N and 500 µg/ml of ASP B, ASP N then tested for 
the induction of micronuclei (MNi) using cytokinesis block micronucleus assay. 
The results are presented in Table 3.7. The dose concentration tests showed that 
200 µg/ml of ibuprofen and 500 µg/ml of aspirin were the optimum doses to use 
in the experiments, without inducing cell cytotoxicity.  
 
3.3.6.1 The frequency of binucleated cells (BiNC), multinucleated cells 
(MultiNC) and nucleoplasmic bridges (NPBs) and nuclear buds 
(NBUDs) after treatment with NSAIDs. 
 
For both the healthy individuals and prostate cancer patients group, see Table 
3.7. The aspirin and ibuprofen bulk and nanotised formulation increased the 
number of BiNC compared to untreated controls. However, this increase was not 
significant. The number of MultiNC decreased 1, 5.3, 5.5, and 4-fold after 
treatment with ASP B, ASP N. IBU B and IBU N respectively in prostate cancer 
lymphocytes when compared to untreated healthy cells (Table 3.7). The Nuclear 
Division Index (NDI) ranged from 1.74 to 1.92 in healthy individuals and from 1.70 
to 2.00 in prostate cancer patients, which were within the normal range limits of 
1.3 to 2.2 (Fenech, 2007). The frequency of NPBs and NBUDs were also within 
the normal range (Table 3.7).  
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3.3.6.2 The micronuclei (MNi) frequency after treatment with NSAIDs. 
 
In the present experiment, the number of MNi in 1,000 binucleated cells was 
determined. The frequency of induced MN was used as an indicator of DNA 
damage (Fenech, 2007). 
In the healthy individual group: The number of MNi in the aspirin nanoform 
treated cells were at the same level as in untreated cells from healthy individuals. 
The treatment of the lymphocytes from the healthy individuals with IBU N, ASP 
N, or ASP B caused a significant reduction in the MNi formation (P ≤ 0.001) 
compared to untreated lymphocytes from prostate cancer patients (Table 3.7 and 
Figure 3.8). There was an increase in the frequency of MNi of BiNC cells treated 
with bulk ibuprofen when compared to the negative control. The data 
demonstrated that the IBU B treatment caused a significant increase in MNi 
formation.  
In the prostate cancer group: The data showed a significant 9-fold increase in 
the MNi frequency in the untreated prostate cancer lymphocytes compared to 
untreated healthy lymphocytes. The number of MNi after the treatments with ASP 
N and ASP B decreased by 4.5-fold and 2-fold, respectively, compared to the 
untreated lymphocytes from the prostate cancer patients (p < 0.05 and p ≤ 0.001, 
see Figure 3.8). In aspirin, the nanotised version saw a 4.5-fold greater decrease 
in the MNi frequency when compared to the bulk counterpart. The prostate cancer 
lymphocytes treated with nanotised ibuprofen showed MN numbers that were 
almost the same levels as those of the negative control group.  
The data obtained from the healthy donors treated with bulk ibuprofen had a 
similar pattern to that of the prostate cancer patients (Table 3.7). The present 
data demonstrated that treatment with aspirin in nanotised and bulk form did not 
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induce chromosome aberrations, as indicated by the decrease in MNi formation 
within the bionucleated cells. The data also, indicated that a decrease in the 
particle size of aspirin does not cause any genotoxicity.  
 
 
Figure 3.8. The average of BiNC scored per 1000 cells per culture from five 
independent experiments; n = 1000. All data have been expressed as means ± 
standard deviations (SD); and compared to untreated lymphocytes (NC) to calculate the 
significance differences. One asterisk (*), two asterisks (**) and three asterisks (***) 
represent significant differences between NC untreated lymphocytes, PC (MMC),  IBU 
B, IBU N and ASP B and ASP N.   
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Subject 
 
Treatment        
Group 
 
 NDI 
 
% 
BiNC 
 
% 
Multi 
 
per 1000 BiNC cells 
 
% 
MoN
C 
BiMNi BiNP
B 
Bi
Bu
ds 
 MNi  
 
Healthy 
Individuals 
Untreated 
Lymphocyt
es 
1.92 59  
 
16.5 
  
1 0 0 3 
0.4 µM 
MMC 
1.80 63 11 59 0 1 22 
ASP  B 
1.85 66  10 1 0 0 1 
ASP N 1.75 68  4.9 0.5 0 0 0 
IBU  B 
1.74 67  3 12 0 1 6 
IBU N 1.85 73  6 5 0 0 2 
 
Prostate 
cancer 
patients 
Untreated  1.90 65 15 9 0 0 7 
0.4 µM 
MMC 
1.70 64  5.4 54 0 0 27 
ASP  B 2.00 69.5 15.5 6 0 0 3 
 
ASP  N 1.80 70  3 2 0 0 2 
 
IBU B 1.77 71  3 13 0 1 9 
 
IBU  N 1.83 76  4 8 0 0 4 
 
Table 3.7. Average of different types of cells in the cytokinesis block micronucleus assay, 
including BiNC, MoNC, and MultiNC. The average of (NDI) and binucleated, mononucleated, 
bionucleated with MNi (BiMNi) nucleoplasm bridges (NPBs) and nuclear buds (NBUDs) in 
lymphocytes following treatment with both bulk and nanotised forms of aspirin and ibuprofen. 
Untreated lymphocytes of prostate cancer patients showed an increased number of MNi 
compared to samples treated with ASP B, ASP N and IBU N. In general, Table 3.7 shows that 
the number of MNi in both prostate cancer patients and healthy individuals declined more in the 
nanotised form of aspirin and ibuprofen compared to the bulk form, indicating that nanotised 
compounds decrease DNA damage. 
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3.4 Discussion  
 
All NSAIDs act through the inhibition of cyclooxygenase (COX) enzyme activity. 
COX is known to play a significant role in the biosynthesis of prostaglandins (e.g. 
PGE2), which can exacerbate the progression of cancer (Antonio et al., 2015) 
and, consequently, tumour development (Day and Graham, 2013; Rao and 
Knaus, 2008). Several studies have shown that NSAIDs, especially aspirin and 
ibuprofen, can influence the hallmarks of cancer, such as cell proliferation, 
evasion of apoptosis, and cell cycle regulation (Burn et al., 2012; Park et al., 
2014).  
However, none of the previous studies on these NSAIDs has tested in vitro the 
effect of both aspirin and ibuprofen, in bulk or nanoform, on the DNA of 
lymphocytes from prostate cancer patients. Genetic defects in DNA repair may 
contribute to higher levels of DNA damage in lymphocytes and target tissue in 
cancer patients (Hanahan and Weinberg, 2000). Because obtaining normal 
primary prostate epithelial cells from healthy individuals is not possible, 
lymphocytes are the focus of this study.  
The alkaline Comet assay used in this study is known for its simplicity, sensitivity, 
time efficiency, and cost effectiveness for assessing DNA integrity in cells 
(Gopalan et al., 2011). 
The Comet assay data showed that the basal level of DNA damage in prostate 
cancer patients is significantly higher than in healthy donors in both OTM and 
percentage of Tail DNA. This result agrees with a previous study that found that 
in many cases, cancer basal level of DNA damage in a cancer patient is higher 
than in a healthy individual (Anderson et al., 2014). 
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Our results also showed, in both the healthy group and the prostate cancer group, 
that exposing lymphocytes to ASP B, ASP N, IBU B, and IBU N caused a 
decrease in DNA damage compared to the negative controls in OTM and 
percentage of Tail DNA (Figures 3.3, 3.4, 3.5 and 3.6) and this reduction was 
significant in the prostate cancer group. However, this decrease was not 
significant in healthy lymphocytes. The ASP N induced a significant decrease in 
DNA damage compared to the ASP B. in fact the ASP N was the most effective 
compound in inducing a significant decrease in DNA damage compared to the 
bulk aspirin (Figure 3.3, 3.4).  
The results demonstrate the ability of NSAID compounds to reduce DNA 
damage, especially with the increased surface reactivity of nanoparticles that 
stems from their large surface area to volume ratio. This finding was in line to 
some extent with a previous study that revealed a geno-protective effect of, 
aspirin when co-administrated with a mitomycin C a known genotoxic agent 
(Niikawa et al., 2008).  
One study showed that administration of aspirin to mice  before treatment with a 
carcinogen Ochratoxin dramatically reduced the number of DNA adducts in the 
urinary bladder and kidney (Obrecht-Pflumio et al., 1996). A similar effect was 
observed when aspirin suppressed the genotoxicity of mitomycin C (MMC) in a 
somatic mutation and recombination test (SMART) in Drosophila melanogaster 
(Niikawa et al., 2006). 
 Moreover, an ibuprofen and thiamine combination possesses a significant 
chemoprotective effect in diethylnitrosamine-induced hepatocellular carcinoma in 
Wistar rats (Afzal et al., 2017). Using the Comet assay, one study found that 
ibuprofen shows no genotoxic effect on whole human blood (Manosij et al., 2010). 
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This reduction in nanotoxicity is potentially important, as it suggests that 
nanotising particles leads to a probable increase in the reactivity of drugs.  
These results, however, were in contrast with a study showing that ibuprofen 
induces dose dependent genotoxicity in the bone marrow of mice (Tripathi et al., 
2012). 
Another study found that aspirin shows weak genotoxicity in the bone marrow of 
mice when evaluating sister chromatid exchanges and chromosomal 
aberrations at the highest dose tested (Giri et al., 1996).  
It is known that some personal characteristics and habits, such as, age, sex, or 
drinking and smoking habits, may modulate the effect of anti-inflammatory drugs 
on DNA damage or repair. In the present study, we found no correlation between 
multiple extrinsic variables and the comet results, suggesting that the observed 
DNA alterations were mainly due to the effect of the aspirin bulk, ibuprofen bulk, 
and aspirin and ibuprofen nano forms. This finding was in line to some extent with 
a previous study by Najafzadeh et al. (2016) found that there were no significant 
differences between the results in relation to confounding factors such as gender, 
smoking, drinking habit, ethnicity and age.  
The cytokinesis-block micronucleus is an important test to measure the ability of 
genotoxic agents to induce clastogenic and aneugenic effects on cell divisions 
and cell cycles (Fenech, 2002).  
In this study, lymphocytes were cultured, treated in vitro with aspirin and 
ibuprofen in bulk and nanotised forms and evaluated for a possible expression of 
MNi; nucleoplasm in both bridges and nuclear buds resulting from chromosome 
breakage and/or a disturbance of chromosome segregation are indicators of 
genomic instability.  
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NDI is a measure of general cytotoxicity and thus a marker of cell proliferation, 
as a considerable degree of chromosomal damage causes a reduction of NDI. In 
both healthy volunteers and prostate cancer patients, the NDI percentages were 
found to be within the normal expected range of 1.3 to 2.2, as seen in (Table 3.7), 
indicating a successful division of cells. 
 Also, the NDI for prostate cancer patients was lower than for healthy donors, 
indicating genomic instability. Further, the MNi frequency was a significantly 
higher in untreated prostate cancer patients than in the healthy donors, and this 
is in agreement with a previous study that found that MNi in lymphocytes from 
lung cancer patients were significantly higher than in those of healthy individuals 
(El-Zein et al., 2006; Lou et al., 2007).  
Furthermore, as compared to the untreated control, treatment with bulk and 
nanotised aspirin decreased MNi frequency in lymphocytes from prostate cancer 
patients. This result is in agreement with studies that have reported that the 
genotoxicity of analgesic compounds assessed by an in vitro micronucleus 
assay, indicating that aspirin failed to induce micronuclei in the normal rat-kidney 
cell line NRK-49F (Antunes et al., 2007; Dunn et al., 1987; Oldham et al., 1986). 
Additionally, in short-term cytogenetic tests in normal human lymphocyte cultures 
treated with aspirin, no significant increase in chromosomal aberrations was 
observed (Antunes et al., 2007). However, nanotised aspirin was capable of 
decreasing the formation of MNi more than the bulk form; this might be related to 
the surfaces of nanoparticles, which should be taken into account due to possible 
electrostatic interactions between the surface of nanoparticles and cellular 
proteins. This conjecture may have important implications for the relationship 
between the potential effects of nanomaterials and their surface modifications 
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(Xia et al., 2006). MNi formation increased after treatment with bulk and nanotised 
ibuprofen, and this result contradicted the Comet assay result. This might be due 
to differences in the exposure time of both assays as the Comet assay had an 
incubation time of 30 min while the MN assay had a more extended incubation 
time of 72 hours.   
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4                             Chapter 4 
 
The protective effect of NSAIDs against 
oxidative damage and quantification of 
DNA repair capacity in peripheral 
lymphocytes from healthy individuals 
and prostate cancer patients. 
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4.1 Introduction 
 
Cancers are associated with pronounced genomic instability when compared with 
normal tissues in the same patient. However, several studies have shown that 
genomic instability is raised not only in tumour tissue but also in non-cancer cells 
of cancer patients, and especially in peripheral lymphocytes (PBLs) (Orlow et al., 
2008; Santos et al., 2010). These previous studies suggested that the grade of 
genome damage found in PBLs indicates an individual’s tendency to develop 
cancer.  
The DNA repair machinery is essential for maintaining and preserving genome 
integrity. Consequently, impairment of the ability to efficiently repair damaged 
DNA is strongly associated with high cancer risk in humans (Moller et al., 2000; 
Zheng et al., 2003). This opinion was first supported by the discovery that rare 
autosomal recessive genetic disorder diseases, such as Fanconi anaemia, 
Bloom’s syndrome, ataxia-telangiectasia (A-T) and Xeroderma pigmentosum 
(XP) (Berwick and Vineis, 2000; Hemminki et al., 2000), are commonly 
associated with genomic instability, a lack of DNA repair and an increased risk of 
developing cancer (Zheng et al., 2003).  
The capacity to repair DNA damaged by endogenous or exogenous genotoxic 
agents, such as oxidation, also differs widely among individuals (Berwick and 
Vineis, 2000; Hemminki et al., 2000). For these reasons, the epidemiology of 
DNA repair capacity and its influence on cancer incidence in humans has become 
an essential area in cancer research.  
A considerable number of epidemiological studies have compared the variations 
in DNA repair capacity between cancer patients and healthy controls to evaluate 
the role of repair in the progression of human cancer (Berwick and Vineis, 2000; 
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Hemminki et al., 2000; Mohrenweiser and Jones, 1998). For example, previous 
research by Dybdahl et al. (1999) showed that a high capacity to repair damaged 
DNA is crucial for protection of psoriasis patients against chemically induced 
basal cell carcinoma. Similarly, Zheng et al. (2003) reported that a low capacity 
to repair damaged DNA has a strong association with lung cancer risk, while 
Ramos et al. (2004) concluded that a lack of DNA repair capacity was a 
predisposing factor in breast carcinoma.  
DNA repair processes are classiﬁed into numerous pathways: homologous 
recombination repair (HRR), non-homologous end-joining (NHEJ), base excision 
repair (BER), nucleotide excision repair (NER) and mismatch repair (MR) 
(Bernstein et al., 2002; Mohrenweiser and Jones, 1998). At present, five different 
types of techniques have been used to evaluate DNA repair capacity.  
The first includes tests based on induction of DNA damage with chemicals or 
physical agents, such as the G2-radiation assay, mutagen sensitivity test and the 
Comet and micronuclei assays. The second involves the use of indirect methods 
for measuring DNA repair, such as un-programmed DNA synthesis (UDS). The 
third type incorporates tests based on more direct measures of repair kinetics, 
such as the host cell reactivation assay (HCR). The fourth type assesses the 
correlation between genetic variation and DNA repair and the fifth integrates 
more than one type of assay (Hemminki et al., 2000).  
Of these various techniques, the Comet assay stands out as a highly sensitive, 
simple assay for detecting all kinds of DNA damage, including single-strand and 
double-strand breaks and alkali-labile lesions (Fairbairn et al., 1995; 
Vandghanooni and Eskandani, 2011). The combination of the Comet assay and 
a mutagen challenge test can be used for indirect determination of an individual’s 
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DNA repair capacity (Duthie et al., 2002; Marcon et al., 2003). Bleomycin (BLM) 
is a radiomimetic agent that can produce single-strand and double-strand breaks 
by composing a complex with ferrous ions and molecular oxygen, resulting in 
generation of oxygen radicals at the site of DNA intercalation (Pastwa et al., 
2001). 
One potent cause of DNA damage is exposure to reactive oxygen species (ROS). 
These are generally tiny molecules, but are highly reactive. They are generated 
as natural products of normal cellular metabolism and include free radicals, such 
as superoxide anion (O2•−) and hydroxyl radical (•OH), as well as non-radical 
molecules like hydrogen peroxide (H2O2) and singlet oxygen (1O2) (Birben et al., 
2012). At low levels, ROS have positive effects on cellular functions; however, 
exposure to environmental stress can lead to overproduction of ROS. High ROS 
levels in living cells are associated with significant adverse modifications and 
damage to macromolecules, including proteins, lipids and DNA, and a cell under 
these conditions is considered to be in a state of oxidative stress (Valko et al., 
2006; Wang et al., 1996).  
Oxidative stress is caused by an imbalance between ROS production and 
scavenging. It occurs in a broad spectrum of human diseases, such as chronic 
inflammation, age-related disease and cancer (Durackova, 2010).  
An increase in ROS levels has been linked to the promotion of tumour cell 
metastasis through increases in vascular permeability, while treatment with ROS 
scavengers can significantly reduce the metastatic potential of tumours in mice 
(Brown and Bicknell, 2001).  
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ROS can also modulate cellular signalling to activate cellular processes such as 
proliferation, differentiation, inflammation responses and cell survival through 
multiple ROS-sensitive signalling pathways, thereby maintaining the cancerous 
phenotype of the cell (Marinho et al., 2014).  
A shift in the balance between oxidants and antioxidants toward a more oxidative 
state is seen in prostate cancer. Some studies have highlighted the changes in 
oxidant and antioxidant status in prostatic tissues and cell lines and have 
indicated that an imbalance between these two antagonists can initiate prostate 
carcinogenesis (Khandrika et al., 2009; Ripple et al., 1997).  
The mechanism underlying this imbalance has not been elucidated, but the 
relationship with cancer suggests that the use of anti-inflammatory drugs, which 
can relieve oxidative stress, may be useful in the prevention or treatment of some 
types of cancer.  
The role played by anti-inflammatory drugs in the prevention of the cancer is still 
poorly understood, but potentially involves their effects on cellular oxidative 
status.  One way to study the oxidant: antioxidant balance in cells is with tert-
butyl hydroperoxide (T-BHP), a well-known inducer of ROS that is commonly 
used to evaluate the cellular injury due to oxidative stress (Kucera et al., 2014).  
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4.2 Aims 
 
The objectives of this study were to test the hypothesis that anti-inflammatory 
drugs, specifically aspirin and ibuprofen, can facilitate DNA repair. The approach 
taken was to use bleomycin (BLM) challenge tests, combined with Comet assays, 
to measure DNA repair capacity in lymphocytes from prostate cancer patients 
and healthy individuals following treatment with both bulk and nanoformulated 
forms of aspirin and ibuprofen. We used T-BHP to induce oxidative damage in 
these lymphocytes to investigate the potential protective effects of the bulk and 
nanoformulated aspirin to obtain a better understanding of the antioxidant 
potency of aspirin in the blood system.  
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4.3 Materials and methods 
 
All chemicals used in this experiments are listed in chapter 2 (Table 2.1)  
The methods for bleomycin challenge assay is described in chapter 2 section 
2.2.11.  
For human lymphocyte isolation methods, please refer to methods in chapter 2 
section 2.2.9.1. 
The method for Detection of reactive oxygen species (ROS) is described in 
chapter 2 section 2.2.12. 
4.4 Results 
 
 The effect of bulk and nano forms of aspirin and ibuprofen on DNA 
repair capacity in bleomycin-pretreated peripheral blood 
lymphocytes from healthy individuals and prostate cancer patients 
BLM is commonly used to study DNA damage and repair (Schmezer et al., 2001; 
Wu et al., 2007). It works by binding to the DNA strands and causing single and 
double-stranded DNA breaks. This BLM experiment involved different treatment 
groups. The first group consisted of peripheral lymphocytes (PBLs) from healthy 
donors and prostate cancer patients; these were pretreated with BLM alone for 
30 mins prior to Comet assays for measurement of the levels of DNA damage. 
The second group consisted of similar lymphocytes pretreated with BLM for 30 
mins; however, in this case, the BLM was removed and replaced with either 
aspirin or ibuprofen (bulk and nanoformulated) and incubated for an additional 30 
mins prior to DNA repair capacity measurements with the Comet assay.  
And the third group sample pretreated with BLM for 30 mins, in this case, BLM 
was replaced with complete RPMI-1640 medium and repaired without any 
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NSAIDs (self repair) in a CO2 incubator for 30mins (37°C) to allow cells to repair 
damage induced by bleomycin. PBLs without treatment (untreated), PBLs treated 
with BLM only and PBLs repaired without any NSAIDs (self repair) were used as 
controls. The results are shown in Figures 4.1 (A&B) and 4.2 (C&D).  
In general, the Comet assay results for Olive tail moments (OTMs) and % Tail 
DNA revealed similar trends for PBLs from prostate cancer patients and from 
healthy individuals in response to NSAID treatment. However, we noted a much 
higher baseline DNA damage (nearly 2.5-fold higher) in PBLs from prostate 
cancer patients than in PBLs from healthy (non-cancer) donors.  
The OTM data also indicated a significantly higher (***p <0.01) induced DNA 
damage in PBLs from healthy individuals and prostate cancer patients after a 30 
min treatment with BLM alone, when compared to the untreated control PBLs 
(Figure 4.1 A, 4.2 C). However, we found differences between the treatment 
groups when we removed the BLM to provide a 30 min repair period and 
evaluated the subsequent DNA damage repair capacity.  
The PBLs from healthy donors showed a significant reduction in the level of DNA 
damage within 30 mins of removal of the BLM and treated with ASP B, ASPN, 
IBU B and IBU N (+++p <0.01) when compared to PBLs treated with BLM with no 
repair period (Figure 4.1A). However, no significant (∆ns) DNA damage reduction 
was detected in these lymphocytes from prostate cancer patients following 
treatment with bulk ibuprofen (IBU B) when compared to PBLs treated with BLM 
with no repair period (Figure 4.2 C and D).  
 
Comparison of the NSAID-treated versus the treated PBLs with bleomycin and 
allowing DNA repair in the absence of NSAIDs (self-repair) (Figures 4.1-4.2 A&B, 
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C&D), showed a significant decline in bleomycin effects in the PBLs from healthy 
donors and prostate cancer treated with both forms of aspirin (ASP B) (∆∆p<0.01) 
(ASP N) (∆∆∆p<0.001) and with nanoformulated ibuprofen (IBU N) (∆∆p<0.01). The 
nanoformulated aspirin showed the best reduction (∆∆∆p<0.001) compared with 
self-repair. The bulk form of ibuprofen also reduced the DNA damage, but the 
reduction was not statistically significant when compared with self-repair in PBLs 
from healthy individuals and prostate cancer patients. The reduction in DNA 
damage in PBLs from healthy donors was nearly 1-fold, 1.5-fold and 1.8-fold 
lower in response to nanoformulated and bulk aspirin and nanoformulated 
ibuprofen, respectively, when compared to the corresponding control value. The 
reduction was nearly double that noted in PBLs from prostate cancer patients. 
 
 
 
 
A 
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Figure 4.1(A & B): The effect of aspirin and ibuprofen bulk and nanoformulation 
after a pre-treatment challenge with bleomycin. A and B show the effect of bulk and 
nanoformulated aspirin (ASP B, ASP N, respectively) and ibuprofen (IBU B, IBU N, 
respectively) after a challenge with bleomycin in peripheral blood lymphocytes from 
prostate cancer patients using Olive tail moment (A) and % Tail DNA (B) in the comet 
assay. The data were analysed by one-way ANOVA followed by a Tukey test to determine 
significant differences.  (*) represents significant differences between all the treatment 
groups compared to control untreated lymphocytes. 2) (∆) represent significant 
differences between all treatment groups compared to self-repair. 3) (+) represent 
significant differences between all treatment groups compared to bleomycin.  *P<0.05; 
**p<0.01 ***p< 0.001, (+++ p = < 0.001, ++ p = < 0.01, + p = < 0.05), and (∆∆∆ p = < 0.001, 
∆∆ p = < 0.01, ∆ p = < 0.05) indicate significances. Errors bars represent SEM.  
 
 
 
 
 
B 
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4.3.2. In vitro measurement of bleomycin-induced DNA damage by alkaline 
comet assays of lymphocytes from prostate cancer patients. 
 
 
 
Figure 4.2 (C&D) The effect of aspirin and ibuprofen after a challenge with bleomycin. C & 
D show the effect of bulk and nanoformulated aspirin (ASP B, ASP N, respectively) and ibuprofen 
(IBU B, IBU N, respectively) after a challenge with bleomycin in peripheral blood lymphocytes 
from prostate cancer patients using Olive tail moment (C) and % Tail DNA (D) in the comet assay. 
The data were analysed by one-way ANOVA followed by a Tukey test to determine significant 
differences. . (*) represents significant differences between all the treatment groups compared to 
control untreated lymphocytes. 2) (∆) represent significant differences between all treatment 
groups compared to self-repair. 3) (+) represent significant differences between all treatment 
groups compared to bleomycin. Errors bars represent SEM. 
C 
D 
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 DNA repair percentage (DRP) in lymphocytes from healthy 
individuals and prostate cancer patients measured with a 
bleomycin challenge assay 
 
Figure 4.3 shows that lymphocytes from healthy individuals were more effective 
in DNA repair than were lymphocytes from prostate cancer patients. DNA repair 
percentage (DRP) values were used to compare the DNA repair capacities 
between different treatment groups. The repair capacity within the first 30 min 
after removal of BLM (self-repair) was lower in PBLs from prostate cancer 
patients (41%) than in PBLs from control subjects (47%).  
Healthy PBLs treated with ASP N showed the highest DNA repair, with 
approximately 88% of the DNA damage repaired within 30 mins when compared 
to ASP N-treated PBLs from prostate cancer patients (85% DNA in a tail 
moment); however, these differences were not statistically significant. Most 
importantly, we observed a 70–87.5% recovery of BLM-induced DNA damage in 
70% of the healthy individuals and in 41–85% of the prostate cancer patients 
(Figure 4.3). This result suggests that the aspirin enhanced repair capacity of 
lymphocytes.  
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Figure 4.3 The range of calculated DNA repair capacity measured as olive tail moment (OTM) 
among lymphocytes from healthy donors and prostate cancer patients after treatment with 
bleomycin, bleomycin + bulk ibuprofen (IBU B), bleomycin + nanoformulated ibuprofen (IBU N), 
bleomycin +  bulk aspirin (ASP B) and bleomycin + nanoformulated aspirin (ASP N).  
***p< 0.001 **p< 0.01 and *p< 0.05) indicate significances. Errors bars represent SEM. 
 
 Aspirin in nanoformulated and bulk form inhibits generation of 
reactive oxygen species (ROS)  
 
 
The Cellular Reactive Oxygen Species Detection Assay utilises DCFDA, a 
fluorogenic dye that quantifies the activity of hydroxyl, peroxyl and other reactive 
oxygen species (ROS) within the cell. Upon diffusion into the cell, DCFDA is 
cleaved to DCF by cellular esterases into a non-fluorescent compound that can 
then be oxidised by ROS into 2’, 7’–dichlorofluorescein (DCF). DCF is a highly 
fluorescent compound, and the fluorescence can be detected and measured. 
Several antioxidants can decrease intracellular ROS and inhibit the metabolism 
of DFC (Wolfe and Liu, 2007). For this reason, the inhibition of DCF can then be 
used to measure the intracellular ROS scavenging activity of antioxidants. T-BHP 
is widely used to evaluate the mechanisms of cellular modifications initiated by 
oxidative stress in cells and tissues (Fatemi et al., 2013). 
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We examined whether nanoformulated and bulk aspirin can affect intracellular 
ROS production. We used DCFDA staining to evaluate T-BHP-induced oxidative 
stress in PBLs from prostate cancer patients and healthy individuals. The PBLs 
were exposed to aspirin (bulk and nanoformulated) alone or in combination with 
100µM T-BHP. We noted that T-BHP significantly increased the intracellular 
reactive oxygen species level compared to basal levels. All treated samples 
showed inhibition of ROS generation when compared to PBLs treated with T-
BHP alone (Figure 4.4). Remarkably, treatment with aspirin alone significantly 
reduced ROS generation to values lower than the control values, and treatment 
with nanoformulated aspirin was the most effective at inhibiting ROS generation.  
 
Figure 4.4 Detection of reactive oxygen species (ROS) generation in lymphocytes after 
treatment with aspirin in bulk and nanoformulated forms. The amount of ROS present in 
normal and experimental lymphocytes. Formation of ROS in normal and treated lymphocytes. 
Cont: untreated lymphocytes; T-BHP: lymphocytes treated with tertiary butyl hydroperoxide (T-
BHP) (toxin control); ASPB & ASPN: lymphocytes treated with bulk aspirin (ASP B) and 
lymphocytes treated with nanoformulated aspirin (ASP N); ASP B + T-BHP: lymphocytes treated 
with aspirin before T-BHP intoxication; ASP N & T-BHP: lymphocytes treated with T-BHP and 
ASP N simultaneously. Each column indicates ±SD, n=3. Data were analysed by one-way 
ANOVA, with Student–Newman–Keuls post hoc tests. Differences between untreated control and 
treatment groups were attributed at *p<0.05; **p<0.01 and ***p< 0.001 indicate significant 
differences. 
 
 
106 
 
4.5 Discussion 
 
An inability to maintain genomic integrity is a major risk factor in carcinogenesis. 
Increases in genomic instability, either spontaneous or mutagen-induced, have 
been regarded as susceptibility factors for malignant transformation (Zheng et 
al., 2003). Consequently, enhancing the DNA repair capacity is crucial for cell 
survival and maintenance of cell cycle control. Considerable inter-individual 
differences have been noted for the initial capacity for repair of DNA damage in 
various studies using in vitro lymphocyte assays.  
Several lines of evidence have suggested that variation in the capacity of cells to 
repair DNA damage among individuals reflects individual genetic background 
variation. Various subpopulations of lymphocytes from the same individuals show 
the identical capacity to repair DNA damage, and the intra-individual difference 
in the repair capacity is significantly smaller than the difference among individuals 
(Mohrenweiser and Jones, 1998; Schmezer et al., 2001). Therefore, measuring 
DNA repair by peripheral lymphocytes can reveal an individual’s overall DNA 
repair capacity.  
Several studies have shown that a defect in DNA repair capacity is an 
independent risk factor for different kinds of cancer, including prostate cancer 
(Blasiak et al., 2004; Frenzilli et al., 2000; Hjertvik et al., 1998; Marcon et al., 
2003; Moller et al., 2000; Tice et al., 2000; Zheng et al., 2003). For example, 
Popanda et al. (2003) found that deficiency in DNA repair is strongly associated 
with an increased risk of developing breast cancer, and Wu et al.(2003) showed 
that patients with lung cancer had a significantly lower DNA repair capacity than 
was observed in healthy controls.  
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Udumudi et al. (1998) reported that lower DNA repair capacity is a principal factor 
for cervical carcinoma risk.  
Measurement of DNA strand breaks using Comet assays has been widely 
applied to assess genotoxicity, to monitor potentially carcinogenic exposures, or 
to evaluate DNA damage and repair in molecular epidemiology (Collins and 
Horvathova, 2001; Olive and Banath, 2006). 
 The comet assay, in particular, has been applied to evaluate the correlation of 
DNA repair capacity in peripheral lymphocytes with the risk of different kinds of 
cancers, including prostate cancer (Schabath et al., 2003; Schmezer et al., 2001). 
The results of our study indicated that lymphocytes from prostate cancer patients’ 
show pronounced genomic instability that leads to an increased basal level of 
DNA damage and low DNA repair capacity (Figure 4.2 C, D and 4.3).   
Baseline levels of DNA damage have been reported as significantly higher in 
breast cancer patients than in healthy donors (Santos et al., 2010). Kurzawa-
Zegota et al. (2012) noticed greater baseline DNA damage in lymphocytes from 
colon cancer patients than from non-cancers donors, and this greater level of 
damage was similarly detected during in vitro treatment with genotoxic agents. 
Najafzadeh et al. (2012) showed that peripheral lymphocytes from patients with 
malignant melanoma and colorectal cancer, or their precancerous states, were 
far more sensitive to genetic mutagenesis than were lymphocytes from control 
participants. Schmezer et al. (2001) did not find any significant differences 
between the baseline levels of DNA damage in lymphocytes from lung cancer 
patients than from healthy donors, but they found an increased sensitivity to 
bleomycin and defects in DNA repair capacity in the lymphocytes from cancer 
patients. A similar lack of DNA repair has been detected in some studies on 
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lymphocytes from patients with lung, head and neck cancers (Altieri et al., 2008; 
Saha et al., 2008; Spitz et al., 2003; Walczak et al., 2012).  
No consensus currently exists on the reasons for the genomic instability observed 
in lymphocytes from cancer patients. One possibility is that the genomic instability 
in lymphocytes is due to the generation of reactive oxygen species, as elevated 
levels were reported in the blood of various cancer patients (Diakos et al., 2014; 
Kryston et al., 2011).  
A body of evidence now supports the occurrence of oxidative stress in breast, 
colon and lung cancer patients (Atukeren et al., 2010; Obtulowicz et al., 2010). A 
second possibility is that DNA damage in lymphocytes may be a result of the 
influence of tumour-associated factors (Smith et al., 2003). Moreover, a 
deficiency of DNA repair may lead to a higher level of DNA damage.  
 
Evidence from epidemiology, biology, genetic and experimental studies now 
suggests an association between chronic inflammation and the initiation or 
progression of various cancers, including prostate cancer (Balkwill and 
Mantovani, 2001; Coussens and Werb, 2002; Mantovani et al., 2008; Thapa and 
Ghosh, 2015). The inflammatory cells, cytokines and chemokines all offer a 
microenvironment that encourages tumour growth by promoting the production 
of reactive oxygen species. This, in turn, causes oxidative DNA damage and 
deficient DNA repair capacity and allows tumour progression by promoting 
angiogenesis (Balkwill and Mantovani, 2001; Coussens and Werb, 2002; 
Mantovani et al., 2008).  
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Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, 
are widely used as effective anti-inflammatory, antipyretic and analgesic drugs, 
and accumulating evidence now suggests that  long-term use of NSAIDs can be 
considered an effective approach for cancer chemoprevention (Baron, 2003; 
Corley et al., 2003; Holick et al., 2003; Mahmud et al., 2004; Palapattu et al., 
2005; Wang et al., 2003).  
Our work was based on the induction of DNA damage in lymphocytes treated 
with bleomycin (BLM). All cells have capacity to repair DNA damage, and 
bleomycin has been used to induce single and double-strand DNA breaks. In the 
present study, we used bleomycin to challenge the cells, and then eliminated the 
bleomycin and treated the cells with nanoformulated and bulk forms of aspirin 
and ibuprofen to test the effects of NSAIDs on DNA repair capacities (Wei et al., 
2005; Zheng et al., 2003).  
Treatment of lymphocytes from healthy participants and prostate cancer patients 
with bleomycin resulted in a significant reduction in DNA repair capacity and 
increase DNA damage, but ASP and IBU treatment prevented this reduction, with 
nanoformulated aspirin giving the best response figure 4.1 (A&B) and (C&D). This 
finding could indicate that aspirin is a stronger antioxidant than ibuprofen, in 
agreement with previous results showing that aspirin can stabilise DNA and 
prevent DNA strand breaks induced by oxidative stress (Chen et al., 2009; Hsu 
and Li, 2002).  
We confirmed this finding by measuring ROS levels following T-BHP-induced 
oxidative stress in lymphocytes from healthy control and prostate cancer patients, 
and we also investigated the potential protective effect of both forms of aspirin. 
T-BHP is a well-documented oxidative stress inducer which has been commonly 
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used in oxidative stress experiments (Wang et al., 2015). Our results showed that 
lymphocytes from prostate cancer patients generated greater levels of ROS than 
did lymphocytes from healthy donors, in agreement with previous studies by 
Toyokuni et al. (1995) and by Kawanishi et al. (2006). Our results also indicated 
that treatment of lymphocytes with aspirin, in nanoformulated or bulk form, 
effectively protected the lymphocytes against T-BHP-induced ROS (Figure 4.4).  
 Moreover, these protective effects significantly decreased the production of T-
BHP-induced ROS by these lymphocytes. The nanoformulated aspirin had a 
more pronounced effect than the bulk form in reducing the ROS, although the 
difference was not statistically significant.  
Human lymphocytes are now believed to metabolise T-BHP by a pathway that 
includes cytochrome P-450 and cyclooxygenases and results in the generation 
of toxic peroxyl and alkoxy radicals (Rush et al., 1985). This metabolic pathway 
could increase the levels of cellular free radicals that would then attack proteins, 
phospholipids and nucleic acids (Yen and Hung, 2000). Therefore, aspirin may 
exert its antioxidant activity by inhibiting this free radical generation. 
 Aspirin is also known to work by inhibiting the activities of cyclooxygenase 
enzymes. Another possibility is that the effect of aspirin reflects its effects on the 
expression of inflammatory mediators. Regardless of the precise mechanism, 
aspirin appears to protect lymphocytes from oxidative stress (Reuter et al., 2010), 
in agreement with the antioxidant role previously described for aspirin.  
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                                                 Chapter 5 
5 Effects of anti-inflammatory drugs on 
major signal transduction pathways 
in isolated lymphocyte cells.  
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5.1 Introduction 
 
Effective cancer chemoprevention can involve the use of specific natural, 
synthetic or chemical agents to restrict, slow the progression of or inhibit 
carcinogenesis, thus preventing the sequence of biological events leading to the 
development of invasive cancer. Epidemiological and clinical studies and animal 
models are supported by evidence from several investigators demonstrating that 
non-steroidal anti-inflammatory drugs (NSAIDs) and inhibitors of cyclooxygenase 
2 (COX-2) may protect against the development of prostate cancer (Norrish et 
al., 1998; Thun et al., 1993) and other tumours, including colorectal (Janne and 
Mayer, 2000), breast (Harris et al., 1999; Thun et al., 1993), lung (Muscat et al., 
2003; Thun et al., 1993), bladder (Thun et al., 1993), ovarian (Cramer et al., 1998; 
Thun et al., 1993), oesophageal and stomach cancers (Thun et al., 1993). 
 The unique pharmacological activities of NSAIDs are attributed to their inhibition 
of COXs in several tissues and cell types. The inhibition of COX-2 is thought to 
underlie their chemopreventive properties, most likely via the induction of tumour 
cell apoptosis (Rao and Reddy, 2004) and the inhibition of tumour cell 
proliferation and angiogenesis (Abdelrahim and Safe, 2005).  
NSAIDs inhibit cell proliferation and change cell cycle progression and can induce 
apoptosis in prostate cancer lines (Narayanan et al., 2006). Amongst the most 
widely studied agents showing inhibitory effects on the expression of the COX-2 
compounds are aspirin and ibuprofen. Aspirin has been shown to have a 
chemopreventive effect on prostate cancer via the contribution of COX-
independent pathways; for instance, it has been found to inhibit the nuclear 
transcription factor kappa B (NF-κB) (Wang et al., 2010).  
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Along a similar line, previous research by Goel et al. (2003) has supported the 
conclusion that aspirin changes the expression of genes involved in mismatch 
repair (MMR) and cell cycle control. Previous experimental evidence has 
indicated the involvement of aspirin in cell cycle progression, although it is not 
clear how NSAIDs are involved in the biochemical pathways. 
 Eukaryotic cells employ control mechanisms, termed ‘cell cycle checkpoints,’ 
that induce cell cycle arrest at specific stages, allowing for the repair of DNA 
damage to maintain genomic integrity and chromosome stability (Ciccia and 
Elledge, 2010; Hartwell and Weinert, 1989). Sensors, transducers and effectors 
make up the DNA damage response pathway. 
 The cell cycle checkpoint pathway is a signal transduction pathway made up of 
damage sensors, signal transducers and effectors. Ataxia-telangiectasia-
mutated kinase (ATM) and ATM and Rad3-related kinase (ATR) are 
phosphatidylinositol-3-like kinases essential for sensing DNA damage and 
activating DNA damage checkpoints, DNA repair and apoptosis (Sarkaria et al., 
1999). 
 ATM, predominantly a nuclear protein, has been identified as the product of a 
gene that is mutated in a rare multisystem disorder, ataxia-telangiectasia (AT). 
AT disorder disrupts the normal production of ATM and is characterised by 
cerebellar degeneration, mostly via the loss of Purkinje and granule cells in the 
cerebellum; immunodeficiency; cell cycle checkpoint defects and cancer 
susceptibility (Savitsky et al., 1995).  
The main pathway of ATM is initiated and activated by double-strand breaks 
(DSBs) and can possibly be stimulated throughout all cell cycle phases. Defects 
in the cell cycle checkpoint mechanism and premature progression during the cell 
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cycle may be lethal to the cells or cause oncogenic transformation (Savitsky et 
al., 1995). The key hallmark of malignant transformation in cells is a loss of 
normal cell checkpoint control, leading to the accumulation of mutations and 
additional genetic abnormalities (Broustas and Lieberman, 2014).  
Once checkpoint arrest control is compromised, induction of the S phase, or 
mitosis, can take place despite the cellular damage and result in genetic 
instability, which may contribute to the development of a malignant clone. During 
this, cells in which checkpoint control is disrupted are most likely subjected to the 
accumulation of more genetic damage (Zhou and Bartek, 2004).  
The tumour suppressor protein p53 plays a key role in the regulation of the cell 
cycle and is considered the main mediator of checkpoint induced arrest in the G1 
phase of the cell cycle. The accumulation and activation of p53 can be initiated 
by a variety of cellular stress signals that transiently stabilise the protein, including 
DNA damage, hypoxia, nucleotide deprivation, viral infection, heat shock and 
mitogenic or oncogenic activation. These lead to the activation of p53 as a 
transcription factor (Lane et al., 1995). 
p53 mediates DNA-damage-induced cell cycle arrest through p21 Waf1, which is 
known as the inhibitor of several cyclin-dependent kinases (CDKs) and a target 
for various signals that induce growth arrest and differentiation to prevent DNA 
replication (el-Deiry et al., 1993).  
p53 can also induce apoptosis, predominantly via Bax (Brady and Gil-Gomez, 
1998). As many as 50% of all cancers exhibit p53 mutations, and regulation of 
this protein is defective in a variety of others (Brady and Gil-Gomez, 1998). p53 
is stabilised after DNA damage, allowing it to activate the ATM and ATR kinases 
(Kastan et al., 2000). ATM is required for efficient activation of the cell cycle 
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checkpoint and homologous recombination following DNA damage (Kastan et al., 
2000). Germline ATM mutations lead to increased sensitivity to ionising radiation, 
immunodeficiency, and a predisposition to cancer (Barzilai et al., 2002). Upon 
stimulation, ATM undergoes autophosphorylation at Ser1981 and dimer 
separation (Bakkenist and Kastan, 2003).  
As a protein kinase, ATM function by activating DNA repair homologous 
recombination and checkpoint proteins, including p53 and checkpoint kinase 2 
(Chk2). ATM has also been previously shown to activate p53 to induce G1 arrest 
in the cell cycle following DNA damage (Kang et al., 2005). ATM and ATR both 
directly stabilize p53 by phosphorylation in vivo on Ser15 and Ser37 (Siliciano et 
al., 1997). They substrate Chk2 phosphorylates p53 on Ser20, have been shown 
to play a significant role in regulating the binding to and degradation by Mdm2 
and thus in stabilizing p53 (Bartek and Lukas, 2003). 
 X-ray repair cross-complementing protein 3 (XRCC3) is a member of the 
RecA/Rad51-related protein family that promotes chromosome stability and is 
involved in DNA repair. XRCC3 plays a crucial role in the homologous 
recombination repair (HRR) pathway. Previous studies have shown that direct 
interaction between XRCC3 and RAD51 may result in their working together in 
recombination repair mechanisms (Brenneman et al., 2000; Chun et al., 2013; 
Liu et al., 1998). 
 Genetic polymorphisms have been found in the XRCC3 gene at locations where 
some associated genetic modifications may alter DNA repair capacity and 
therefore be related to increases or decreases in cancer risk.  
This chapter will investigate the effects of the nano and bulk forms of two well-
known ant-inflammatory drugs, aspirin and ibuprofen, on some key regulatory 
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signal transduction pathways and DNA-damage-regulating proteins in human 
prostate lymphocyte cells. 
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5.2 Material and Methods 
 
 
Please refer to the Chapter 2 Materials and Methods section 2.2.9 for Western 
blot and section 2.2.10 for qPCR.  
5.3 Results 
 
 Analysis of p53 and XRCC3 expressions after in-vitro treatment of 
lymphocytes from healthy individuals and prostate cancer patients 
with nano-sized and bulk forms of aspirin and ibuprofen 
 
5.3.1.1 Analysis of p53 protein expression after NSAID treatment in vitro 
using a Western blot test 
 
p53, a tumour suppressor protein, plays many roles in several cellular outcomes, 
such as apoptosis, the ability to induce cell cycle arrest, DNA repair and 
angiogenesis (Zambetti, 2014). Because apoptosis is an essential process for 
killing cancer cells, we investigated whether p53 protein levels would be changed 
in the lymphocytes of prostate cancer patients compared to those of healthy 
control subjects after treatment with the nano and bulk forms of aspirin and 
ibuprofen. Western blotting was carried out, and the protein’s expression was 
analysed in lymphocytes from three prostate cancer patients and three healthy 
individuals and compared to untreated lymphocytes as described in section 
2.2.9.10.  
Figure 5.1, (B and C) shows that p53 was up-regulated in the lymphocytes of 
prostate cancer patients after treatment with aspirin bulk (ASP B) 1.6-fold and 
aspirin nano (ASP N) 1.9-fold compared to the untreated controls. 
 However, p53 expression was reduced in the lymphocyte cells after treatment 
with ibuprofen bulk (IBU B) and IBU N in both healthy volunteers and prostate 
cancer patients. Also, p53 showed a 1.3-fold increase in the lymphocytes of 
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healthy individuals treated with ASP B, a 1.6-fold-increase after treatment with 
ASP N a 0.67-fold decrease after treatment with IBU B and a 0.66-fold decrease 
after treatment with ibuprofen nano (IBU N) in healthy volunteers Figure 5, (A and 
C). Our observation of the increased in vitro expression of p53 in the lymphocyte 
cells after treated with aspirin indicate that aspirin has apoptotic potential.  
 
 
 
     
 
B 
A 
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5.3.1.2 Protein expression analysis of p21 after NSAID treatment 
 
It is well documented that p53 mediates cell cycle arrest in the G1 phase through 
the transcriptional activation of p21 Waf1/Cip1, an inhibitor of CDKs 2, 3, 4 and 
6. Western blot analysis was used to examine the expression of the p21 CDK 
inhibitor. After 24 hours, the p21 protein level was up-regulated in the ASP B-
treated lymphocytes from healthy donors and prostate cancer patients (Figure 
5.2, A and B). However, the difference between the increases in the tested 
protein’s expression profile in the prostate cancer patients and the controls was 
not significant (Figures 5.2). Also, no change in the p21 levels was observed in 
the lymphocytes of healthy donors or prostate cancer patients on exposure to 
C 
Figure 5.1. (A, B) Immunoblot analysis of the p53 protein in healthy volunteers and prostate 
cancer patients treated with ASP B, ASP N, IBU B, and IBU N. Actin was used as an internal 
control protein to normalise the data. (C) Bar graphs exhibiting fold changes in protein 
expression levels. Data are represented by the mean ± SEM of three experiments. 
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ASP N, IBU B or IBU N, indicating the presence of a p53-independent mechanism 
for p21 Waf1/Cip1 up-regulation in these cells. 
 
 
 
5.3.1.3 Evaluation of XRCC3 protein expression in vitro using a western 
blot test 
 
There are two useful mechanisms for repairing double-strand breaks, 
homologous recombination (HR) and non-homologous end-joining (NHEJ), of 
which HR is the more precise. The XRCC3 gene encodes a member of the 
RecA/Rad51-related protein family, known to participate in HR to maintain 
chromosome stability and repair DNA damage (Thacker and Zdzienicka, 2004). 
Figure 5.2. (A, B) Immunoblot analysis of the p21 protein in healthy volunteers and prostate 
cancer patients treated with ASP B, ASP N, IBU B and IB N. Actin was used as an internal 
control protein to normalise the data.  
 
 
A 
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XRCC3 was therefore chosen for investigation in the present study. The western 
blot test was used to evaluate XRCC3 protein expression in lymphocytes from 
prostate cancer patients and healthy volunteers who were treated with 500µg of 
the nano and bulk forms of aspirin and ibuprofen. Untreated cells were used as 
controls to determine the cut-off value of XRCC3 overexpression. As shown in 
Figure 5.3, A, B and C, the level of XRCC3 expression was notably increased in 
the lymphocytes from both prostate cancer patients and healthy donors after 24-
hour exposure to both the nano and bulk forms of aspirin. However, the 
expression of XRCC3 was reduced after treatment with both forms of ibuprofen. 
In both cases, there was no statistical difference between the XRCC3 expression 
levels of untreated lymphocytes and of those treated with aspirin or ibuprofen.  
 
 
A 
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Figure 5.3. (A, B) Immunoblot analysis demonstrating changes in XRCC3 expression after 24-h 
treatment with both forms of aspirin and ibuprofen compared with untreated lymphocyte samples. 
Actin was used as a loading control. (C) Bar graphs exhibiting fold changes in the protein 
expression levels. Data are represented by the mean ± SEM of three experiments (n=3 for each 
treatment). 
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  NSAIDs activate the ATM and ATR signalling pathway independent 
of DNA damage in lymphocyte cells.  
 
 
Based on our previous results, we concluded that NSAIDs reduce DNA damage 
in lymphocytes. We further investigated the effects of both forms of aspirin and 
ibuprofen on the gene expression of ATM and ATR in lymphocyte cells. Total 
RNA was isolated from lymphocyte cells that had been treated for 24 hours with 
both forms of aspirin and ibuprofen and was subjected to quantitative RT-PCR. 
The results were consistent with the induction of significant increases in p53 and 
p21 protein levels in lymphocytes within 24 hours after treatment with ASP N and 
ASP B, respectively (Figures 5.1 and 5.2, A and B). 
 
The real-time PCR results are shown in Figure 5.4 and indicate that all examined 
gene expressions associated with DNA damage and repair, such as that of ATM 
mRNA, were significantly increased after treatment with ASP B, ASP N and IBU 
N. However, the best result was obtained with ASP N (Figure 5.4). ATR 
expression was also increased significantly with IBU N. This suggests that 
NSAIDs do not activate ATM and ATR through the induction of DNA double-
strand breaks (Figure 5.4, 5.5). 
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Figure 5.4 The influence of aspirin and ibuprofen, nano-sized and bulk form, on the 
expression of ATM mRNA in lymphocyte cells. β-actin was used as an internal control   
gene. ATM gene expression analysis was performed on lymphocytes from healthy 
individuals (blue bar) and prostate cancer patients (red bar) after 24-hour treatment. Values 
are the means of three independent experiments, and the error bars represent SDs. The p 
values are * p<0.05, ** p<0.01, and *** p<0.001. 
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Figure 5.5 ATR expression in lymphocyte cells after 24 hours of exposure to aspirin and 
ibuprofen, nano and bulk forms. The fold changes in ATR gene expression using qRT-PCR 
are shown. Results represent three experiments. Values are the means of three independent 
experiments, and the error bars represent SDs. The p values are * p<0.05, ** p<0.01, and *** 
p<0.001. 
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5.4 Discussion 
 
Anti-inflammatory drugs have attracted considerable attention as one of several 
drug types that may exhibit cancer chemopreventive activity, in particular for 
prostate cancer (Narayanan et al., 2004). The current interest in these drugs is 
based on observations from epidemiological, clinical, and animal studies in which 
they have shown antineoplastic effects (Giovannucci et al., 1995; Greenberg et 
al., 1993; Thun et al., 2002).  
The exact mechanisms by which these drugs inhibit tumour formation and growth 
remain unclear. One proposed mechanism is their direct inhibition of COX in 
prostate cells, as prostaglandin levels are enhanced in prostate cancer (Wang et 
al., 2011). Moreover, COX-2 overexpression in epithelial cells contributes to the 
inhibition of apoptosis and proliferation (Sobolewski et al., 2010). 
 However, the chemopreventative effects of NSAIDs are not based exclusively 
on their COX inhibition, as NSAIDs can trigger cell death by apoptosis in cells 
that lack detectable COX-2 activity (Yu et al., 2002). The genetic predisposition 
to cancer and hyper-sensitivity to ionising radiation detected in AT patients can 
be associated with chromosomal instability, abnormalities in genetic 
recombination and failure to activate cell signalling for programmed cell death 
and cell cycle checkpoints in response to DNA-damage agents. ATM mutations 
are involved in the development of sporadic human cancers such as leukemia 
(Stilgenbauer et al., 1997).  
The loss of heterozygosity at the ATM gene locus has also been reported in many 
cancers, including metastatic prostate carcinoma (Angèle et al., 2004; Ruijter et 
al., 1999). These prior studies suggested that the ATM gene encodes a protein 
that senses damage and transduces signals into cells for promoting apoptosis 
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(Marinoglou, 2012; Shiloh, 1997). Recent evidence also points to the possibility 
that ATM proteins may stimulate effective defence mechanisms against oxidative 
injury (Barzilai et al., 2002; Semlitsch et al., 2011; Watters, 2003).  
Our results show that the activation of ATM-dependent checkpoints occurs 
independently of aspirin’s anti-inflammatory properties. Our study’s indications 
that ATM participates in the aspirin-mediated checkpoint response include the 
auto-phosphorylation of ATM and its targets, p53 and p21 (Figure 5.4, 5.1 and 
5.2), as well as ATM’s effectiveness at controlling cell cycle arrest and apoptosis 
(Figure 5.1, C).  This indicates that ATM’s effect on cell cycle arrest and apoptosis 
is one of the study’s indications that it participates in the checkpoint response 
mediated by aspirin.  
Some oncogenes and specific tumour suppressor genes play a crucial role in 
human prostate cancer carcinogenesis (Isaacs and Kainu, 2001; Turner and 
Watson, 2008). Most cancer cells have a defective tumor suppressor gene for 
p53, rendering this protein incapable of controlling cell proliferation and resulting 
in ineffective DNA repair. The most frequent genetic changes to p53 in cancer 
tissues are missense mutations, which result in a ‘loss-of-function’ phenotype. 
This type of alteration forms in numerous cancers, including prostate cancer 
(Muller and Vousden, 2014; Supek et al., 2014).  
Recent studies have shown that small-molecule drugs may activate p53 to 
suppress cancer cell proliferation via cell cycle arrest or apoptosis. This opens 
up new possibilities for fighting and preventing cancer (Fuster et al., 2007). It is 
well documented that p53-inducible pro-apoptotic genes trigger apoptosis 
through both the extrinsic and intrinsic apoptotic molecular pathway (Kuribayashi 
and El-Deiry, 2008). The stabilisation of p53 has also been found to mediate 
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apoptosis, as shown after treatment with aspirin (Goel et al., 2003). P53 
phosphorylation and stabilisation by non-genotoxic stress have both been well 
documented in previous studies. For instance, treating colon or lung cancer cells 
with taxol or nocodazole leads to the stabilisation and phosphorylation of p53 at 
serines 6, 15, 33, 46 and 392 (Saito et al., 2003). However, these studies did not 
explore the mechanism of ATM signalling in human prostate carcinoma cells. Our 
results show that 24-hour treatment with both the nano and bulk forms of aspirin 
activates and stabilises the p53 protein at the post-translational level (Figure 5.1, 
C), suggesting that aspirin may ensure p53-dependent action—for instance, cell 
cycle arrest and apoptosis.  
Treating lymphocytes from prostate cancer patients and healthy volunteers with 
both forms of aspirin and ibuprofen resulted in p53-mediated cell cycle arrest and 
apoptosis. 
The CDK inhibitor p21 is a key transcriptional target of p53 and mediates cell 
cycle arrest in G1 and G2. In our study, we indicated the CDK inhibitor p21 as 
the critical mediator for an aspirin-dependent G1/S checkpoint. A previous study 
by Hardwick et al.(2004) showed that p21 was up-regulated at both the gene and 
protein levels in HT29 cells treated with 5-mM aspirin. Consistent with this finding, 
the present study also revealed a significant increase in the expression of p21 
after treatment with aspirin (Figure 5.2, A and B), suggesting that the nano-sized 
aspirin induced the inhibition of cell proliferation via cell cycle arrest.   
ATM activation has been shown after treatment with genistein (isoflavonoid), in 
which the ATM-dependent phosphorylation of p53 on Ser15 stimulates p21 
expression (Chang et al., 2004). However, genistein is known as a possible DNA-
damaging agent because it inhibits topoisomerase II by stabilisation of the DNA 
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cleavage complex, an event predicted to cause DNA damage (Ye et al., 2001). 
Another study showed that Indole-3-carbinol activates the ATM signalling 
pathway independent of DNA damage to stabilize p53 and induce G1 arrest of 
human mammary epithelial cells (Brew et al., 2006).  
In our previous results in chapter 3, the Comet assay showed that aspirin did not 
induce DNA damage. Thus, our study is the first account of aspirin signalling 
through the ATM and ATR pathway without inducing DNA damage. Our results 
suggest an ATM-dependent mechanism of action for aspirin in the 
chemoprevention of prostate cancer. Aspirin is mostly effective via the p21 
pathway, as its antiproliferative activity is p53 dependent.  
The main effect of ATM activation is the up-regulation of p21. It has been 
indicated that ATM is recruited to the site of DNA damage, and it can directly bind 
to and phosphorylate proteins involved in DNA repair, such as c-Abl, Brca1, Nbs1 
and replication protein A (Jimenez et al., 1999). This suggests that by activating 
the G1/S checkpoint, aspirin increases opportunities for lymphocyte cells to repair 
DNA damage before replication or to induce apoptosis, both of which may 
contribute to maintaining the integrity of genomic DNA.  
Sensor protein complexes scan the DNA for abnormalities and translate into 
activating signals for downstream target proteins, such as the ATM kinase. 
Despite numerous studies on the molecular components of checkpoints, 
however, both the identities of these sensors and their mechanisms of action 
remain unclear.  
It seems possible that aspirin interferes with such sensors upstream of ATM. The 
identification of additional aspirin targets aside from COX-2 will help in the 
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understanding of its antitumor effects and in the design of novel chemopreventive 
agents.  
 
XRCC3 is a Rad51 paralog and is involved in homologous recombination and the 
repair of DNA double-strand breaks. Our results show that XRCC3 protein 
expression, measured by immunoblotting analysis, is increased in lymphocytes 
after 24-hour aspirin treatment compared to its expression in untreated cells 
(Figure 5.3). This result is consistent with a previous finding indicating that 
XRCC3 depletion by siRNA in MCF7 cells could inhibit cell proliferation, cause 
increased DNA damage and promote p53-dependent cell death (Loignon et al., 
2007).  
In contrast, a previous study investigating XRCC3 expression in the breast cell 
line found that aspirin can induce the overexpression of XRCC3-induced cisplatin 
resistance (Xu et al., 2005). 
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6.1 Discussion 
 
The human body contains approximately 1013 cells, and each of them is 
calculated to receive tens of thousands amount of DNA damage insults per day 
(Lindahl and Barnes, 2000). The resulting lesions can block genome replication 
and transcription, and if unrepaired or incorrectly repaired, these lesions lead to 
mutations that threaten cell or organism viability and finally may cause genome 
instability and cancer (Lindahl and Barnes, 2000). Consequently, evaluation of 
genotoxicity mechanisms has become an important part of drug validation 
processes. The molecular genetic mechanisms of aspirin and ibuprofen nano and 
bulk forms are not fully understood, especially in lymphocyte cells and these 
mechanisms therefore warrant additional study. The comet assay and 
micronucleus assay have been accepted as a valid test for genotoxicity by the 
regulatory agencies due to their sensitivity and high statistical power in identifying 
mutagenicity in the form of the DNA and chromosomal damage. As this work is 
exploratory, the in vitro comet and micronucleus assays were used as 
recommended for NPs (Magdolenova et al., 2014).  
The probable causative linkage that is best established in humans is the relation 
between chronic inflammation-induced DNA damage and the incidence of 
cancer. Strong links exist between the presence and persistence of inflammation 
at the particular site where pre-cancerous lesions develop (Grivennikov et al., 
2010), suggesting that inflammation promotes cancer development and 
progression. The hallmarks of chronic inflammation include up-regulation of pro-
inflammatory mediators and dynamic changes in the microenvironment that 
promote the malignant transformation of cells and carcinogenesis via several 
events, including enhanced incidences of DNA damage, enhanced cellular  
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proliferation and inhibition of apoptosis (Hofseth and Ying, 2006). A role for 
inflammation in tumour generation is now generally accepted, and inflammation 
is now a vital target in cancer prevention and treatment.  
The present studies investigated the effect of two well-known anti-inflammatory 
drugs, aspirin and ibuprofen, on DNA damage in peripheral lymphocytes from 
healthy volunteers and from patients with prostate cancer to determine whether 
these drugs have genoprotective or genotoxic effects on lymphocyte cells 
(Chapter 3). 
Our comet assay results indicate that no DNA damage occurred in either study 
group treated with aspirin or ibuprofen in either the bulk (ASP B, IBU B) or nano 
(ASP N, IBU N) forms. In fact, ASP N treatment significantly decreased the DNA 
damage (figures 3.3, 3.4, 3.5, 3.6 and tables 3.2, 3.3), indicating a possible 
genoprotective effect of this formulation. NSAIDs act by inhibiting COX activity, 
thereby reducing the effects of inflammation, so this is now a fundamental drug 
class being investigated to discover factors to improve the outcome of several 
cancerous states, beyond acting as a preventative measure and a standard 
(Brune and Patrignani, 2015).  
The CBMN assay was used to investigate the formation of micronuclei generated 
by treatment with aspirin and ibuprofen in both the bulk and nano forms. The 
micronucleus frequency was significantly increased in patients with prostate 
cancer when compared to healthy individuals (figure 3.8 and table 3.7). The 
prostate cancer group, following treatment with ASP N and ASP B, showed a 
significant decrease in the frequency of micronuclei, with ASP N showing 
significantly different levels when compared to ASP B. However, the frequency 
of micronuclei was increased after treatment with IBU B and IBU N in both groups, 
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and the frequency of micronuclei was higher for IBU B than for IBU N (figure 3.8 
and table 3.7). The nuclear division index ranged from 1.74–1.92 for healthy 
donors and from 1.70–2.00 for patients with prostate cancer (table 3.7), which fell 
within the normal range of 1.3–2.2 (Fenech, 2007). These results indicate that a 
decrease in drug particle size is associated with the surface atom ratio increase, 
and the reactivity also increases. The comet and micronucleus assay results 
agree with the findings of Najafzadeh et al. (2016) in which aspirin showed an 
anticancer effect in lung cancer. Several experimental and clinical studies have 
also demonstrated the chemo-preventive potential of aspirin use in cancer 
prevention in association with inhibition of metastasis and reduction in cancer 
incidence and mortality in colorectal, adenocarcinoma, prostate, lung, pancreatic, 
breast and oesophageal cancers (Bosetti et al., 2012; Rothwell et al., 2012; 
Streicher et al., 2014). All these previous studies, however, contradict the results 
of studies that indicate no relationship between aspirin use and a reduction in 
cancer incidence (Cook et al., 2005; Gann et al., 1993). Similarly, no association 
has been indicated between aspirin use and an increased incidence of breast 
cancer (Friis et al., 2008; Johnson et al., 2002).  
The comet assay findings prompted a further study to investigate DNA repair 
capacity using a challenge assay. The basic purpose of challenge assays is to 
expose cells to a DNA damaging agent and then measure how the subsequent 
DNA repair of cells responds in the presence and absence of NSAID. The aim 
here was to determine whether particle size (nano vs bulk) affected the ability of 
aspirin and ibuprofen to facilitate DNA repair in lymphocytes from patients with 
prostate cancer and healthy volunteers. 
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Previous evidence showed that capacity for DNA repair is one of the important 
determinants of susceptibility to cancer (Gaivao et al., 2009). Lymphocytes were 
challenged with BLM and then the BLM was removed to allow DNA repair. Some 
DNA repair was tested in the presence of NSAIDs, as previously discussed. The 
average background DNA damage in lymphocytes was higher in the untreated 
prostate cancer group than in the healthy donor’s figures 4.1–4.2 (A, B and C, D). 
Following exposure to BLM, the repair was slower in lymphocytes from the 
prostate cancer group than from the healthy volunteers (figure 4.3). These 
differences could have arisen due to changing genetic backgrounds, such as 
polymorphisms in the genes coding for repair. A previous study conducted by; 
Cheng et al. (2002) showed that polymorphism and the level of expression of 
nucleotide excision repair genes was related to an increased risk of head and 
neck cancers. Differences in the efficiency of nucleotide excision repair could 
influence the repair of oxidative damage induced by irradiation. Following 
exposure of lymphocytes to BLM, we examined the protective effects of NSAIDs 
on the BLM-induced genotoxicity. Figures 4.1 and 4.2 show that DNA damage 
decreased in cells treated with both forms of aspirin and ibuprofen. However, the 
nano-sized aspirin showed the best reduction of DNA damage when compared 
to cells treated with BLM only. The genotoxicity of BLM is thought to mainly reflect 
the excessive production of ROS. Therefore, treating cells with aspirin may 
reduce BLM-induced oxidative stress through the radical scavenging activity of 
the aspirin.  
Evidence also suggests that aspirin may increase the capacity of DNA repair 
mechanisms (Dibra et al., 2010). The X-ray repair cross-complementing protein 
3 (XRCC3) is essential for maintaining chromosomal stability and repairing DNA 
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damage (Brenneman et al., 2000). Genetic polymorphisms have been found in 
the XRCC3 gene at locations where some associated genetic modifications may 
alter DNA repair capacity. This then could be related to increases or decreases 
in cancer risk. Therefore, XRCC3 protein expression was determined by western 
blots of nuclear lymphocyte extracts (figure 5.3, A, B and C). This is the first 
report, to the author’s knowledge, to examine a role for aspirin and ibuprofen in 
nano and bulk form on the expression of the XRCC3 protein. As shown in (figure 
5.3, A, B and C), the level of XRCC3 expression was notably increased in the 
lymphocytes from both prostate cancer patients and healthy donors after a 24 h 
exposure to both the nano and bulk forms of aspirin. However, the expression of 
XRCC3 was reduced after treatment with both forms of ibuprofen, indicating that 
only aspirin is involved in the DNA repair.  
Chronic inflammation is associated with oxidative stress and free radical 
production, which can damage genomic DNA and enhance the development of 
prostate carcinogenesis, particularly in the presence of androgens (Ames and 
Wakimoto, 2002). The relationship between the nanoparticle-induced ROS 
production and toxicity is well documented (Fu et al., 2014). The literature has 
described the role of aspirin as an antioxidant and how it promotes resistance of 
endothelial cells to oxidant injury (Grosser et al., 2003). However, another study 
showed that aspirin showed a poor antioxidant effect (Guerrero et al., 2004). 
No reports are available that describe a role for the antioxidant effects of aspirin 
(either bulk or nano-sized) in the protection of lymphocytes from patients with 
prostate cancer and healthy donors against cell death caused by ROS. 
Accordingly, we investigated whether ASP N would overcome an oxidising 
environment or alternatively reduce some of the DNA damage generated in the 
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presence of TBHP by ROS. ASP N reduced ROS formation and was the most 
effective at inhibiting ROS generation (figure 4.4), suggesting that ASP N does 
not induce ROS and has antioxidant properties. The antioxidant activity of aspirin 
has been implicated as a potential mechanism to explain the cancer preventative 
effects of aspirin. It is considered an antioxidant with the ability to scavenge *OH 
radicals, as demonstrated in vitro (Shi et al., 1999). Ferritin appears to be a 
molecular target of aspirin with a particular potential for clinical significance. 
Moreover, ferritin induction by aspirin might explain earlier observations showing 
that aspirin is capable of directly protecting cultured lymphocytes from oxidant 
injury. The results of the present investigation suggest that, by increasing the 
synthesis of iron-scavenging ferritin, aspirin may specifically remove iron ions 
from the site of oxygen radical formation. Aspirin may therefore effectively 
interrupt the reaction cascade that leads to oxidative stress and tissue damage, 
thereby explaining its protective action and demonstrating an antioxidant function 
of newly synthesised ferritin under these conditions. 
The mechanism of action of the NSAIDs was further examined by exploring how 
the NSAIDs exert their control on apoptosis. The tumour suppressor protein, p53, 
is involved in several cellular outcomes, such as apoptosis and angiogenesis. 
Therefore, some proteins associated with p53 were examined by Western 
blotting to clarify whether aspirin and ibuprofen (nano and bulk versions) affect 
the viability of lymphocyte cells through actions on the p53 protein and effects on 
p21. We found that ASP N up-regulated expression of the p53 and p21 proteins. 
The data indicate that aspirin (nano and bulk) induced p53 mediated cell cycle 
arrest and apoptosis in lymphocytes through stabilisation of the p53 protein. 
These ﬁndings provide a new insight into the cancer chemoprevention properties 
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of anti-inflammatory drugs (figure 5.1,A and B) via effects on cell cycle 
progression that activates cellular checkpoints in lymphocytes.   
Gene expressions of ATM and ATR were also evaluated by quantifying the level 
of mRNA using qRT-PCR in order to determine the possible effects of treatment 
of lymphocytes with both bulk and nano forms of aspirin and ibuprofen. The 
results show for the first time that treatment of lymphocytes with both forms of 
aspirin and ibuprofen significantly increased the levels of ATM mRNA; however, 
the highest expression was obtained with ASP N (figure 5.4). ATR expression 
was also increased significantly with IBU N (figure 5.5). These findings suggest 
that NSAIDs do not activate ATM and ATR through the induction of DNA double-
strand breaks. 
Aspirin can also affect mitochondrial functions. It increases the mitochondrial 
membrane permeability, causing the release of cytochrome c, resulting in the 
activation of caspases followed by cell apoptosis in several cell lines (Dikshit et 
al., 2006).  
The electron transport reactions involving cytochrome c are as follows: 
Fe2+-cytochrome c + 8 H+in + O2 → 4 Fe3+-cytochrome c +2 H2O + 4 H+out Two 
electrons are delivered from two molecules of cytochrome c in the CuA and 
cytochrome a sites to the cytochrome a3- CuB binuclear centre, reducing the 
metals to the Fe2+ and Cu+ forms. The hydroxide ligand is protonated and 
removed as water, producing a void in the middle of the metals that is filled by 
O2. The oxygen is quickly reduced, with two electrons arriving from the 
Fe2+cytochrome a3, which is changed to the ferryl oxo form (Fe4+=O). The oxygen 
atom close to CuB picks up one electron from Cu+, and a second electron and a 
proton from the hydroxyl of Tyr (244), which is converted into a tyrosyl radical: 
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the second oxygen is converted to a hydroxide ion by picking up two electrons 
and a proton. A third electron from another cytochrome c is passed through the 
first two electron carriers to the cytochrome a3- CuB binuclear centre, and this 
electron and two protons transform the tyrosyl radical back to Tyr and the 
hydroxide bound to CuB2+ to a water molecule. The fourth electron from another 
cytochrome c flows through CuA and cytochrome a to the cytochrome a3- CuB 
binuclear centre, reducing the Fe4+=O to Fe3+, with the oxygen atom picking up a 
proton and regenerating this oxygen as a hydroxide ion coordinated in the middle 
of the cytochrome a3- CuB centre, as it was at the start of this cycle. The net 
process is that four molecules of reduced cytochrome c are used, along with four 
protons, to reduce O2 to two water molecules. 
 
Aspirin and ibuprofen in their existing forms have drawbacks in their 
bioavailability. In biopharmaceutics classification system (BCS), aspirin is a class 
III drug and therefore its rate of dissolution and rate of diffusion (absorption) are 
its limiting steps. Ibuprofen is a BCS class II drug, so it is only slightly soluble in 
water; poor solubility can lead to low bioavailability and therefore bioavailability is 
limited by its dissolution rate. Nano-suspension forms can improve the solubility 
and increase the bioavailability of both drugs. Our comparison of the nano-
formulation of the drugs to their bulk forms demonstrates that a decrease in 
particle size yields a difference in response. In all cases, the nano form of the 
drug gave a better response than the bulk form. This highlights the potential of 
these drugs in their nano form for use as therapeutic options.  
Nano-particles have a larger surface area than the bulk forms and the surface 
atoms are more reactive since, as the surface atoms ratio increases, the reactivity 
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also increases. At the nano-scale, a huge number of atoms at the surface are 
exposed. These atoms will strongly participate in any reaction, whereas in bulk 
material, most of the atoms lie in the interior and can participate only weakly in 
any reaction (De Jong and Borm, 2008). Nano-particles, because of their small 
size, can also extravasate through the endothelium in inflammatory sites, 
epithelia and tumours or can penetrate microcapillaries. In general, the nano-size 
of these particles allows for efficient uptake by a variety of cell types and selective 
drug accumulation at target sites (Panyam et al., 2003).  
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6.2 Conclusion 
 
Anti-inflammatory drugs have great potential to be used as adjuvants and in 
combination therapy in cancer treatment. They thus represent a novel, less 
toxic treatment option than conventional treatment methods. Unfortunately, the 
use of these agents is currently restricted due to their side effects. The present 
study, however, has demonstrated increased activity when particle size is 
decreased to the nano scale, offering bioavailability without increasing genetic 
toxicity during in vitro assays on human lymphocytes. It is the researchers’ 
hope that the data presented on the genotoxicity mechanisms of NSAIDs 
agents in lymphocytes will shed new light on cancer prevention and treatment. 
 
The results demonstrated, via comet and micronucleus assay, that aspirin nano 
(ASP N) causes a significant decrease in DNA damage compared to aspirin bulk 
(ASP B) and ibuprofen nano (IBU N). Micronuclei (MNi) decreased after ASP N 
and ASP B in healthy participants and prostate cancer patients. Gene 
expression analysis of ATM and ATR suggested that changes in transcript levels 
of these genes do not necessarily correlate with DNA damage. Instead, XRCC3 
expression is up-regulated as protein in the lymphocytes as a result of exposure 
to aspirin. Aspirin may thus have the capacity to upregulate XRCC3 expression 
and, by extension, function, which has important implications regarding the 
response of host cells to chemotherapeutic agents. The significance and utility 
of this study is further underlined by the finding that aspirin was capable of 
decreasing reactive oxygen species and DNA strand breaks in human 
lymphocytes. 
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6.3 Further work 
 
In the literature, no research has yet described a mechanism for aspirin nano-
form effects on Bcl, COX1 and COX2 gene expression. Additionally, aspirin has 
been found to inhibit IkB kinase (IKK) b and prevent NF-kB activation. The only 
COX independent target that is known to directly interact with aspirin is IKK. 
Transcription of several proteins involved in inflammatory responses and 
angiogenesis is promoted by NF-kB; therefore, inhibition of this pathway may also 
contribute to the observed anticancer effects. Studying the effect of aspirin nano 
on the protein expression of IKK and NF-kB will be very important as will 
understanding the effects of aspirin on antioxidant defences against these ROS, 
such as the glutathione redox cycle and catalase. 
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8.1 Appendix I 
 
 
Centre Number: 
 CONSENT FORM FOR PATIENTS 
 
Title of Project: Effect of small (nano) particles on white blood cells in patients 
with chest diseases compared to white blood cells in people without chest 
diseases. (Version 3, 07- 07- 09) 
Reviewed by Leeds Central Research Ethics Committee 
(REC) (REC reference number: 12/YH/0464) 
1. I confirm that I have read and understand the information sheet 
(version 3, 19- 06-09) for the above study. I have had the 
opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason, 
without my medical care or legal rights beingaffected. 
 
3. I understand that relevant sections of my medical notes and 
data collected during the study may be looked at by 
individuals from the NHS Trust or the University of 
Bradford, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access 
to my records. 
 
4. I agree that the sample I have given and the information 
gathered about me can be stored at the University of Bradford, 
as described in the attached information sheet. 
 
5. I agree to take part in the above study. 
 
Name of Patient                          Date                                Signature 
 
 
Name of Person taking 
  
Date 
  
Signature 
 
     
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in 
medical notes. 
School of Life Sciences 
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8.2 Appendix II 
 
 
 Participant Information Sheet for patient 
 
Study title: Genotoxic effects of nano and bulk forms of aspirin and ibuprofen on 
blood samples from prostate cancer patients compared to those from healthy 
individuals.  
Reviewed by Leeds Central Research Ethics Committee (REC)  
(REC reference number: 12/YH/0464) 
 
Invitation to the research study 
 
We would like to invite you to take part in a research study. Before you 
decide you need to understand why the research is being done and what 
it would involve for you. Please take time to read the following information 
carefully. Talk to others about the study if you wish to and you will be 
allowed around 24hours to consider this. 
(Part 1 tells you the purpose of this study and what will happen 
to you if    you take part. 
Part 2 gives you more detailed information about the conduct 
of the study).  
Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish 
to take part. 
 
Part 1 
 
What is the purpose of the study? 
In this study white blood cells will be treated in a test tube with very small 
chemical particles to determine if patients with cancerous and inflammatory 
diseases are more at risk after exposure. A blood sample of around 6-8 
teaspoons (40 ml) will be taken. Samples will be stored only for the duration 
of the study and used for studies of a similar nature or to check original 
responses. The research is for a PhD programmes involving post-doctoral 
fellows and PhDs. 
 
Why have I been invited? 
 
You have invited because you have disease states and we should like to 
determine if these small chemical particles could be more harmful to you 
than to people without diseases state than those without such disease. 
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Do I have to take part? 
It is up to you to decide. We shall outline the study and go through this 
information sheet, which we shall then give to you. We shall ask you to sign a 
consent form to show you have agreed to take part. You are free to withdraw 
at any time, without giving a reason.  This would not affect the standard of care 
you receive. 
 
Part 2 
What will happen to me if I take part? 
A single blood sample will be taken and you will not need to attend the Clinic 
again for this research study. A brief questionnaire will need to be completed by 
the researchers. 
 
We shall need to access your notes so that they can be linked in an anonymous 
way to your clinical data which can be tied up with the research results. Each 
individual will be given a coded study number. 
 
The data obtained will only be available to the research team and will not be 
returned to you. Responses will be compared only on group basis i.e. collective 
responses from patients with chest diseases compared to collective responses 
from people without chest diseases. Results could be published in the form 
of scientific papers. The work will benefit the medical and scientific community 
at large, but will not be of direct benefit to you as an individual. If, however, you 
would like more information, Dr BK Jacobs will be prepared to talk to you 
individually about study results. 
 
People who cannot take part in the study. 
People who are not well enough to take part will be excluded (e.g. those with 
anaemia) If you have any further questions, you could contact the research team:  
Professor Diana Anderson, Established Chair in Biomedical Sciences, BSc MSc 
PhD DipEd FSB, FATS, FRC Path, FIFST, FBTS, FRSM, FHEA, FRSC, 
University of Bradford Richmond Road, Bradford, West Yorkshire BD7 1DP, 
United Kingdom and Honorary Research Consultant to Bradford NHS Trust. 
Email:d.anderson1@bradford.ac.uk. 
 
Dr Mojgan Najafzadeh MD, PhD post-doctoral fellow. Division of Medical 
Sciences, University of Bradford, Richmond Road, Bradford, BD7 1DP and 
Honorary Research Consultant
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8.3 Appendix III 
 
 DATA COLLECTION FORM 
(To be completed by the Doctor) 
 
STUDY TITLE:   
 
Genotoxic effects of nano and bulk forms of aspirin and ibuprofen on blood samples 
from prostate cancer patients compared to those from healthy individuals. 
 
REVIEWED BY LEEDS East RESEARCH ETHICS COMMITTEE (REC) 
(REC REFERENCE NUMBER: (12/YH/0464) 
 
PATIENT NUMBER                                         DATE OF SAMPLE 
 
AGE 
 
SEX (PLEASE TICK) CONSENT 
ETHNIC GROUP INFORMATION SHEET 
 
OCCUPATION 
 
 
CURRENT SMOKER  
CIGARETTES  
ALCOHOL Y / N 
 
DIET 
 
VITAMINS / ANTI-
OXIDANTS (PLEASE 
LIST) 
 
PRESCRIBED DRUG USE 
(PLEASE LIST) 
 
PAST SMOKER Y/N      
 HOW MANY/MUCH PER Y /NDAY?             
              CIGARS           
   
   
 
 
 
 
 
Y / N 
 
 
 
 
 
Western Asian OMNIVORE VEGETARIAN VEGAN 
 
 
 ASIAN OMNIVORE VEGETARIAN VEGAN 
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RECREATIONAL DRUG USE 
 
IF YES PLEASE LIST 
 
MEDICAL 
 
Cancer inflammatory disease 
Extent site 
 
 
CANCER   
Inflammation diseases  
Precancerous state  
Other medical conditions please list  
Family history of cancer and 
inflammatory disease 
 
Chemotherapy or radiotherapy  
 
 
 
 
 
 
 
 
 
 
 
Y/N 
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8.4 Appendix V 
 
 Solution for Comet and micronucleus assays 
 
 
Buffers/Reagents Chemical constituents of 
reagents 
Low melting point agarose 
(LMP) (storage at RT) 
0.5% (w/v) LMP in PBS  
Normal melting point agarose 1% (w/v) NMP in ddH2O2 
Final lysis solution 89% lysis solution             
100% DMSO                        
1% triton X-100 
Fresh electrophoresis buffer 
(storage at 4 oC) 
1930 ml ddH2O                      
60 ml 10 MNaOH                   
10 ml 200 mM Na2EDTA.2H2O 
(pH 13.5) 
Neutralising buffer storage at 4 
oC) 
12.11 Trizma Base pH 7.5 
250ml ddH2O2 
Ethidium Bromide (EtBr)  10mg/ml ddH2O2 
Final Ethidium Bromide solution  20 µg/ml in  ddH2O2 
Cytochalasin B storage at -20 
oC 
10 mg of Cyto-B re-suspend in 
2.5 ml of DMSO, diluted 1:4 in 
RPMI 1640 medium. 
Phytohaemagglutinin storage at 
– 20 oC 
2mg PHA , 5ml RPMI 1640 
medium 
Basic Medium storage at - 4 oC 84% RPMI 1640 medium 
15%FBS, 1% Pen-Strep 
solution 
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8.5  Appendix VI 
 Western Blotting: Solution preparations, Gel 
electrophoresis &Transblotting 
 
12% resolving gel 
H2O2 6.6 ml 
30% acrylamide mix 8.0 ml 
1.5 M Tris-HCl (pH 8.8) 5 ml 
5.0 ml 10% SDS 0.2 ml  
ammonium persulfate  0.2 ml  
TEMED 0.01ml 
 
5% stacking gel 
H2O2 6.8 ml 
30% acrylamide mix 1.7 ml 
1.5 M Tris-HCl (pH 8.8) 1.25 ml 
5.0 ml 10% SDS 0.1 ml  
ammonium persulfate 0.2 ml  0.1ml 
TEMED 0.01ml 
 
Preparation of solutions for western blot: 
Tank Buffer: Add the following:  
Tris Base 30 g 
Glycine 144 g 
SDS 10g 
Now make up to 1 litre of dH2O 
 
Transblot Buffer 10X: Add the following:  
Tris Base 30 g 
Glycine 144 g 
Now make up to 1 litre of dH2O 
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Transblot Buffer 1X: Add the following for each run of western 
blot:  
10X Transblot buffer 100 ml 
Methanol 100 ml 
SDS 0.15 g 
Fill up to 800 ml of dH2O. 
 
 
 
 
 
 
 
 
 
 
 
  
194 
 
8.6 Appendix VII: Abstracts titles presented for Conference 
Contributions. 
 
Azeza Guma, Adolf Baumgartner, Mojgan Najafzadeh, Mohammad 
Isreb, and Diana Anderson. Genotoxic evaluation of nano- and bulk 
forms of aspirin and ibuprofen in lymphocytes from prostate 
cancer patients and healthy individuals. UKEMS Annual Meeting, 
London, June 2016 (Poster). 
   
2. Azeza Guma, Adolf Baumgartner, Mojgan Najafzadeh, Mohammad 
Isreb, and Diana Anderson.  Protective Effect of both nano and bulk 
forms of aspirin   against tert-butyl hydroperoxide and bleomycin-
induced oxidative stress in lymphocyte from prostate cancer 
patients and healthy individuals. Molecular Epidemiology Group UK 
(MEGUK) Spring Meeting, Aberdeen, March 2017 (Poster). 
 
3. Azeza Guma, Adolf Baumgartner, Mojgan Najafzadeh, Mohammad 
Isreb, and Diana Anderson. Expression of p53, ATM and ATR after in-
vitro treatment of lymphocytes from healthy individuals and 
prostate cancer patients with nano-sized and bulk forms of anti-
inflammatory drugs. UKEMS Annual Meeting, Leuven, June 2017 
(Poster). 
 
 
 
